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Abstract 
 
Dengue disease is a mosquito-borne condition that has become a major public 
health concern. Dengue severity can be classified into mild Dengue fever (DF) and 
severe Dengue or Dengue hemorrhagic fever (DHF). Genetic polymorphisms and 
variations in the host immune response are believed to contribute to different degrees 
to the disease progression. In this study, factors that have an influence on Dengue 
infection were identified. Genetic variants in the complement system, of which the 
degree of activation increases with Dengue severity, were identified. There was no 
association between the disease and complement genetic variants (complement factor 
H [CFH] rs3753394, CFH rs1061170, CFH rs800292, complement factor B (FB) 
rs12614/rs641153 and complement C3 rs2230199) in Thai cohorts. By contrast, with 
multiplex bead immunoassay, numerous biological markers measured in the plasma of 
Dengue patients were shown to increase the risk of Dengue severity. Up-regulation of 
plasma matrix metalloproteinase 3 (MMP-3) was shown to be associated with the risk 
of developing DHF even though recombinant MMP-3 (rMMP-3) did not affect 
endothelial permeability in vitro. Finally, an early predictive model to predict DHF 
was examined by using binary logistic regression. Low platelet cell count and high 
plasma levels of Monocyte chemotactic protein 2 (MCP2) were identified as early 
indicators. Sensitivity, specificity, and accuracy of the test were 73.17%, 83.13% and 
82%, respectively. These data might be useful in the development of therapeutic 
agents and predictive markers for Dengue infection. 
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1.1 Dengue disease 
 
1.1.1 History 
 
Dengue disease was first identified during World War II, but Dengue-like 
disease had been previously described in the ancient Eastern hemisphere. The well-
described Dengue symptoms were reported in the Philadelphia outbreak of 1780 
(Halstead, 2008). Dengue disease has been documented in all continents except 
Antarctica. It is mostly found in tropical and subtropical areas, but rarely reported in 
Africa (Halstead, 1980). It is possible that black Africans are genetically resistant and 
rarely express severe disease, even though a high prevalence of antibodies has been 
found (Halstead et al., 2001). 
 
In the 1900s, the first vector, Aedes aegypti, was identified. Aedes agypti and 
Aedes albopictus are urban mosquitoes carrying Dengue viruses that readily enter into 
the urban cycle and transmit virus to humans (Simmons et al., 2012). These 
mosquitoes poorly transmit sylvatic viruses, suggesting that zoonotic viruses do not 
readily enter into the human community (Moncayo AC, 2004). By contrast, wild 
mosquitoes (e.g. Aedes leutocephalus and Aedes furcifer) probably carry urban virus 
(Diallo et al., 2005). As yet, urban virus has not been isolated from infected sub-
primates in Africa (Halstead, 2008). 
 
Dengue virus was isolated in a laboratory in 1943-1944 (Gubler, 2002). 
Inoculation of virus known to be harmful to humans does not produce infection in 
several animals, including chickens, guinea pigs, rabbits, hamsters, rats, but does 
infect primates (Halstead, 2008). Infection of primates may be asymptomatic but with 
viremia occurring at levels sufficient to infect mosquitoes.  
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1.1.2 Infectious agents 
 
Classification: 
 
Dengue virus belongs to the Flaviviridae family within the Flavivirus genus 
(Flavi= yellow). Serological relationships between flaviviruses have been determined 
using antibodies associated with hemagglutination-inhibition (HAI) and neutralization 
(WHO, 1997). Complement fixation activity has also been associated with the viral 
NS1 protein (Muller and Young, 2013). Dengue serogroups are composed of 4 
serotypes (Den1-4) and nucleotide sequencing has revealed that NS3 and NS5 
proteins are highly conserved between Dengue viruses, suggesting a genetic 
relationship (Perera and Kuhn, 2008). 
 
Virion structure and morphology: 
 
The Dengue virion is composed of three structural proteins: the smallest 
protein, capsid (C), which covers the viral genome, the envelope (E) protein and the 
membrane (M) protein (Perera and Kuhn, 2008). Two types of particles are 
recognized as 1) mature extracellular virion with M protein and 2) immature 
intracellular virion containing precursor M (prM), which is proteolytically cleaved 
during the process of maturation to yield M protein. However, partially mature virions 
have also been detected in the extracellular environment.  
 
 Virus particles are spherical with a lipid envelope derived from the host cell 
membrane. Carbohydrate, which comprises about 10% of the virion, presents as 
glycolipids and glycoproteins. The virus particle is about 50 nM in diameter in the 
mature particle and 60 nm in the immature form, according to the different 
arrangement of PrM/E heterodimers (Perera and Kuhn, 2008). In the immature virion, 
E and prM proteins form 60 trimeric spikes protruding outward from the virion 
surface. During the maturation process, Pr is cleaved from prM under acidic 
conditions (pH 5.8-6.0) in the trans-golgi network, generating the smooth mature 
particle with 90 homodimers of E proteins (Figure1.1) ((Perera and Kuhn, 2008).  
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Figure 1.1: Structure of Dengue virus (Perera and Kuhn, 2008): a) A 60 prM-E 
trimeric form of the immature Dengue virus generates a spiky virion in the 
endoplasmic reticulum (ER) at neutral pH. B) The prM-E is dissociated and changed 
to 90 dimers that lie flat under acidic conditions in the trans-golgi network (TGN). 
This conformational change can be reversible upon raising the pH. C) The pr protein 
is cleaved by the host serine protease Furin, in the TGN and forms a ‘cap’ on the 
homodimers. D) The mature virion is secreted into the extracellular environment, 
releasing pr proteins from the surface. 
  
The genome is single-stranded, positive-sense RNA about 11 kbp, including a 
5’type I cap (m7 Gppp), and a 3’ terminus lacking a poly-A tail (Halstead, 2008). It 
contains a single open reading frame encoding 10 proteins: 3 structural proteins (C, 
prM and E) and 7 non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and 
NS5) (Figure 1.2). This single polyprotein is subsequently cleaved by host and viral 
enzymes.  
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Figure 1.2: Dengue viral genome (Whitehead et al., 2007) 
 
 
Proteins encoded by the virus: 
 
Structural proteins 
 
 Capsid protein (C) is about 113 amino acids (aa) with two highly basic 
domains at the N and C termini. It is found in the nucleus, nucleoli and cytoplasm of 
infected cells. Capsid is important in assembly of the virion and it also interacts with 
ribonucleoprotein suggesting a role in viral replication (Halstead, 2008). 
 
 Matrix protein (M) has 2 forms depending on the maturity of the virus: 
immature PrM, and mature M protein. Co-synthesis of prM and E proteins is essential 
for protein folding, assembly of E protein and fusion of the mature virion (Halstead, 
2008). Immature virus has been reported to be more acid resistant than the mature 
form, which is important for transporting the virion to the cell surface. PrM contains 6 
cysteine residues that form disulfide bridges. During virus release, prM is cleaved by 
Furin within the trans-Golgi network, generating M protein (Perera and Kuhn, 2008). 
However, some immature virions, containing prM/E heterodimer have been found in 
the extracellular environment. 
 
 Envelope protein (E) (495aa) is important in virus attachment to cells and 
fusion to the membrane. It is also a major target for neutralizing antibodies 
(Whitehead et al., 2007). By crystallization, 3 domains of the E protein have been 
identified: domains I, II, and III (Rothman, 2011).  
 
 
 27 
Non-structural proteins 
 
NS1 protein is a glycosylated protein that forms dimers in the endoplasmic 
reticulum (ER). At the cell membrane, NS1 is still found in its dimeric form; however 
in the extracellular environment, NS1 (soluble NS1; sNS1) appears to be a hexameric 
form of three dimeric subunits (Muller and Young, 2013). Circulating sNS1 can bind 
to the surface of both infected and uninfected cells via interaction with 
glycosaminoglycans (GAGs) (Muller and Young, 2013, Avirutnan et al., 2007). The 
sNS1 is able to activate complement directly or by binding to anti-NS1 antibodies 
(Avirutnan et al., 2006). Viewed by immunolocalization, intracellular NS1 is found 
with a double stranded replicative form, suggesting an involvement in viral replication 
during the early stage of infection (Muller and Young, 2013).   
 
 NS3 protein is a viral multifunctional protease, whose function involves 
cleavage of the viral polyprotein as well as playing a role in viral replication (Perera 
and Kuhn, 2008). NS3 does not function individually, but requires the presence of 
NS2B for efficient activity (Perera and Kuhn, 2008). 
 
 NS5 protein is the largest and the most conserved sequence between Dengue 
viruses (67% sequence identity) (Perera and Kuhn, 2008). It has two activities; the C 
terminus encodes the viral RNA-dependent RNA polymerase (RdRp), while the N 
terminus contains a methyltransferase motif, suggesting a role in viral replication 
(Perera and Kuhn, 2008). 
 
 Other NS proteins (NS2A, NS2B, NS4a, and NS4b) have been identified in 
close association with other molecules to form a viral replicating complex, playing a 
role in viral replication. 
 
1.1.3 Replication strategy  
 
Dengue virus attaches to receptors on the surface of target cells via receptor-
mediated endocytosis and the virus fuses with a vesicle membrane in a pH-dependent 
manner, followed by uncoating of the viral genomic complex. Several cellular 
receptors specific to viral binding have been identified. The presence of 
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glycosaminoglycans (GAGs), especially heparan sulfate, is important for viral binding 
in vitro (Germi et al., 2002). However, this attachment is just an initial step since 
other receptors are required for binding and entry. For example, heat-shock protein 70 
(HSP70), and HSP90 are potential receptors on monocytes and macrophages (Reyes-
Del Valle et al., 2005). An important receptor on immature dendritic cells is DC-
SIGN (Dendritic Cell-Specific Intracellular adhesion molecule-3-Grabbing Non-
integrin; CD209), which is able to bind high mannose oligosaccharides found on the 
envelope protein of Dengue virus (Tassaneetrithep et al., 2003). In addition, virion-
antibody complexes can bind to the Fc receptor or complement receptor on the surface 
of some immune cells, such as monocytes and macrophages (Cardosa et al., 1983, 
Nielsen, 2009). This antibody-mediated infection is specifically called “antibody 
dependent enhancement” (ADE) and it is believed to contribute to the development of 
severe Dengue hemorrhagic fever (DHF) (Halstead, 2003). After uncoating, viral 
RNA is translated into a single polyprotein, which is then cleaved by proteases to 
produce structural and non-structural proteins. With the host machinery and the viral 
proteins, replication occurs. Assembly of the virus takes place at the intracellular 
membrane. Capsid protein associates with the viral genome at the ER membrane, 
while viral prM and E proteins move to the ER and Golgi apparatus to be modified by 
glycosylation. The virion is subsequently transported through exocytic vesicles, where 
prM protein is cleaved by Furin to form mature virus prior to release. The process of 
replication is summarized in Figure 1.3. 
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Figure 1.3: Dengue replication cycle (Mukhopadhyay et al., 2005). 
 
1.1.4 Clinical features of Dengue disease 
 
 Dengue infection has a broad spectrum of clinical manifestation. Most patients 
infected with Dengue show few signs of infection and recover without a severe 
clinical presentation. Nevertheless, a small percentage will present with clinical 
symptoms and progress to severe illness with plasma leakage. Despite the small 
proportion who develop severe disease, Dengue infection is a life-threatening disease 
especially in children and the number of infected individuals tends to increase every 
year.  
 
The course of infection: 
 
 Dengue disease is a systemic infection and the time course is largely divided 
into the febrile, critical, and recovery phases (Figure 1.4). 
 
 30 
Febrile phase; lasts for 2-7 days. Patients typically have a high fever (≥ 
38.5ºC) accompanied by headache, myalgia, and arthralgia. The liver is often 
enlarged after a few days of fever. The total white blood cell (WBC) count 
progressively decreases. The symptoms at the early stage are difficult to discriminate 
from other febrile illnesses (OFIs), and also are indistinguishable between mild and 
severe Dengue. 
 
Critical phase; (defervescense); usually occurs on day 3-7 of illness. At this 
period, the fever drops to 37.5-38 ºC. Increases in haematocrit and vascular 
permeability, together with a progressive decline in WBC count and platelet count 
may occur. Patients with a high vascular permeability may develop plasma leakage. 
Pleural effusion and shock may be detectable depending on the degree of leakage. 
Following a long period of shock, organ impairment and metabolic acidosis may 
present and contribute to severe hemorrhage. 
 
 Recovery phase; occurs 24-48 hours after the critical period. General well-
being gradually returns to normal. The WBC count starts to increase whereas the 
platelet count recovers later. 
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Figure 1.4: Course of Dengue infection (Organization, 2009). 
 
 
Classification of Dengue severity: 
 
 The clinical features of Dengue disease are classified based on its severity into 
three categories: undifferentiated fever, Dengue fever (DF) and Dengue hemorrhagic 
fever (DHF) (Organization, 2009). DHF can be further divided into 4 severity grades. 
DHF grade III and IV is also named Dengue shock syndrome (DSS). Even though 
there have been many reports of difficulties in the use of this classification, it is 
widely used at the present time (Simmons et al., 2012). 
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Dengue Fever (DF)  
 
The clinical features of DF are dependent on the age of infected patients. 
Infants and young children may have undifferentiated fever with maculopapular rash. 
Older children and adults may present with fever, headache, muscle/joint/bone pains, 
rash, nausea and vomiting. Leucopenia is usually detected. Hemorrhage is 
uncommon. 
 
Dengue hemorrhagic fever (DHF) 
 
The major patho-physiological change that determines DHF is plasma leakage. 
Thrombocytopenia, hemoconcentration, and coagulation abnormality generally 
present in DHF grade I and II. When accompanied by hypotension, it is designated as 
DHF grade III, and IV or DSS. Complications in DSS may include pleural effusions, 
liver dysfunction, shock, and severe bleeding. The spectrum of DHF is shown in 
Figure 1.5. 
 
 
 
 
Figure 1.5: The spectrum of DHF (WHO, 1997). 
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Type of Infection: 
 
 There are two types of Dengue infection: primary and secondary infection. 
Primary infection is defined as the first infection with a slow and low titer of antibody 
response. Between days 3 and 5 after the onset of infection, seroconversion from 
negative to positive IgM anti-Dengue antibody together with a decline in viremia is 
detectable. IgG titers are low at the end of the first week and slowly increase. The 
secondary infection is characterized by re-infection with Dengue virus which can be 
either a homologous or heterologous serotype. The antibody titers are extremely high 
and may cross-react with different Dengue serotypes as well as other flaviviruses. IgG 
antibody is detectable during the acute phase and may rise after two weeks of 
infection. The peak IgM titer in secondary infection is usually lower than that in 
primary infection.  
 
Lab diagnostic tests: 
 
 A lab diagnostic test for Dengue infection is essential in order that appropriate 
treatments may be administered. The ideal test should be cheap, sensitive (few false-
negatives), specific (few false-positives), rapid, stable at room temperature, easy to 
use, machine-less, as well as delivered to those who need it (Blacksell, 2012). 
 
So far, lab diagnostic tests to confirm Dengue infection include virus isolation, 
detection of viral nucleic acid (RNA) and viral antigens as well as anti-Dengue 
antibodies (Simmons et al., 2012). During the early stage of infection (within 5 days 
of initial onset), virus and viral products may be detected in plasma, serum or tissues. 
Virus isolation is a very effective technique to confirm the disease; however, this 
technique is laborious, expensive and usually takes several days (Peeling et al., 2010). 
Alternatively, detection of viral nucleic acid is a reliable test and only takes about 2 
days to get the results; however, this method still requires expensive machines and 
reagents (Peeling et al., 2010). NS1 antigen ELISA is promising since it can be 
detected within one day. Sensitivity of NS1 detection can exceed 90% in persons with 
primary infection during febrile phase, and NS1 antigen may be detected after fever 
for several days (Simmons et al., 2012). Still, the sensitivity and the accuracy are 
lower in the secondary infection, probably due to the interference of the serological 
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response to previous infection (Ty Hang et al., 2009, Tricou et al., 2010, Felix et al., 
2012). NS1 detection may become more powerful if the test is used in combination 
with serological methods (Blacksell, 2012).  
 
 At the end of the acute phase, when viremia and viral products are 
undetectable, serological tests detecting IgM and IgG levels become meaningful. IgM 
can be detected in the early days (4 days after a fever). Primary and secondary 
infection can also be determined by this IgM/IgG capture ELISA (Simmons et al., 
2012). IgM titer in the primary infection is higher than that in the secondary infection. 
In contrast, IgG titer in the secondary infection is very high. However, recent 
vaccination/infection of antigenically-related flaviviruses such as Japanese 
encephalitis virus can interfere with the diagnosis (Simmons et al., 2012).  The 
diagnostic tests for Dengue infection are depicted in Figure 1.6.  
 
 
 
Figure 1.6: Diagnostic tests for Dengue infection (Peeling et al., 2010).  
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1.1.5 Immune responses to Dengue infection 
 
 Elimination of viral infection requires both innate and adaptive immune 
responses. Innate immunity refers to non-specific responses and does not require 
previous antigenic exposure. This develops rapidly after infection. It comprises non-
specific barriers including skin, phagocytic cells, natural killer (NK) cells, acute phase 
proteins such as complement factors, and cytokines. In Dengue infection, increases in 
complement activation, NK cell activation, and inflammatory cytokines have been 
described. Adaptive immunity refers to the response to the previous antigenic 
exposure. This system mainly refers to T and B lymphocytes. In contrast to the innate 
immune response, the adaptive immune response develops slowly, but more 
specifically, and effectively. Activation of T cells and B cells has been demonstrated 
in Dengue infection. However, these observations only represent the immune 
response against infection and do not provide insight about protective immunity.  
 
  
Innate Immunity:  
 
Soluble factors 
 
 Interferon 
The interferon-dependent innate immune response is necessary for protection 
against dengue infection. Type I IFNs (IFN-α/β) are produced promptly, within an 
hour, after infection and induce antiviral activity. In vitro studies have revealed that 
Dengue infection stimulates interferon secretion (Kurane et al., 1992, Kurane and 
Ennis, 1988) and pretreatment with inteferon is able to control Dengue infection 
(Diamond et al., 2000). IFN-receptor knock-out mice are also susceptible to Dengue 
infection (Shresta et al., 2004).  The mechanism by which interferon blocks Dengue 
infection is thought to involve inhibition of the RNA replication step (Diamond and 
Harris, 2001). In vivo studies have revealed that these IFNs are highly activated in 
uncomplicated cases, yet they are less effective in severe disease [reviewed in 
(Espada-Murao and Morita, 2011)]. The underlying mechanisms that suppress IFN 
activation are not fully understood. One explanation is that the virus has an ability to 
counteract these molecules. NS2A and NS4B may be key factors that block IFN 
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signaling pathways (Jones et al., 2005). A restricted IFN response therefore, could 
enhance infection associated with severe disease. In addition, an altered profile of 
IFN-producing cells may account for a differential immune response. For example, 
levels of plasmacytoid dendritic cells, the potent IFN-α producing cells, are decreased 
in DHF compared to DF cases (Pichyangkul et al., 2003).   
 
Type II interferon (IFN-γ) is mainly produced by T cells and NK cells. The 
IFN-γ receptors are highly expressed on monocytes and macrophages, as well as 
endothelial cells. IFN- γ production by Dengue virus-specific T lymphocytes has been 
revealed in vitro (Kurane et al., 1989a, Kurane et al., 1989b). The effect of IFN- γ on 
Dengue infection in vitro remains obscure since both stimulatory and inhibitory 
consequences have been reported. Pre-treatment of IFN-γ can inhibit infection in 
HepG2 cells, foreskin fibroblasts, and monocytes (Diamond et al., 2000, Sittisombut 
et al., 1995). On the other hand, IFN-γ can also induce infection in mononuclear cells 
in the presence of enhancing antibody (Diamond et al., 2000, Kontny et al., 1988). In 
addition the relationship between IFN-γ response and disease severity is not clear 
(Srikiatkhachorn and Green, 2010). Some publications have shown high levels of 
IFN-γ in DHF cases, but not in others [reviewed in (Espada-Murao and Morita, 
2011)].  Inconsistency may be due to experimental design, time to sample collection 
and population sampling (Srikiatkhachorn and Green, 2010). However, time course 
studies show that IFN- γ level peaks at an early time point, and this increased level 
has been observed in DHF cases with plasma leakage (Libraty et al., 2002).    
 
 Cytokines 
The cytokine storm theory has been proposed to contribute to Dengue severity. 
Massive production of cytokines is believed to be a product of T cell activation. 
However, this does not explain cytokine production in infants with primary infection, 
indicating that other determinants may be involved in this process (Nguyen et al., 
2004). It has been hypothesized that maternal antibodies enhance infection and these 
may be responsible for the increased cytokine response in this situation. In vitro 
studies have also shown that Dengue infected cells such as keratinocytes, dendritic 
cells and endothelial cells can release cytokines (Surasombatpattana et al., 2011, 
Dejnirattisai et al., 2008, Dalrymple and Mackow, 2012, Avirutnan et al., 1998). 
Variations in viral load also have an influence on cytokine induction. For example, 
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expression of IL8, MIP-1α, RANTES by monocytes could be up-regulated by a small 
amount of virus, whereas production of TNF-α and IL1β requires higher viral loads 
(Chen and Wang, 2002).  
 
Complement system 
 
Complement appears to have both protective and pathogenic roles in viral 
infection. On one hand, complement can attack infected cells, inhibiting viral 
production. C1q, the complement component is able to bind avidly with IgG, 
restricting “antibody-dependent enhancement” (ADE) in in vitro studies and in mice 
(Mehlhop et al., 2007, Yamanaka et al., 2008). Mannan binding lectin (MBL) also 
neutralizes Dengue infection through complement activation-dependent and 
independent pathways (Avirutnan et al., 2011a). An experiment in immunodeficient 
mice has confirmed that complement is able to suppress viral infection since C3-/- 
mice are more susceptible to West Nile virus infection, another virus in the 
Flaviviridae family (Mehlhop et al., 2005). 
 
 Excessive complement activation, on the other hand, could exacerbate the 
disease. High plasma levels of sC5b9 complex, C3a and C5a are associated with 
severe disease (Nascimento et al., 2009, Avirutnan et al., 2006, Bokisch et al., 1973). 
Moreover, in vitro studies have shown that IgM-virus-complement complexes could 
enhance viral infection in macrophages through complement receptor 3 (CR3) 
(Cardosa et al., 1983). NS1 is also able to activate the complement, exacerbating the 
disease (Muller and Young, 2013).  
 
Natural Killer (NK) cells 
 
NK cells are capable of killing virus-infected cells rapidly within an hour. 
Lysis of target cells by NK cells is not MHC-restricted and does not require the 
specific recognition of viral products. NK cells recognize target cells via a variety of 
receptors and lyse these cells by release of cytotoxic granules. The role of NK cells in 
Dengue infection is not well understood. Activation of NK cells has been reported 
during acute Dengue infection and is more profound in DHF (Green et al., 1999a). 
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Adaptive immunity: 
 
Antibody responses 
 
 Interpretation of antibody responses to Dengue infection needs knowledge of 
previous exposure. Pre-existing antibodies from previous infection or pre-
immunization with flaviviruses are commonly detected. In primary infection, IgM 
antibodies increase after the decline of viremia and have the highest activity in a 
primary infection, whereas IgG antibodies exceed IgM production during secondary 
infection (Peeling et al., 2010). The role of antibody in Dengue infections have been 
demonstrated in several mechanisms such as neutralization, antibody-dependent 
enhancement (ADE), antibody-dependent complement activation, opsonization, and 
antibody-dependent cellular cytotoxicity (ADCC). In neutralization, antibodies 
interact with the viral structural E proteins, inhibiting viral entry and uncoating of the 
viral genome (Halstead, 2003). Neutralizing IgG antibodies persist for many years and 
are able to protect against re-infection with the same serotype. Non neutralizing 
antibodies, on the other hand, may be responsible for immune enhancement of 
Dengue infection (ADE). In addition, antibodies specific to the NS1 protein could 
bind the NS1 on the cell surface, triggering complement lysis (Muller and Young, 
2013). Phagocytic cells, such as macrophages, can opsonize and kill virions marked 
by antibodies. Antibodies can also attach to antigens on the cell surface, followed by 
the recruitment of Fc-receptor bearing cells to kill these cells by means of ADCC. The 
mechanisms of neutralization, ADE, and antibody-dependent complement lysis are 
summarized in Figure 1.7.  
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Figure 1.7: Antibody responses to Dengue infection [modified from (Rothman, 
2011)].  
 
 
T lymphocytes 
 
Dengue-specific T cells target Dengue-infected cells and subsequently 
proliferate, and produce cytokines. T cell epitopes are found throughout the Dengue 
polyprotein, but most identified epitopes reside on the NS3 protein. In primary 
infection, T cell responses to the infecting serotype are characterized, even though 
some cross-reactive T cell responses are also identified (Kurane et al., 1989a, Kurane 
et al., 2011). These cross-reactive T cell responses may enhance the severity of the 
disease. An experiment to determine the heterogeneity among virus-specific T cells 
has found that most T cells produce TNF-α, which may lead to an increased risk of 
DHF during secondary infection (Rothman, 2011).  Recognition of the heterologous 
serotype may stimulate different degrees of T cell activation. Recently, it has been 
demonstrated that Dengue-specific memory T cells in secondary infection show low 
affinity to the current virus, but higher affinity to others, which may be strains from 
previous infections (Mongkolsapaya et al., 2003). This partial recognition of infecting 
virus by T cells may reduce viral elimination, and profound T cell activation may alter 
the cytokine profiles, increasing immunopathology. 
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1.1.6 Pathogenesis of the disease  
 
To better understand the pathogenesis of Dengue infection, several models 
have been developed. The immune response against Dengue infection has been 
generally studied in clinical experiments due to the lack of appropriate animal models.  
The interaction between innate and adaptive immunity has also been studied in vitro, 
but this does not totally reflect the complex interactions between the different arms of 
the immune systems. Infection of laboratory strains of Dengue virus into immortal 
cell lines may not fully explain the in vivo mechanism. Overall, interpretation of the 
results has to be considered a weakness of each model. 
  
Epidemiological and clinical observations: 
 
 In the clinical studies of Dengue infection, many observations have been 
drawn. Primary infection with any one of four serotypes generates lifelong antibodies 
to the homologous serotype. Almost all cases of primary infection show either no sign 
of symptoms or mild disease, whereas a small percentage are severe cases, most of 
which are seen in infants (Halstead, 2003). It has been hypothesized that maternal 
anti-Dengue antibodies are transferred to those infants and these antibodies may not 
neutralize virus but enhance infection via ADE (Halstead, 2003). Secondary infection 
with heterologous serotypes is more complex than primary infection since nearly all 
cases re-infected with a different serotype show severe DHF. In addition, plasma 
leakage, a hallmark of DHF, occurs during defervescence (when viremia is declining), 
suggesting that this mechanism is probably mediated by the host immune response 
(Simmons et al., 2012). 
 
Mechanisms of Dengue disease:   
 
 The mechanisms that determine Dengue severity are not fully understood but 
are likely to be a combination of multifactorial processes (Figure 1.8). After Dengue 
virus is injected into the dermis, immature Langerhans cells (LCs) and keratinocytes 
are infected. LCs migrate from the site of infection and subsequently spread through 
the lymphatic system. Viral antigens have been isolated in many cells such as DCs, 
monocytes, and macrophages (Martina et al., 2009, Noisakran et al., 2010). In the 
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post-mortem tissues, viral antigens have also been detected in endothelial cells in 
several organs, particularly in the liver (Martina et al., 2009). The viral replication in 
these cells could reflect the viral load in the blood, which is correlated to the disease 
severity. In addition to high viremia, thrombocytopenia and platelet dysfunction may 
account for the fragile capillary, resulting in hemorrhage (Noisakran and Perng, 
2008). Infection also activates immune responses, which may enhance rather than 
reduce the disease. NS1 proteins can activate the complement pathway, leading to 
vascular leakage and inflammation (Avirutnan et al., 2006). In secondary infection, 
pre-existing antibodies can enhance infection via ADE (Halstead, 2003). Anti-NS1 
antibodies also act as auto-antibodies, resulting in release of inflammatory cytokines 
such as IL6 and IL8 leading to inflammation and/or apoptosis (Martina et al., 2009). 
Over-produced, low-avidity, cross-reactive T cells might delay viral clearance, and 
produce massive amounts of cytokines (Rothman, 2011). Other soluble mediators can 
also change the function of endothelial cells, leading to plasma leakage (Martina et 
al., 2009).   
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Figure 1.8: Proposed mechanisms of Dengue infection (Martina et al., 2009). 
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Determinants of susceptibility to Dengue infection and severity: 
 
Viral determinants 
 
Different viral genotypes may determine Dengue severity. Well established 
examples have been reported in the Western hemisphere. After Dengue 1 was 
introduced into the Caribbean region in 1977, an introduction of Asian genotype 
Dengue 2 in Cuba in 1981 was accompanied with the occurrence of DHF; however, 
similar introductions of Dengue 1 in 1990 and an American strain Dengue 2 in 1995 
in Peru did not result in DHF (Halstead, 2003). Sequence analysis of these two strains 
of Dengue 2 revealed that six different amino acids were found, contributing to 
structural changes and differences in virulence (Halstead, 2003).   
 
Host determinants 
 
1. Genetic factors 
 
 There are some ethnic groups that show tendency to develop DHF while 
others may have mild DF. In 1981, the DHF/DSS risk ratio in whites: blacks: mixed 
in Cuba was reported as 5.5:1:1.8 (Coffey et al., 2009). Similar data from 1997 and 
2001 Cuban Dengue epidemics were observed and confirmed the 1981 data that 
blacks are more resistant to develop DHF than whites (de la et al., 2007). However, 
interpretation of these findings must be done with caution since other factors, such as 
viral genotype and vector transmission, could also be determinants of disease 
outcome. 
 
 In addition to ethnicity, several gene polymorphisms have been shown to 
influence susceptibility to Dengue infection. Human Leukocyte Antigens (HLAs) 
show great variability and some of these variations are associated with Dengue 
severity.  For example, HLA-A2 and HLA*0207 correlate with susceptibility to 
infection in the Thai population, whereas HLA-A24 and HLA*0203 are protective 
(Wagenaar et al., 2004). Association between Dengue susceptibility and 
polymorphisms have also been characterized in several other genes such as Fc 
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receptors, Vitamin D receptor, IL4, IL1-RA  (Loke et al., 2002), TNF-α (Vejbaesya et 
al., 2009), and  DC-SIGN(Sakuntabhai et al., 2005, Wang et al., 2011).  
 
2. Immunological factors 
 
The immune status in the Dengue-infected individuals may develop in two 
directions—protective or pathogenetic. In most instances, immunopathogenesis 
occurs in secondary infection with a heterologous serotype. Several mechanisms in 
controlling the disease severity have been proposed. 
 
 Humoral immune response 
a. Pre-existing antibodies 
Immune enhancement of Dengue infection was first described in the 1970s. 
Increased levels of viremia were observed in rhesus monkeys during secondary 
infection as compared to the primary infection. It was not known how the immune 
system enhanced infection until 1977, when it was discovered that antibodies were the 
mediators (Halstead, 2008). Pre-existing heterotypic antibodies are unsuccessful at 
neutralizing the currently infecting virus, but enhance viral entry into Fc receptor-
bearing cells through the process of ADE. In humans, IgG1 and IgG3 subclasses are 
responsible for ADE and peripheral blood mononuclear cells (PBMCs) have Fc 
receptors on their surfaces. It is well-established that ADE occurs when antibodies are 
directed against viral epitopes that are not involved in the viral attachment and 
uncoating process. However, a great number of studies have also demonstrated that 
homotypic neutralizing antibodies are able to produce ADE at a dilution above the 
neutralization level (sub-neutralizing concentration) (Halstead, 2003). Recently, it has 
been discovered that anti-prM antibodies fail to neutralize the virus even at high titers 
(Dejnirattisai et al., 2010). The prM proteins, in general, are cleaved during the 
process of maturation, implying that anti-prM antibodies are unable to bind most viral 
particles. Cleavage of prM; however, is not complete, contributing to the release of 
partially mature virions which contain some prM molecules on their surfaces. These 
prM components are enough for anti-prM antibodies to recognize and drive ADE 
(Dejnirattisai et al., 2010).  
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Dengue-antibody complexes not only enhance viral infection via ADE, but 
also suppress IFN-mediated antiviral responses. Dengue infection of the human 
monocytic cell line THP-1 via ADE can disrupt interferon-related proteins, the 
retinoic acid inducible gene I (RIG-I) and the melanoma differentiation associated 
gene 5 (MDA-5), as well as enhance the expression of anti-inflammatory cytokines 
such as IL6 and IL10 (Ubol et al., 2010, Chareonsirisuthigul et al., 2007).  
 
Although ADE can increase viral titer, there are some questions that remain 
unknown. First, DHF can appear in primary infection, albeit at a low percentage, in 
older children and adults. Second, although high viremia is associated with Dengue 
severity, viral titer at the time of leakage is well below the peak level. In addition, 
there are some patients who have high viremia but do not develop plasma leakage. 
These findings suggest that other mechanisms may be at work in these cases 
[reviewed in (Rothman, 2011)]. 
 
b. Autoantibodies 
Anti-NS1 antibodies are able to cross-react with several host cell components 
including blood clotting factors, integrin/adhesion molecules, extracellular matrix 
(ECM), etc (Muller and Young, 2013). Not only are anti NS1 antibodies cross-
reactive to several tissues in mice (Nielsen, 2009), these antibodies can also bind to 
the surface of human platelets and endothelial cells and subsequently induce 
inflammatory cytokines such as IL8, IL6 and MCP-1 as well as ICAM-1 expression, 
followed by an increased adhesion of PBMCs to endothelial cells (Muller and Young, 
Lin et al., 2005). Moreover, cells exposed to anti-NS1 antibodies may undergo 
‘programmed cell death’ since DNA fragmentation and phosphatidylserine exposed 
on the cell surface are found in these cells (Lin et al., 2002). These findings suggest a 
possible role for these antibodies in the endothelial dysfunction and vascular damage 
that is an underlying mechanism of DHF/DSS. 
 
 Cross-reactive T cell responses 
 Cross reactive T cells have been proposed to contribute to Dengue severity 
during secondary infection. Generally, the efficiency to eradicate infected cells 
depends on the avidity of activated T cells. Expansion of CD8+ T cells with low 
avidity to the currently infecting virus but high avidity to a presumed previous 
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serotype has been demonstrated (Mongkolsapaya et al., 2003). This memory T cell 
repertoire may out-compete the naïve T cells contributing to incomplete viral 
elimination and produce high levels of pro-inflammatory cytokines such as TNF-α, 
leading to apoptosis and inflammation (Mongkolsapaya et al., 2003).   
 
 Complement activation  
Imbalance of complement activation has been observed in Dengue disease. For 
example, high levels of C3a and C5a have been found to correlate with Dengue 
severity (Nascimento et al., 2009). These anaphylatoxins are known to have an effect 
on vasodilatation and promote degranulation of polymorphonuclear cells such as 
neutrophils. Mediators released from the degranulation can induce local inflammation 
and systemic disturbance, if generated in a high concentration.  In addition, there is a 
correlation between increased disease severity and an imbalance in the levels of 
complement factor H (CFH) leading to abnormal regulation of the alternative 
complement pathway (Nascimento et al., 2009). The association between 
dysregulation of complement components and Dengue disease is summarized in table 
1.1.  
 
During secondary infection, anti-NS1 antibodies are able to bind NS1 proteins, 
followed by formation of an immune complex which activates complement and 
generates C3a and C5a (Avirutnan et al., 2006). In the absence of anti-NS1 antibodies, 
NS1 proteins can interact with Clusterin, a complement regulator, increasing the 
formation of the C5b9 complex on the cell surface, followed by cell lysis (Kurosu et 
al., 2007). This C5b9 complex is correlated with disease severity (Avirutnan et al., 
2006). Soluble NS1 has also been shown to function in immune evasion since it can 
inhibit the classical and lectin pathways by interacting with C1s and C4BP, leading to 
a decrease in the formation of the C5b9 complex on infected cells and an increase in 
viral replication (Avirutnan et al., 2010, Avirutnan et al., 2011b). 
 
 Soluble mediators 
It is believed that high viral loads and activation of low-avidity cross-reactive 
T cells are responsible for the cytokine storm as well as secretion of several 
mediators, leading to increased plasma leakage. Differential viral replication and T 
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cell activation may account for different cytokine profiles and different vascular 
permeability patterns. The soluble mediators, either alone or in combination, are able 
to deregulate the function of immune and non-immune cells. For example, Dengue 
virus is able to increase the cell surface expression of vascular endothelial growth 
factor receptors (VEGFR) on endothelial cells, but suppresses expression of the 
soluble form (sVEGFR2) in vitro (Srikiatkhachorn et al., 2007). Up-regulation of 
surface VEGFR promotes binding of VEGF on endothelial cells, contributing to 
changes in endothelial morphology and increases in cell permeability 
(Srikiatkhachorn et al., 2007). In clinical observation, disease severity is correlated 
with an increased plasma level of vascular VEGF-A together with a decline in 
sVEGFR2 and the VEGF-sVEGFR2 complex (Srikiatkhachorn et al., 2007).  
  
3. Others host factors 
 
Other possible risk factors for development of DHF/DSS include sex and age. 
Retrospective studies in Vietnam have revealed that most Dengue cases admitted to 
hospital between 1996 and 2009 were males, yet females had a higher risk of 
developing DSS and death. In addition, the mortality rate was high in young children 
but declined with increasing age (Anders et al., 2011, Guzman et al., 2002). The 
underlying mechanisms for the association between these factors and disease severity 
however, remain unknown. 
 
1.1.7 The role of endothelial cells in Dengue infection 
 
 Endothelial cells are the fluid barriers of blood vessels that play an important 
role in controlling coagulation as well as the extravasation of fluids, platelets and 
blood cells.  Endothelial cells can become activated by inflammatory cytokines and 
regulate the recruitment of leukocytes to the site of inflammation by expressing cell 
adhesion molecules such as E-selectin, ICAM-1, and VCAM-1 (van Hinsbergh, 
2012). Transportation of solutes and plasma proteins across the endothelium through 
inter-endothelial junctions is generally well-orchestrated; however, external stimuli 
and inflammatory mediators can change endothelial cell function, prolonging 
permeability (Komarova and Malik, 2010).  
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In vitro experiments have shown that Dengue virus, TNF-α, or a combination 
of both can affect endothelial permeability (Dewi et al., 2004). Addition of peripheral 
blood mononuclear cells (PBMCs) to infected endothelial cells also enhances this 
phenomenon (Dewi et al., 2008). PBMCs are able to induce morphological changes in 
endothelial cells and decrease the expression of VE-cadherin (vascular endothelial 
cadherin), the adhesion molecules that maintain endothelial cell integrity. Moreover, 
Dengue infection of endothelial cells in the presence of non-neutralizing antibodies 
can activate complement (Avirutnan et al., 1998). Infected endothelial cells also 
release RANTES and IL8, which are able to recruit immune cells, particularly 
neutrophils (Avirutnan et al., 1998). Cell death was also demonstrated in the same 
study. These evidences suggest that Dengue virus might damage endothelial cell 
integrity. 
 
Although in vitro infection of endothelial cells has been demonstrated, 
infection of endothelial cells in vivo has not been elucidated. In post mortem studies, 
Dengue antigens (structural proteins) but not its genome were detected in endothelial 
cells in the liver, lung and heart without evidence of endothelial cell damage (Jessie et 
al., 2004) (Salgado et al., 2010). It is noteworthy that detection of viral antigen is not 
proof of viral replication since it might be the product of killed virus or degraded 
immune complexes (Jessie et al., 2004). Nevertheless, another study has shown that 
NS3 protein could be detected in the splenetic endothelial cells but not in other 
tissues, implying that endothelial cells in the spleen may be supportive for viral 
propagation (Balsitis et al., 2009).  In IFN-receptor deficient mice, ADE could 
enhance infection in liver sinusoidal endothelial cells and correlated to disease 
severity (Zellweger et al., 2010).  Although this finding provides an important role for 
endothelial cells in Dengue pathogenesis in mice, there is no evidence to support 
ADE-mediated infection in primary human endothelial cells in vitro (Arevalo et al., 
2009).   
 
As a whole, it is difficult to conclude if Dengue actively replicates in 
endothelial cells in vivo. Limitations in studies of human specimens, which were 
usually collected after the peak of viremia, and the lack of suitable animal models 
makes it difficult to completely understand Dengue pathogenesis.  
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1.1.8 Markers of Dengue disease  
 
Dengue infection ranges from asymptomatic infection, mild DF, to four-grade 
DHF. During the early stage of infection, the signs and symptoms are 
indistinguishable between mild and severe disease and there are no accurate indicators 
to predict the development of DHF currently. Although attempts to find the predictive 
indicators are ongoing, many markers associated with Dengue severity have been 
characterized.  
 
Clinical markers:  
 
Platelet count and haemoconcentration level 
 
 Thrombocytopenia and haematocrit are recognized in Dengue infection. A 
platelet count below 100,000 cells per cu mm, together with an increase in 
haematocrit of 20%, is a criterion to determine DHF (1997). These changes are 
usually found during day 3 to day 8 and appear to reach their peak at the 
defervescence stage. Platelet cell counts and haemoconcentration level could serve as 
monitoring indicators for disease progression. 
 
White blood cell count 
 
The white blood cell (WBC) count in DHF varies during the onset of the 
illness since leucopenia or mild leucocytosis may be present. A drop in WBC count 
due to a reduced number of neutrophils  however, is usually observed at the end of the 
febrile phase while elevated lymphocyte numbers and the presence of atypical 
lymphocytes (enlarged lymphocytes) is commonly detected before defervescence 
(1997). 
 
Liver proteins 
 
Detection of liver dysfunction is a common finding in DF but more 
pronounced in DHF. A reduction in proteins due to the loss of albumin can be 
observed. Elevated plasma levels of liver aminotransferases, which include aspartate 
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aminotransaminases (AST) and alanine aminotransaminases (ALT), are detected 
(1997). 
 
Viral load and NS1 products: 
 
High viral nucleic acid and NS1 protein levels in plasma appear to correlate 
with disease severity (Srikiatkhachorn and Green, 2010). The peak of viral titer and 
NS1 levels occurs during the early stage of febrile illness before declining during 
defervescence (first 72 hours). In primary infection, NS1 can be detected in plasma 
taken as much as 12 days after disease. Nevertheless, detection of NS1, although a 
promising marker, may be more complicated in a secondary infection when anti-NS1 
antibodies are present. Beyond 5-7 days of illness, NS1 is rarely detected [reviewed in 
(Muller and Young, 2013)]. 
 
Biological markers: 
 
Several studies have demonstrated a great number of plasma protein markers 
associated with Dengue severity. These markers are summarized below and in the 
table 1.1. However, heterogeneity in the timing of sample collections in each study 
makes it difficult to compare some observations. Interpretation of these results 
therefore, must be done with caution since Dengue disease is a time-course dependent 
illness.  
 
Complement system 
 
Abnormal levels of complement components are found in Dengue disease and 
seem to associate with the severity. For example, an increase in soluble C5b9 
complex, C3a, C4a and C5a, and MBL together with a decrease in plasma factor H 
was reported in DHF patients (Nascimento et al., 2009, Avirutnan et al., 2006).  
 
Cytokines and Chemokines 
 
In vitro studies have demonstrated that infected cells (dendritic cells, 
keratinocytes, endothelial cells etc.) can induce production of interferons, 
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proinflammatory cytokines and chemokines including TNF-α, IL8, RANTES, MIG, 
IP10, ITAC etc, depending on the cell type (Dejnirattisai et al., 2008, Avirutnan et al., 
1998, Surasombatpattana et al., 2011, Dalrymple and Mackow, 2012, Ho et al., 2001). 
This postulates that several cytokines might be released to eliminate the infection 
during the early stage of illness; however, there are some conflicting results in some 
cytokines measured in the plasma of Dengue patients. This might be due to the timing 
of sample collection. More information about the timing of these cytokine profiles is 
required.  
 
During the late stage, cellular immune responses have a greater influence on 
disease than the innate cytokines. It has been postulated that activation of cross-
reactive Dengue-specific CD8+ T cells during a secondary infection may play a role in 
the massive production of cytokines, leading to DHF (Mongkolsapaya et al., 2003). 
Infection of peripheral blood mononuclear cells (PBMC) in vitro produces Th1 
cytokines, such as IFN-γ, IL2, and IL6, in the early stages but induces Th2 cytokine 
production (IL4, IL5, and IL10) in the later stages (Chaturvedi et al., 1999).  In viral 
infection such as HIV, a shift from Th1 to Th2 tends to lead to severe pathogenesis.  
This has also been described in Dengue infection and appears to be associated with 
the severity of disease (Chaturvedi, 2009).  
 
Soluble receptors 
 
Association between soluble cellular receptors of ligands, including cytokines, 
and disease severity has been reported in several studies. Up-regulation of soluble 
receptors associated with T cell activation, such as sIL2R, sCD4, and sCD8 has been 
reported in plasma of DHF patients on day 3-4 after the onset (Kurane et al., 1991). In 
one study, sIL2R was correlated with the increase in liver enzymes (Libraty et al., 
2002). A progressive decline of sVEGFR2 (soluble vascular endothelial growth factor 
receptor 2) accompanied with a decline in sVEGFR2-VEGF complexes and a rise in 
free VEGF was correlated to DHF (Srikiatkhachorn et al., 2007). Because VEGF is 
important in vascular permeability, changes in sVEGFR2 may regulate the plasma 
leakage, a hallmark of DHF, in vivo.  Elevations in the soluble form of TNF-α 
receptors have also been reported in DHF (Libraty et al., 2002), even though there 
have been conflicting results in some studies (Wang et al., 2007, Braga et al., 2001).   
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Coagulation and Endothelial cell activation and damage 
 
Imbalance in coagulation and fibrinolytics is found in Dengue disease. In DHF 
patients, Von Willebrand factor, tissue plasminogen activator (tPA), plasminogen 
activator inhibitor-1 (PAI-1), tissue factor, and thrombomodulin were 
elevated(Sosothikul et al., 2007, Huang et al., 2001). In addition, thrombopoietin 
(TPO), which is a regulator of platelet production, was also increased in DHF patients 
and conversely correlated with the platelet counts (Matondang et al., 2004, Cardier et 
al., 2006).  
 
Activation of endothelial cells contributes to changes in permeability. 
Increased levels of soluble endothelial surface molecules (sICAM1 and sVCAM) 
have been reported in the plasma of DHF patients (Cardier et al., 2006). An 
association between Dengue severity and elevated levels of matrix metalloproteinase 
9 (MMP9), which is able to increase endothelial permeability, has been published 
(Kubelka et al., 2010). However another study showed no difference in MMP9 levels 
between DF and DHF in any stage of illness (Voraphani et al., 2010).   
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Table 1.1: Soluble factors associated with Dengue disease 
 
Soluble factors 
Stage of 
detection 
Findings References 
Complement system 
sC5b-9 Acute DHF > DF (Avirutnan et al., 2006) 
C3a C4a and C5a Acute DHF > DF (Nascimento et al., 2009) 
C1q Acute DHF = DF (Nascimento et al., 2009) 
Mannose binding lectin (MBL) Acute DHF > DF (Nascimento et al., 2009) 
Factor D Acute DHF = healthy control > DF (Nascimento et al., 2009) 
Factor H Acute DF = healthy control > DHF (Nascimento et al., 2009) 
Cytokines 
IFN-α Acute, Febrile DHF, DF > healthy control (Kurane et al., 1993) 
IFN-γ 
Not specified severe > mild (Bozza et al., 2008) 
Not specified DHF = DF (Braga et al., 2001) 
Acute Dengue > healthy control (Azeredo et al., 2001) 
Acute, Febrile DHF > healthy control; DF > healthy control (Kurane et al., 1991) 
TNF-α 
Not specified DHF, DF with hemorrhage > DF (Braga et al., 2001) 
Acute Dengue > healthy control (Azeredo et al., 2001) 
Acute, Febrile DHF3, DHF4 > DHF1, DHF2 (Hober et al., 1993) 
Macrophage inhibitory factor (MIF) Acute, Febrile 
DHF-survivors > DF; DF > healthy control 
(Chen et al., 2006) 
DHF-non survivors > DHF-survivors; DHF-non 
survivors > DF 
IL1β Not specified severe > mild (Bozza et al., 2008) 
IL2 Acute, Febrile DHF > healthy control; DF > healthy control (Kurane et al., 1991) 
IL4 Not specified severe > mild (Bozza et al., 2008) 
IL6 
Acute, Febrile 
DHF-non survivors > DF; DF > healthy control 
(Chen et al., 2006) 
DHF-non survivors > DHF-survivors 
Not specified severe > mild (Bozza et al., 2008) 
IL7 Not specified severe > mild (Bozza et al., 2008) 
IL10 
Acute, Febrile 
DHF-non survivors > DHF-survivors; DHF-non 
survivors > DF 
(Chen et al., 2006) 
Acute Dengue > healthy control 
(Azeredo et al., 2001, 
Pérez et al., 2004) 
Acute, Febrile DHF > DF; Dengue > OFI (Green et al., 1999c) 
IL12 
Acute, Febrile Dengue =  healthy control (Pérez et al., 2004) 
Acute, Febrile DHF > DF; Dengue > OFI (Green et al., 1999c) 
Acute, Febrile DF > DHF1 > DHF2 (Pacsa et al., 2000) 
IL13 Not specified severe > mild (Bozza et al., 2008) 
IL1 receptor antagonist (IL1Ra) Febrile DHF-non survivor > DHF-survivor (Suharti et al., 2003) 
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Chemokines 
CCL4 (MIP1-β) 
Not specified severe < mild (Bozza et al., 2008) 
Acute, Febrile Dengue > OFI (Becerra et al., 2009) 
CCL5 (RANTES) Acute, Febrile DF = healthy control > DHF (Pérez et al., 2004) 
CCL2 (MCP1) Not specified DSS > healthy controls (Avirutnan et al., 1998) 
CCL8 (MCP2) 
Febrile & 
Defervescence 
Dengue > OFI (Becerra et al., 2009) 
CXCL8 (IL8) 
Acute DHF3, DHF4 > DHF1, DHF2 and DF (Raghupathy et al., 1998) 
Not specified DSS > healthy controls (Avirutnan et al., 1998) 
CXCL9 (MIG) Febrile DHF > DF (Dejnirattisai et al., 2008) 
CXCL10 (IP10) 
Febrile DHF > DF (Dejnirattisai et al., 2008) 
Febrile & 
Defervescence 
Dengue > OFI (Becerra et al., 2009) 
CXCL11 (ITAC) Febrile DHF > DF (Dejnirattisai et al., 2008) 
 
Soluble receptors  
sCD4 Acute, Febrile 
DHF > DF; DHF > healthy control; DF > healthy 
control 
(Kurane et al., 1991) 
sCD8 
Acute, Febrile DHF > DF; DHF > healthy control 
Defervescence DHF > DF; Dengue > OFI (Green et al., 1999b) 
sIL2Ra 
Acute, Febrile DHF = DF > healthy control 
(Valero et al., 2008) 
Acute, Febrile DHF3 > DHF1, DHF2 
Acute, Febrile 
DHF > DF; DHF > healthy control; DF > healthy 
control 
(Kurane et al., 1991) 
Defervescence DHF > DF; Dengue > OFI (Green et al., 1999b) 
sVEGFRII 
Febrile & 
Defervescence 
DHF < DF 
(Srikiatkhachorn et al., 
2007) 
sTNFRI 
Febrile & 
Defervescence 
Dengue > OFI (Green et al., 1999b) 
sTNFRII (p75) 
Acute Dengue > healthy control (Azeredo et al., 2001) 
Febrile & 
Defervescence 
DHF > DF; Dengue > OFI (Green et al., 1999b) 
not specified DHF = DF > healthy control (Braga et al., 2001) 
Coagulation and endothelial function   
Von Willebrand factor (VWF) Febrile DHF > DF (Sosothikul et al., 2007) 
Tissue plasminogen activator (tPA) 
Acute DHF, DSS > DF; DHF, DSS > healthy control (Huang et al., 2001) 
Defervescence DHF > DF (Sosothikul et al., 2007) 
Plasminogen activator inhibitor 
Febrile & 
Defervescence 
DHF > DF (Sosothikul et al., 2007) 
Tissue factor (TF) Febrile DHF > DF (Sosothikul et al., 2007) 
Soluble thrombomodulin (sTM) 
Febrile & 
Defervescence 
DHF > DF (Sosothikul et al., 2007) 
TPO 
Thrombocytope
nia phase 
DHF > DF (Matondang et al., 2004) 
Acute, Febrile DHF > DF; DF > healthy control (Cardier et al., 2006) 
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MMP-9 
Not specified severe > mild = control (Kubelka et al., 2010) 
Febrile, and 
Toxic stage 
control > Dengue (Voraphani et al., 2010) 
ADAMTS13 Febrile DHF < DF (Sosothikul et al., 2007) 
VEGF 
Defervescence DHF > DF 
(Srikiatkhachorn et al., 
2007) 
Acute, Febrile DHF > DF = OFI (Tseng et al., 2005) 
sICAM1 Acute, Febrile DHF = DF > healthy control (Valero et al., 2008) 
sVCAM Acute, Febrile DHF3, DHF4 > DHF1, DHF2, DF (Koraka et al., 2004) 
Others 
GMCSF Not specified severe > mild (Bozza et al., 2008) 
TRAIL Acute, Febrile Dengue > OFI (Becerra et al., 2009) 
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1.1.9 Treatment, vaccine development, prevention and control 
 
 Treatment of disease 
 
 So far, there is no specific treatment for Dengue disease. Supportive care and 
fluid replacement are suggested. Blood transfusion may be required if persons have 
severe bleeding. Paracetamol is sufficient for high fever. Aspirin, Ibuprofen, and other 
non-steroidal anti-inflammatory agents (NSAIDs) should be avoided .  
 
 Vaccine development 
 
 Due to an increased number of severe Dengue cases, particularly in children 
around the world, the development of an effective vaccine against all Dengue 
serotypes is urgently needed. The ideal vaccine must induce anti-Dengue antibodies to 
the level of protection against any of the four serotypes, provide life-long protection, 
require minimal booster immunization and be low cost (Whitehead et al., 2007). 
 
 Impediments to the development of a Dengue vaccine are the immune 
responses that enhance Dengue infection and a lack of animal models. Pre-existing, 
non-neutralizing heterotypic antibodies and cross-reactive T cell responses increase 
the risk of developing DHF/DSS, and these features must be considered in a vaccine 
design. Animal models have been limited to develop immunogenicity in mice and 
monkeys. Immunocompromized models have been useful but only in some aspects of 
pathogenesis (Mathew and Rothman, 2008). So far, a licensed vaccine is not 
available. Current vaccines are mainly focused on lived-attenuated virus vaccines. 
The most promising candidate is a live-attenuated tetravalent vaccine based on a 
chimeric yellow fever-Dengue virus (CYD-TDV) (Guy et al., 2010). This vaccine is 
composed of four vaccines using a backbone of yellow fever vaccine 17D (YFV 17D) 
expressing E and prM proteins of each Dengue virus serotype (Guy et al., 2010). So 
far, CYD-TDV has been under evaluation in phase IIb to phase III trials (Sabchareon 
et al., 2012). Other candidates in the early phase of vaccine development include live 
attenuated Dengue and recombinant subunit vaccines (Whitehead et al., 2007). 
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 Prevention and control 
 
 Preventing Dengue transmission depends on controlling mosquito vectors. 
Mosquitoes’ habitats such as water storage containers should be emptied or covered to 
prevent access by mosquitoes. Insecticides should be used to kill adult mosquitoes. 
Active monitoring and surveillance of vectors should be performed.  
 
 Recently, there are new attempts to control the vector since the current 
approaches are inefficient to prevent transmission. For example, genetically modified 
male mosquitoes have been generated that fertilize the wild-type female mosquitoes in 
order to reduce the number of eggs (Simmons et al., 2012). Introduction of the 
bacterium Wolbachia spp. into mosquitoes can partially limit Dengue infection and 
may compete with the natural mosquito populations (Simmons et al., 2012).  
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1.2 Complement system 
 
1.2.1 Complement system 
 
Several lines of evidence show that Dengue disease is mediated by 
immunological processes, including the complement system. The complement system 
comprises three pathways: classical, mannose-binding lectin (MBL), and alternative 
(Figure 1.9) (Zipfel and Skerka, 2009). The classical pathway is triggered by an 
interaction of C1q with antigen-antibody complexes, whereas the lectin pathway begins 
with a binding of MBL with mannose on the surface of pathogens. The alternative 
pathway (AP) is spontaneously and constantly activated through the hydrolysis of C3 and 
serves as an amplification loop for the classical and the lectin pathways. The hydrolyzed 
C3 molecules then combine with factor B and factor D to produce C3 convertase 
(C3bBb). The other two pathways also generate C3 convertase however, in a different 
form (C4bC2a). These enzymes are necessary for cleaving C3, a central component of all 
complement pathways, to C3a, and C3b. The C3a is known as an anaphylactic molecule, 
whereas the C3b molecule can either be deposited on nearby surfaces, or combine with 
additional C3 convertases and subsequently function as C5 convertases. These enzymes 
cleave C5 to C5a, another anaphylactic peptide, and C5b, which recruits other 
components (C6-9) to a target surface and promote formation of the C5b-9 membrane 
attack complex (MAC), generating pores on the surface. Additionally, the C3b 
molecules function as opsonins which bind covalently to pathogens and thereby target 
them for destruction by phagocytic cells that express C3b receptors on their surfaces 
(Zipfel and Skerka, 2009). 
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Figure 1.9: The complement pathways: Classical, Mannan-binding Lectin, and 
Alternative (Zipfel and Skerka, 2009). 
 
 
1.2.2 Dysregulation of complement regulators and diseases 
 
Complement, which lacks the ability to discriminate between self and non-self 
requires complement regulators to protect host surfaces from damage during 
complement activation. The complement system, as a result, gets rid of only modified 
host cells, or microbial agents. With the cooperation of multiple regulators, activation 
and inhibition of complement is well-regulated in vivo. However, dysfunctional 
complement regulators (mutation and polymorphisms) may lead to uncontrolled 
activation and non-specific damage to cells (Zipfel and Skerka, 2009). These defects 
contribute to several diseases such as the kidney diseases (atypical Haemolytic 
Uraemic Syndrome [aHUS] and Membranoproliferative Glomerulonephritis Type II 
[MPGN II]), the retinal disease (Age-related Macular Degeneration [AMD]), 
Systemic Lupus Erythomatosus (SLE), infectious diseases, etc. (Zipfel and Skerka, 
2009). A critical step to control complement activation appears to be in the AP since it 
is regularly activated. Factor H (CFH) is a major regulator in this pathway and can 
regulate both in the fluid phase and on cellular membrane surfaces.  
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The complement factor H family:  
  
The factor H family is composed of CFH protein, CFH-like protein 1 
(CFHL1), and CFH-related proteins (CFHRs). Genes encoding for these proteins are 
located on human chromosome 1q32 within the RCA (the regulator of complement 
activation) cluster. The gene cluster and the structure of these proteins are shown in 
figure 1.10. 
 
CFH protein is an abundant plasma protein, the level of which varies widely 
(116-562 µg/ml) in the population (de Cordoba and de Jorge, 2008). It is 
constitutively produced by the liver, but also synthesized by epithelial cells, 
lymphocytes and umbilical vein endothelial cells (Rodriguez de Cordoba et al., 2004). 
This protein is a 155-kDa single chain glycoprotein, composed of 20 short consensus 
repeat domains (SCR), each of which contains about 60 amino acids (Rodriguez de 
Cordoba et al., 2004). The N-terminal end of the protein (SCR 1-4) is a site for co-
factor activity of factor I mediated C3b cleavage and decay accelerating activity 
against C3bBb, whereas the surface binding/cell surface regulation is found in the C-
terminal region (SCR 19-20) (Zipfel et al., 1999). CFH protein blocks the formation 
of C3 convertase by sequestering C3b from factor B and promoting dissociation of 
these enzymes once formed. It also acts as a co-factor for the factor I-mediated 
proteolytic cleavage of C3b to inactive C3b (iC3b). This is then fragmented to C3dg 
and C3c (Pickering and Cook, 2008).  
 
CFHL1 is the product of alternative splicing of CFH gene and produced in the 
liver similar to CFH. It comprises the first seven N-terminal domains of CFH 
indicating an ability to regulate complement activity and four amino acids specific to 
CFHL1 at the C terminus (Jozsi and Zipfel, 2008).   
 
CFHRs are encoded by CFH-related genes which share sequence similarity to 
CFH in both amino acids and nucleotides (Jozsi and Zipfel, 2008). There are five 
similar CFHR proteins (CFHR1-5) whose functions are supposed to be similar to 
CFH, suggesting an overlapping function in the immune system and regulation. A 
homology alignment shows that CFHR proteins have two major conserved regions 
located in the N-, and C- termini. The N-termini are related to SCRs 6-9 of CFH, 
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which mediates binding to heparin and C-reactive protein (CRP). The C-termini of 
these proteins show an identity in a different degree to the SCRs 19-20 of CFH (Jozsi 
and Zipfel, 2008). This homology suggests that the C-terminus may be involved in 
cell surface binding.  
 
  CFHR1 contains 5 SCRs and is identified in two glycosylated forms 
(CFHR1α and CFHR1β). The plasma concentration is about 70-100 μg/ml (Skerka 
and Zipfel, 2008). CFHR1 is able to bind C3b, suggesting a role in the complement 
regulation (Skerka and Zipfel, 2008). It can also bind to surfaces of pathogens such as 
Borrelia burgdorferi, Candida albicans, Psuedomonas aeruginosa and Group A 
streptococci (Skerka and Zipfel, 2008, Jozsi and Zipfel, 2008). In addition, CFHR1 
has an ability to block C5a-mediated chemoattraction of neutrophils (Fritsche et al., 
2010). 
 
  CFHR2 contains 4 SCRs and is identified in two glycosylated forms. 
The plasma concentration is unidentified and the function has not been determined 
(Skerka and Zipfel, 2008).  
 
  CFHR3 contains 5 SCRs. Multiple glycosylated forms are detected in 
plasma. The concentration is unidentified. A role of CFHR3 may involve binding to 
C3b and C3d molecules as well as to heparin (Jozsi and Zipfel, 2008, Skerka and 
Zipfel, 2008). It is capable of inhibiting activity of C3 convertase and blocking C5a-
mediated chemoattraction of neutrophils (Fritsche et al., 2010). 
 
  CFHR4 has two separate forms (CFHR4a and CFHR4b). The CHFR4a 
contains 9 SCRs and the CFHR4b includes 5 SCRs. The plasma concentration is not 
determined. It may function in complement regulation in the form of a CFH cofactor 
(Skerka and Zipfel, 2008). It can also bind to C3b and C3d (Jozsi and Zipfel, 2008).  
 
  CFHR5 is composed of 9 SCRs. The concentration is undetermined. It 
is able to bind to heparin, C3b, and CRP (Skerka and Zipfel, 2008, Jozsi and Zipfel, 
2008).  
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Figure 1.10:  The CFH protein family (Jozsi and Zipfel, 2008). A) Arrangement of 
the CFH and the CFHRs genes. The CFH gene encodes for CFH and CFHL1 whereas 
the CFHR4 gene encodes for CFHR4a and CFHR4b. The sites of non-allelic 
recombination are marked by the dot and the solid lines, resulting in a CFH: CFHR1 
hybrid gene or a large deletion of CFHR3 and CFHR1 respectively. B) Short 
consensus repeats (SCRs) of the CFH protein family. The SCRs of CFH share 
homologous domains with other proteins in the family. The numbers indicated in the 
SCRs are the numbers of the SCR domain and the numbers indicated above are the 
identity of the domains compared to those of CFH protein. The protein binding 
domains of CFH are specified below. 
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1.2.3 Polymorphisms in the CFH genes associated with diseases   
 
CFH gene cluster 
 
Several polymorphisms/mutations have been identified in the CFH gene. 
Single nucleotide polymorphisms (SNPs) in exon 2 (CFH-62 V/I, G184A; rs800292) 
and in exon 9 (CFH-402 Y/H, T1204C; rs1061170) are associated with AMD (de 
Cordoba and de Jorge, 2008). A SNP in the promoter (CFH C-332T; rs3753394) is 
associated with Meningococcal disease (MD) (Rodriguez de Cordoba et al., 2004). 
Recently, CFH C-332/T and CFH-62 V/I have been found to associate with Dengue 
disease (Pastor et al., 2013). Moreover, missense mutations that cluster within SCR 
19-20 are identified in individuals with aHUS (Rodriguez de Cordoba et al., 2004).  
 
So far, the biological function has been largely studied in CFH C-332T, CFH-
62 V/I, and CFH-402 Y/H. CFH C-332T is located in the NF-ΚB binding site, 
implying that this polymorphism may affect transcriptional processes (Warwicker et 
al., 1997, Caprioli et al., 2003). CFH-62 I binds to C3b more effectively than CFH-62 
V; therefore, it can better compete with FB, leading to reduced complement activation 
(Tortajada et al., 2009). CFH-402 H has an impaired binding to heparin and C-
reactive protein, affecting cell surface binding and inflammation (Laine et al., 2007). 
 
In addition to SNPs, sequence analysis shows repetitive regions between the 
CFH and the CFHRs, resulting in DNA rearrangement, gene conversion or DNA 
duplication/deletion. Non-allelic homologous recombination between CFHR1 and 
CHFR3 causes a deletion between these two genes (ΔCFHR3-1) (Hageman et al., 
2006, Spencer et al., 2008) (Figure 1.10 a). An association between this deletion and 
diseases has been largely studied in aHUS and AMD. This deletion increases the risk 
of aHUS, while it is protective in AMD (Spencer et al., 2008); however, the reason 
why the CFHR3-1 deletion differently functions in these two diseases is still 
ambiguous (Skerka and Zipfel, 2008). Moreover, a novel polymorphic deletion 
affecting CFHR1 and CFHR4 has been detected in healthy individuals and among 
patients with aHUS (Moore et al., 2010). 
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Combination of polymorphisms in complement proteins CFH, Factor B (FB), and C3 
 
An association between diseases and genetic variation in the complement is 
not only focused on an individual gene, but also in a combination of polymorphisms. 
Recently, it has been shown that polymorphisms in CFH, FB and C3 (collectively 
called ‘complotype’) are associated with a 6-fold increased complement-dependent 
hemolytic activity in vitro (Heurich et al., 2011). FB and C3 are complement 
activators in the AP while CFH is a regulator. Therefore, alternative complement 
activation can be influenced by genetic determinants and this evidence has been 
shown in AMD (Hageman et al., 2005, Gold et al., 2006, Yates et al., 2007). 
Individuals who have increased susceptibility to AMD show high activation of 
complotype (FB-32 R/R: rs12614 [C] and rs641153 [G]; CFH-62 V/V: rs800292 [G]; 
and C3-102 F/F where F is denoted as ‘fast electrophoresis allele’: rs2230199 [G]) 
while individuals with the low activation of complotype have a reduced risk of AMD 
(FB-32 Q/Q rs12614 [C] and rs641153 [A]; CFH-62 I/I: rs800292 [A]; and C3-102 
S/S where S is denoted as ‘slow electrophoresis allele’: rs2230199 [C]). Consistent 
with these data were the findings that CFH-32 I, FB-32 R can bind to C3b effectively 
and C3-102 F can increase target cell lysis in vitro (Tortajada et al., 2009, Montes et 
al., 2009, Heurich et al., 2011). 
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1.2.4 Utilization of CFH by microorganisms 
 
Microbes including bacteria, fungi, and viruses have strategies to evade the 
immune responses. Recruiting host complement regulators such as CFH is a 
mechanism which microbes exploit to defend against complement activation. Binding 
of microbial molecules to CFH have been explored in numerous studies (Figure 1.11). 
 
Several bacteria have been found to bind CFH, restricting killing by human 
complement. For example, Borrelia species, the bacteria that causes Lyme borreliosis, 
express complement regulator-acquiring surface proteins (CRASP1-5), all of which 
bind to CFH, CFHL1 and CFHR1 but with different affinity (Jozsi and Zipfel, 2008). 
Ligands of the Neisseria family including porin 1 A (Por1A) and factor H binding 
protein (fHbp), M protein of Streptococci, LenA and LfhA of Leptospira interrogans 
can also interact with CFH (Ngampasutadol et al., 2008, Schneider et al., 2009, Jozsi 
and Zipfel, 2008). In addition to bacterial ligands, non-structural protein 1 (NS1) of 
West Nile virus (WNV), a member of the Flaviviridae family, can recruit CFH to the 
surface of infected cells, preventing lysis from complement activation (Chung et al., 
2006). Interaction of CFH to glycoproteins (gp120 and gp41) on HIV particles has 
also been demonstrated (Pinter et al., 1995a, Pinter et al., 1995b).  
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Figure 1.11: Binding of CFH to pathogens and their ligands [Modified from (Ferreira 
et al., 2010)]. SCR domains of CFH are shown in the numbers 1 to 20. Names in 
parentheses are the microbes’ ligands known to interact with CFH. Unknown 
interacting domains are indicated by question marks. 
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1.3 Matrix Metalloproteinases 
 
1.3.1 Matrix Metalloproteinases (MMPs): overview 
 
Matrix metalloproteinases (MMPs) are metallo-endopeptidases (also called 
matrixins) that require zinc ions in their active sites (Birkedal-Hansen et al., 1993, 
Parks et al., 2004). The first MMP was discovered in Xenopus’ tail in 1961 and the 
latest MMP was discovered over 40 years later (Greenlee et al., 2007). Mammalian 
MMPs comprise 24 members and were originally identified based on their substrate 
specificity such as collagenases (MMP-1, -8, and -13), gelatinases (MMP-2, and -9), 
stromelysins (MMP-3, -10 and -11), elastases (MMP-7, and -12), and membrane-
typed MMPs (MT-MMPs; MMP-14, -15, -16, and -17) (Nagase et al., 2006). The 
additional number system based on the order of discovery and structural classification 
were sequentially applied (Greenlee et al., 2007). The list of MMPs is shown in the 
Figure 1.12. 
 
 
 
Figure 1.12: The discovery of MMPs (Greenlee et al., 2007). MT-MMP (membrane-
type MMP), XMMP (Xenopus MMP), CMMP (Chicken MMP) 
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1.3.2 General structures of MMPs 
 
The basic structure of MMPs includes a propeptide domain (about 80 amino 
acids), a catalytic domain (about 170 amino acids), and a C-terminal hemopexin-like 
domain (about 200 amino acids) (Nagase and Woessner, 1999). The schematic picture 
of MMPs is shown in Figure 1.13. 
 
 
 
Figure 1.13: Structures of MMPs (Sternlicht and Werb, 2001). Pre, N-terminal signal 
sequence that is removed after synthesis; Pro, propeptide domain with a zinc-ligating 
thiol group (SH); F, Furin binding site; Vn, Vitronectin-like domain; catalytic, 
catalytic domain; Zn, zinc binding domain; II,  fibronectin type II domain; H, hinge 
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region; hemopexin, hemopexin-like domain containing four repeats with the first and 
last linked by a disulfide bond; TM, transmembrane domain with cytoplasmic tail (C); 
GPI, a glycophosphatidyl inositol membrane-anchoring signal; C/P, cysteine/proline 
rich domain;  IL-1R-like, interleukin-1 type II receptor-like domain. 
 
 The propeptide domain contains a conserved region called ‘Cysteine switch 
motif’ (PRCG [V/N] PD). Cysteine in this region can interact with the zinc ion at the 
zinc binding motif in the catalytic domain, keeping MMP inactive (Nagase et al., 
2006). In addition, MMP-11, MMP-21, MMP-23, MMP-28, and MT-MMPs have the 
conserved sequence (RX [K/R]R) recognized by Furin, leading to activation of MMPs 
intracellularly (Nagase and Woessner, 1999).  
 
 The catalytic domain contains the zinc-binding motif (HEXXHXXGXXH; 
where X is a variable amino acid) and the “methionine turn” (XXMXP), which is 
eight residues after the zinc binding motif (Nagase and Woessner, 1999). This 
methionine is thought to maintain the structure around the zinc-binding site (Nagase 
et al., 2006). Also, MMP-2 and MMP-9 have an additional three repeats of fibronectin 
type II (gelatin) domain essential for digestion of collagens and gelatins (Nagase et 
al., 2006). 
 
 The hemopexin-like domain is at the C-terminus of the enzymes. This domain 
is essential for cleaving triple helical collagens (Nagase et al., 2006). It is also 
necessary for cell surface activation of pro MMP-2 by MT1-MMP (Nagase et al., 
2006). Matrilysins (MMP-7, and MMP-26) and MMP-23 lack this domain (Nagase et 
al., 2006). 
 
In addition to these three basic structures, there are additional domains in 
some MMPs such as a transmembrane domain which is important for anchoring the 
enzyme to the cell surface (Sternlicht and Werb, 2001).  
 
1.3.4 Regulation of MMPs 
 
MMPs activities are tightly regulated in transcriptional and post-
transcriptional levels. They are controlled by several factors including growth 
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hormone, cytokines/chemokines, cell adhesion molecules as well as extracellular 
matrix (ECM) (Nagase et al., 2006). MMPs are generally expressed low levels in 
normal conditions and are synthesized as inactive proenzymes but can be 
transcriptionally induced by inflammatory cytokines e.g. TNF-α, and IL1-β, as well as 
by cell-cell interaction (R Hanemaaijer, 1993, Cornelius et al., 1995, François Mach, 
1999, Lacraz et al., 1994). Exceptions to this are proMMP-8, proMMP-9, and 
proMMP-25 that are stored in the granules within the neutrophils (Greenlee et al., 
2007). 
 
The secreted form of proMMPs can be activated by tissue and plasma 
proteinases. They can also be activated by organic mercury compounds, low pH, heat 
and sodium dodecyl sulfate (SDS) in vitro (Nagase et al., 1990, Greenlee et al., 2007). 
These biological and chemical compounds as well as physiological treatments lead to 
disruption of the cysteine-zinc interaction exposing the catalytic active site, which is 
further cleaved by MMPs themselves (Nagase et al., 1990, Nagase et al., 1992, Suzuki 
et al., 1995, Greenlee et al., 2007). Exceptions to this are some MMPs including 
MMP-11, MMP-28 and MT-MMPs. These MMPs contain Furin recognition 
sequences and are activated in the trans-golgi network (TGN) by Furin before they 
reach to the cell surface (Nagase et al., 2006).  
 
Regulation of MMPs is also controlled through compartmentalization 
(Greenlee et al., 2007). Activation of MMP-2 generally occurs on the cell surface and 
depends on the expression of MT1-MMP (MMP-14) and TIMP2 (tissue inhibitors of 
matrix metalloproteinase 2) (Nagase et al., 2006). Hemopexin-like domain of pro-
MMP2 binds to the C-terminus of TIMP2. This enzyme-inhibitor complex interacts 
with two active MT1-MMPs on the cell surface: one MT-MMP acts as a receptor and 
another one acts as an activator of pro-MMP-2. However, excessive TIMP2 can 
prevent the binding of the second MT1-MMP, inhibiting the activation process. 
 
Finally, their activities are controlled by two types of endogenous inhibitors: 
α2-macroglobulin and tissue inhibitors of metalloproteinases (TIMPs) (Greenlee et 
al., 2007). The α2-macroglobulin is an abundant plasma glycoprotein which is able to 
irreversibly inhibit several types of proteinases including MMPs. By contrast, TIMPs 
(TIMP1-4) can reversibly inhibit all MMPs tested but with different efficiencies 
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(Nagase et al., 2006). TIMPs form a non-covalent complex to the catalytic domain of 
MMP in a 1:1 ratio (Nagase et al., 2006).  
 
1.3.5 MMP substrates 
 
MMPs are able to degrade not only ECMs but also target non-ECM substrates 
such as growth factors/receptors, cytokines/chemokines, and adhesion molecules 
(Manicone and McGuire, 2008). Since MMPs can target multiple kinds of proteins, 
they can influence the abilities, functions, and localization of several proteins. 
Therefore, abnormalities due to impaired MMPs can be seen in MMP-null mouse 
strains (Table 1.2; modified from (Manicone and McGuire, 2008)). 
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Table 1.2: Abnormalities in MMP-null mice   
MMP-null mice Abnormalities 
MMP2-null Impaired eosinophil egression in allergic lung inflammation 
 Increased immune-mediated arthritis 
 Enhanced myocardial inflammation in TNF-α induced cardiomyopathy 
 Enhanced autoimmune encephalomyelitis 
 Enhanced experimental colitis 
MMP3-null  Decreased neutrophil recruitment in model of acute lung injury 
 Decreased neutrophil recruitment in LPS-induced neuroinflammation 
 Impaired contact hypersensitivity 
 Enhanced collagen-induced arthritis 
 Reduced accumulation of macrophages in atherosclerotic plaques 
 Reduced macrophage-chemoattractant activity 
 Reduced recruitment of CD4+ Lymphocytes into intestinal mucosa 
MMP7-null  Reduced neutrophil efflux in bleomycin-induced lung injury 
 Lack of activation of TNF-α on macrophages 
MMP8-null  Delayed neutrophil recruitment and resolution. Reduced neutrophil apoptosis 
 Decreased neutrophil recruitment to dermis surrounding chemical-induced skin tumors 
MMP9-null  Reduced inflammation in experimental colitis 
 Diminished egression of leukocytes in allergic lung inflammation 
 Enhanced airway inflammation in allergic lung inflammation 
 Decreased lymphocyte recruitment and mononuclear inflammation in allergic lung inflammation 
 Decreased immune-mediated arthritis 
 Protected from lethal endotoxic shock 
 Prolonged contact hypersensitivity 
 Reduced experimental autoimmune encephalomyelitis 
 Diminished Dendritic cell migration 
 Increased neutrophil recruitment in IL13-induced lung injury 
 Impaired macrophage infiltration in atherosclerosis 
 Reduced neutrophil influx, mortality and bacterial burden during infection with Francisella Tularensis 
MMP10-null  Altered inflammatory responses 
MMP12-null  Decreased eosinophil and macrophage recruitment in IL13-induced lung injury 
 Reduced macrophage migration and influx in smoke-induced emphysema 
 Reduced macrophage recruitment and improved function in spinal cord injury 
 Reduced neutrophil influx to alveolar space in acute lung injury 
 Reduced release of TNF-α from macrophages after smoke exposure 
MMP13-null  Attenuated inflammatory reaction during cholestasis 
 
 
1.3.5 Roles of MMPs 
 
The role of MMPs in normal conditions has been described in ECM 
remodeling, embryonic development and morphogenesis (Greenlee et al., 2007). For 
example, Drosophila melanogaster1-MMP (DM1-MMP1) is necessary for fly 
development as an experiment has shown that flies with mutant DM1-MMP1 protein 
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are smaller and irregularly shaped (Greenlee et al., 2007). Embryonic development of 
zebrafish requires MMP-2 (Greenlee et al., 2007). Xenopus MMP-7 (XMMP-7), 
which is homolog to human MMP-7, and XMMP-9 have been found during 
embryonic development (Greenlee et al., 2007). 
 
MMPs also function in tissue and wound repair (Gill and Parks, 2008), 
inflammation and immune response to infection (Manicone and McGuire, 2008, 
Elkington et al., 2005, Parks et al., 2004). For example, soon after injury IL8 and 
MMP-7 are secreted from injured epithelial cells. IL-8 then accumulates on the 
heparan sulfate of syndecan-1, a transmembrane proteoglycan on the surface of 
epithelial cells, whilst MMP-7 sheds the ectodomain of syndecan-1, releasing the 
syndecan-1/IL-8 complex leading to recruitment of neutrophils to the site of injury 
(Parks et al., 2004). MMP-7 is able to cleave Epithelial (E)-cadherin facilitating cell 
migration and also shed the membrane-bound FAS ligand on the cell surface, 
inducing apoptosis (Parks et al., 2004). Neutrophil elastase together with MMP-9 is 
released from activated neutrophils to fight against pathogens such as Gram negative 
bacteria (Parks et al., 2004). In addition, several MMPs are up-regulated during 
angiogenesis, suggesting a role in blood vessel formation (Greenlee et al., 2007). 
Blocking activities of MMPs with the MMP inhibitor also affects organ regeneration 
in newts, hydra, and zebrafish (Greenlee et al., 2007).  
 
MMPs can be found either in a soluble form or at the cell surface. It has been 
hypothesized that these two forms may play different roles in their regulating 
activities. For example, the active cell membrane-bound MMP-9 on the surface of 
neutrophils resists inhibition by TIMPs although it can cleave ECMs in vitro as the 
soluble MMP-9 (Greenlee et al., 2007). MMP-8 on the surface of activated 
neutrophils also resists inhibition by TIMPs (Greenlee et al., 2007).  
 
Collectively, MMPs can facilitate migration of immune cells to the sites of 
infection, regulate permeability, modulate activity of cytokines and chemokines, as 
well as generate a chemokine gradient (Gill and Parks, 2008, Nagase et al., 2006, 
Sharma et al., 1996).   
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1.3.6 MMPs in infectious diseases 
 
Recently, many publications have demonstrated MMPs activities in infectious 
diseases. The cerebrospinal fluid (CSF) levels of MMP-9 relate to HIV and HTLV-1 
infection associated neurological diseases (Sporer et al., 1998, Giraudon et al., 1998). 
HIV-infected macrophages also increase MMP-2 secretion, which then cleaves 
CXCL12 (stromal cell derived factor -1; SDF-1) to a neurotoxin (Zhang et al., 2003). 
MMP-9 mediated blood brain barrier (BBB) permeability can facilitate West Nile 
virus (WNV) entry to the brain of infected mice (Wang et al., 2008).  Up-regulation of 
MMP-3 and MMP-9 promote cell invasion induced by Epstein Barr virus and 
Hepatitis B virus (Lan et al., 2013, Balasubramanian et al., 2011, Chung et al., 2004). 
An increase of plasma MMP-9 is detected in Dengue patients and associated with 
disease severity (Kubelka et al., 2010). In addition, soluble factors secreted from 
Dengue infected-dendritic cells increase vascular endothelial cell permeability in an 
MMP-9 dependent manner and decrease the expression of VE-cadherin and Pecam-1 
on endothelial cells (Luplertlop et al., 2006).  
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2.1 Buffers and reagents 
 
3% carboxymethylcellulos (3% CMC; Sigma-Aldrich, USA) 
3 g of carboxymethylcellulos in water 100 ml 
 
1.5% CMC 
3% CMC 50 ml, 2xMEM (Invitrogen, USA) 45 ml, Fetal Bovine Serum (FBS) 3 ml, 
streptomycin (10x) 1ml and penicillin (10x) 1ml 
 
3, 3′-Diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich, USA) 
DAB 0.6 mg, H2O2 20µl, and 8% NiCl2 100 µl in PBS 10 ml 
 
MACS buffer  
0.5% FBS, 2 mM EDTA in PBS 
 
FACS wash  
2% FBS, 1% Human serum (PAA, Austria) 0.5% BSA (Sigma-Aldrich, USA), 0.5% 
NaN3 in PBS 
 
FACS fix solution  
1% formaldehyde in PBS 
 
Assay Buffer  
50 mM Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, pH 7.5 (Filtered 
with 0.2 micron filter) 
 
Phenylmethanesulfonyl Fluoride (PMSF, M.W. 174.2)   
0.2 M stock in 2-propanol 
 
MMP-3 substrate (R&D systems, USA) 
2 mM stock in DMSO  
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Chymotrypsin (Sigma-Aldrich, USA).) 
10 mg/ml stock in 1 mM HCl  
 
FITC-dextran (Sigma-Aldrich, USA) 
25 mg/ml stock in DMSO 
 
SDS-PAGE gel 
10% acrylamide resolving gel: water 1.9 ml, 30% acrylamide 1.7 ml, 1.5 M Tris (pH 
8.8) 1.3 ml, 10% SDS 0.05 ml, 10% APS 0.05 ml, TEMED 0.002 ml 
5% stacking gel: water 0.68 ml, 30% acrylamide 0.17 ml, 1 M Tris (pH 6.8) 0.13 ml, 
10% SDS 0.01 ml, 10% APS 0.01 ml, TEMED 0.001 ml 
 
SDS-PAGE gel loading buffer (4x) 
Water 4 ml, 0.5 M Tris-HCl (pH 6.8) 8 ml, SDS 1.6 g, Glycerol 8 ml, bromophenol 
blue 4 mg 
 
SDS-PAGE running buffer (5x) 
Tris 15.1 g, Glycine 94 g, 10% SDS 50 ml, made up to 1L with water 
 
Western blot transfer buffer 
24 mM Tris-base, 192 mM Glycine, 20% Methanol  
 
4x non-reducing loading dye 
0.02 % Bromphenol blue, 40% Glycerol, 8% SDS, and 250 mM Tris-HCl (pH 6.8)   
 
0.1% PBS-T 
1 ml of tween-20 in 1xPBS 1L 
 
ELISA coating buffer 
50 mM sodium bicarbonate pH 9.5 (1 tablet of bicarbonate; Sigma Aldrich, USA) in 
100 ml water  
 
2N H2SO4 
1.96 ml of 99% H2SO4 made up to 10 ml with water 
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2.2 Patients and Controls  
 
Patients with Dengue disease were children admitted during acute febrile 
illness and recruited from Songkla and Khonkan hospitals in Thailand during 2001-
2008. Clinical biochemical analysis was conducted on the day of presentation, and 
follow-up. Viral diagnosis was established using RT-PCR and disease severity was 
graded according to WHO guidelines: DF and DHF grades 1 to 4.  Primary and 
secondary infection was determined by IgM/IgG ELISA. Patients with other febrile 
illnesses were those presenting with fever and having undetectable dengue viral 
genome and an anti-dengue antibody titre lower than the cut off value for an acute-
dengue infection. Healthy volunteers were recruited from Siriraj Hospital, Thailand. 
Heparin and EDTA plasma were aliquotted and kept at -70 ºC.  Written informed 
consent was obtained and sample collection approved by the Institutional review 
board (IRB).  
 
Clinical biochemical analysis was conducted on the day of presentation. The 
markers assessed included Hematocrit (Hct), white blood cell count (WBC), 
polymorphic mononuclear cells (PMN); lymphocyte, atypical lymphocyte, monocyte, 
basophil and eosinophil numbers; platelet count, liver aspartate aminotransaminases 
(ast), liver alanine aminotransaminases (alt), liver total protein (lft_protein), and 
liver_albumin (lft_albumin). 
 
The processes of genomic DNA extraction, viral diagnosis, severity 
classification, identification of primary/secondary infection, and clinical biochemical 
analysis were performed by staff in Thailand. 
 
2.3 Dengue virus infection in vitro 
 
C6/36 cell lines were cultured in 10% FBS, 10% TPB (Sigma-Aldrich, USA) 
Leibovitz L-15 (Invitrogen, USA)   supplemented with streptomycin and penicillin at 
28°C. Vero cell lines were maintained in MEM (Invitrogen, USA) supplemented with 
10% FBS at 37°C in a CO2 incubator. Dengue virus serotype 2 strain 16681 (DV2) 
was propagated in C6/36 cells. Cells were plated for 2 days until 90% confluent. At 
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the day of infection, cells were maintained in 1.5% FBS, 10% TPB L-15 without 
antibiotics, and infected with the virus at a multiplicity of infection of 0.01 for 3 
hours, then topped up with 1.5% FBS, 10% TPB L-15 to 10 ml in a T75 flask. 
Infected cells were incubated at 28°C until cytopathic effect (CPE) could be seen. 
Mock infected cells were used as a negative control. 
 
To titrate the virus in the supernatant, Vero cells (2.5x104) in a volume of 
125μl were plated on each well of a 96-well plate and incubated for 2 days in a CO2 
incubator. On the day of infection, 70μl of media was discarded from the cells. The 
viral supernatant was 10-fold serially diluted with MEM supplemented with 3% FBS 
and added into the cells in a volume of 50μl for 2 hours at 37 °C. The infected cells 
were then overlaid with 125μl of MEM containing 1.5% carboxymethylcellulos 
(Sigma-Aldrich, USA) and 3% FBS, and incubated for a further 2 days. Infected foci 
were observed by immunoperoxidase staining. Briefly, the infected cells were washed 
with PBS three times, fixed with 100 μl of 3.7% formaldehyde for 10 minutes and 
permeabilized with 100 μl of 2% triton-X 100 for 15 minutes at room temperature. 
Following washing with PBS three times, 50μl of 4G2 (monoclonal antibody 
supernatant against Dengue E protein) was added for 1 hour at 37ºC. Following 
washing with PBS three times, 50μl of rabbit anti mouse-HRP (1:1000; DAKO, 
Denmark) in PBS containing 2% FBS and 0.05% tween-20 were added for 1 hour at 
37ºC. Following washing with PBS three times, 50μl of DAB (Sigma-Aldrich, USA) 
was added for 5-10 minutes in the dark or until the infectious foci were clearly visible. 
The reaction was stopped by discarding the solution and washing with distilled water. 
Number of foci were counted by ELISpot reader (AID EliSpot Reader Systems, USA) 
and reported as foci forming units per ml. All the experiments with live virus were 
performed in the Biosafety level 3 facilities. 
 
2.4 Genotyping 
 
Genomic DNA (25 ng) was amplified by PCR using CERTAMP high fidelity 
polymerase (Biotools, Spain). Single nucleotide polymorphisms (SNPs), primer 
sequences, and PCR product sizes are listed in appendix A1. PCR cycling for the 
factor H (CFH) rs3753394, rs1061170 and rs6677604 variants was 94°C for 3 
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minutes and 35 cycles of 94°C for 30 seconds, 57°C for 1 minute, and 72°C for 1 
minute, followed by 72°C for another 10 minutes. For Factor B (rs12614 and 
rs641153), the conditions were 94°C for 3 minutes and 35 cycles of 94°C for 30 
seconds, 60°C for 1 minute, and 72°C for 2 minutes, followed by 72°C for 10 
minutes. The PCR conditions for C3 (rs2230199) were 94°C for 2 minutes, 20 cycles 
of 94°C for 30 seconds, and 1 minute at 65°C which was decreased by 0.5°C every 
cycle, and another 20 cycles of 94°C for 30 seconds, 55°C for 1 minute, and 72°C for 
1 minute, followed by 72°C for another 5 minutes. Following purification using the 
ChargeSwitch PCR Clean-up kit, (Invitrogen, USA) amplicons were sequenced and 
the SNP genotype recorded.  
 
The CFH rs800292 variant was determined using a Taqman SNP genotyping 
assay (#4351379, Applied Bioscience, USA). The reaction was performed by real-
time PCR (Applied Bioscience, USA) and the condition used were 95°C for 10 
minutes and 40 cycles of 92°C for 15 seconds, and 60°C  for 1 minute. Results were 
analyzed by the Sequence Detection System Software version 2.3 (Applied 
Bioscience, USA). 
 
2.5 Copy number assays 
 
CFHR3-1 copy number was detected using a combination of (i) Taqman 
copy number assay probes (Applied Bioscience, USA), (ii) multiplex ligation-
dependent probe amplification assay (MLPA, MRC Holland, Netherlands) and (iii) 
genotyping of rs6677604 (a SNP within intron 12 of the CFH gene that has been 
shown to tag the CFHR3-1 deletion).  
 
Taqman copy number assay: 40 ng of genomic DNA samples were mixed with 
Taqman genotyping master mix (Applied Bioscience, USA), Taqman copy number 
reference RNaseP (#4403328, Applied Bioscience, USA), and Taqman probes 
specific to either CFHR1 or CFHR3 (Applied Bioscience, USA). The reaction was 
performed by real-time PCR (Applied Bioscience, USA) and the conditions used were 
95°C for 10 minutes and 40 cycles of 92°C for 15 seconds, and 60°C for 1 minute. 
Results were analyzed by the CopyCaller software (Applied Bioscience, USA). DNA 
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samples with known copy number were used as the reference samples. Duplicates for 
each DNA sample were performed. 
 
MLPA: 200 ng of genomic DNA samples were denatured at 98ºC for 5 
minutes, and hybridized with SALSA MLPA P236 ARMD mix-1 probemix covering 
for CFH, CFHR3, CFHR1, and CFHR2 (MRC Holland, Netherlands) at 60ºC for 16 
hours. The hybridized DNA samples were ligated at 54ºC for 15 minutes and the 
temperature was increased to 98ºC for 5 minutes. Following the ligation reaction, 10 
μl of ligation products were added into the PCR polymerase mix at 60ºC and the PCR 
reaction was started immediately. PCR condition was 35 cycles of 95°C for 30 
seconds, 60°C for 30 seconds, and 72°C for 60 seconds, followed by 72 °C for 20 
minutes. PCR products were mixed with the GeneScan 500 ROX Size Standard 
(Applied Bioscience, USA) in Hi-Di Formamide (Applied Bioscience, USA) and 
separated using capillary electrophoresis (3730xl DNA Analyser, Applied 
Biosystems, USA). 
 
Results were analyzed by Gene Mapper software (Applied Bioscience, USA). 
The peak heights of the probes amplified in each sample were exported to EXCEL. 
The heights were normalized by dividing each peak with the total heights of all house 
keeping probes in each sample. Each normalized height was divided by the average of 
the normalized heights in the three control samples, which are known to contain two 
copies of CFHR3 and CFHR1. Copy number variation was determined by these 
relative heights to the controls.  The presence of two copies of genes gave the 
approximate relative height of 1. Heterozygous deletion (1 copy) gave a relative 
height of 0.35-0.50, while homologous deletion (0 copies) gave less than 0.35.  
 
2.6 CFH and NS1 interaction assays 
 
To determine if CFH interacted with NS1, ELISA, Far Western and 
immunopreciptiation techniques were utilized. 
 
ELISA: 5 µg/ml human CFH (QUIDEL, USA) in carbonate buffer was coated 
on a 96-well MaxiSorp plate (NUNC, Denmark) at 4°C overnight and each well was 
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washed with 0.1% PBS-T for three times. Following blocking with 5% (w/v) 
skimmed milk for 2 hour at 37ºC and washing with 0.1% PBST for three times, either 
mock or DV2 supernatant was then added to the wells and incubated at 37°C for one 
hour. Following washing with 0.1% PBS-T for three times, NS1 was detected by 
adding 5 µg/ml 1F11 (monoclonal mouse anti-NS1 antibody) for 1 hour at 37ºC 
followed by alkaline phosphatase-conjugated goat anti-mouse antibody (1:10000; 
Sigma-Aldrich, USA) for 1 hour at 37ºC and detection substrate (0.001 mg/ml p-
nitrophenylphosphate, BioRad, USA) for 1 hour at room temperature in the dark.  The 
absorbance was measured at 405 nm on the ELISA reader (TECAN, Switzerland). 
 
The reciprocal approach comprised of coating plates with 1F11 (10 µg/ml) in 
carbonate buffer at 4ºC over night. Following washing with 0.1% PBS-T for three 
times and blocking with 3% BSA for 1 hour at 37ºC, either mock or DV2 supernatant 
was then added to the wells and incubated for one hour at 37°C. Following washing 
with 0.1% PBS-T for three times, 5µg/ml CFH was added and incubated for one hour 
at 37°C. CFH was detected using goat anti-human CFH at a dilution of 1:2000 
(Quidel, USA) followed by horseradish peroxidase-conjugated mouse anti-goat 
antibody at 1:30000 (Sigma-Aldrich, USA).  Detection substrate (3,3´,5,5´-
tetramethylbenzidine; R&D systems, USA) for 30 minutes.   Signal development was 
stopped by addition of 2N H2SO4. The absorbance was measured at 450/620 nm on 
the ELISA reader (TECAN, Switzerland). 
 
Far western blotting: Supernatants from mock treated- or DV2 infected cells, 
500 ng of recombinant NS1 (rNS1; Abcams, UK), 500 ng of CFH, or 500 ng of 
Neisseria Factor H binding protein (fHbp; a gift from Prof. Chris Tang, University of 
Oxford, UK)  were added to non-reducing loading dye, and loaded onto a 10% SDS-
PAGE (buffer and reagents section). The gel was run at 100V for 30 minutes and then 
the voltage was increased to 120V for 1 hour. The gel was transferred onto a 
nitrocellulose membrane in a semi-dry blotting unit with western blot transfer buffer. 
After transfer at 0.05A for 1 hour, the membrane was blocked with 5% skimmed milk 
for 1 hour at room temperature and rinsed with PBS. The membrane was cut into 
strips before processing further.  
The membrane strips of supernatants, rNS1 or fHbp were rinsed with PBS and 
incubated with 200μl of CFH (5 µg/ml) at 4ºC overnight. The membrane strips of 
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CFH were also applied with 200μl of mock supernatant, DV2 supernatants, or rNS1 
(5 µg/ml) at 4ºC overnight. Following washing with 0.1% PBS-T for 5 minutes three 
times, goat anti-human CFH (Quidel, USA) at a dilution of 1:1000, 1F11 (neat 
supernatant) and mouse anti-fHbp (a gift from Prof. Chris Tang, University of 
Oxford, UK) at a dilution of 1:1000 were added onto the strips at 4ºC overnight in 
order to detect CFH, NS1 or fHbp, respectively. Following washing with 0.1% PBS-T 
for 5 minutes three times, either anti goat-HRP (1:10000; Dako, Denmark) or anti 
mouse-HRP (1:1000; Dako, Denmark) was added onto the strips at room temperature 
in the dark for 1 hour. Following washing with 0.1% PBS-T for 5 minutes three times, 
the strips were incubated with western HRP substrate (Millipore, USA) for 5 minutes. 
Photographic film (Sigma-Aldrich, USA) was used to visualize the signal. 
  
Co-immunoprecipitation: mock and DV2 supernatant were incubated with 
protein A (Roche, USA), followed by rotating at 4 °C for one hour and centrifuging at 
10,000 rpm for 2 minutes. Supernatants were then incubated with 5 µg/ml CFH for 3 
hours at 4°C followed by 1F11 (5 µg/ml) for 1 hour. Protein A was then added to the 
mixture and rotated overnight (4ºC). After centrifuging, beads were washed for 5 
minutes three times using 0.1% PBS-T and the bound protein eluted using 10μl of 2x 
non-reducing loading buffer.  The eluate was analysed by 12% SDS-PAGE. NS1 and 
CFH were detected using 1F11 and goat anti-human CFH antibody respectively. 
 
2.7 Multiplex bead assay 
 
Cytokines, chemokines, soluble receptors, growth factors, and matrix 
metalloproteinases in this study are listed in appendix A2 and measured according to 
the manufacturer’s protocols. Briefly, heparin/EDTA plasma samples as well as cell 
culture supernatant were diluted as recommended. Any samples that were above the 
upper standard range were further diluted. Diluted samples, controls, and standards 
were added to the microparticle mixture for 2 hours at room temperature in the dark 
on a microplate shaker. Following washing, biotin antibody cocktail was added, and 
further incubated for 1 hour. Following washing with washing buffer, Streptavidin 
conjugated with phycoerythrin was added for 30 minutes. Analytes were measured by 
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Bioplex 200 (Bio-Rad, USA). Data were analyzed by Bioplex manager 4.1.1 software 
(Bio-Rad, USA).  
 
2.8 Peripheral blood mononuclear cells (PBMCs) isolation 
and activation  
 
50 ml bloods taken from healthy donors were diluted with plain RPMI 1640 
(PAA, Austria) in a 1:1 ratio. 35 ml diluted blood was gently overlaid on top of 15 ml 
lymphoprep (Nycomed, Norway) in a 50 ml falcon tube, followed by centrifuging at 
2000 rpm for 30 minutes at room temperature with no break. PBMCs were drawn off 
at the interface layer between the serum and lymphoprep using a pastette. They were 
transferred to a new 50 ml tube, and washed three times with plain RPMI 1640 for 10 
minutes at 2000 rpm, 1000 rpm and 1500 rpm, respectively. Cells were resuspended 
in RPMI 1640 supplemented with 10% fetal bovine serum (R10) and counted. 
 
Activated PBMCs were generated by stimulating cells (1-2 x106 cells/ml) with 
100 ng/ml phorbol 12-myristate 13-acetate (PMA) and 500 ng/ml ionomycin for 24 
hours. Cells were washed with R10 three times before performing an experiment. 
Activated PBMCs were confirmed with anti-CD69 antibody conjugated with 
fluorescence (Dako, Denmark) by flow cytometry using a FACSCalibur (BD 
Biosciences, USA). 
 
2.9 Dendritic cells preparation, infection and co-culture 
 
CD14+ cells were isolated by positive selection from PBMCs using MACS 
CD14 microbeads (Miltenyi Biotec, Germany). Briefly, PBMCs were centrifuged at 
300 g for 10 minutes. Cell pellet was resuspended in 80μl of MACS buffer per 10μl of 
CD14 microbeads per 107 total cells. Cell suspension was rotated at 4 ºC for 30 
minutes and washed by adding 2 ml buffer per 107 total cells prior to centrifugation at 
300 g for 10 minutes. Cell pellet was resuspended up to 108 in 500μl of buffer, 
applied on to the column and washed three times with buffer. The magnetically 
labeled cells were flushed out by adding the appropriate amount of R10. CD14+ cells 
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were counted and the purity of CD14+ cells was determined by flow cytometry using 
anti CD14-PE antibody (eBioscience, USA). CD14+ cells at 5x105 cells/ml were 
cultured in R10 with 20 ng/ml human rGM-CSF (First link, UK), and 25 ng/ml 
human rIL-4 (eBioscience, USA) for 5 days at 37 ºC in a 5% CO2 incubator. On day 
3, half of the culture media was carefully discarded and replaced with fresh media 
with GM-CSF at 40ng/ml and IL-4 at 50ng/ml. Immature dendritic cells (DCs) were 
harvested, counted and confirmed with anti CD83-FITC (BD Biosciences, USA), anti 
CD14-PE, and anti CD209 (DC-SIGN; R&D systems, USA) followed by anti mouse 
IgG conjugated with phycoerythrin (anti mouse-PE; Dako, Denmark) by flow 
cytometry using the FACSCalibur.   
 
For infection of DCs, cells were treated with mock or infected with DV2 for 2 
hours at a multiplicity of infection (MOI) of 2. Cells were washed twice with R10 
before performing an experiment. Infectivity was determined at 24 hours after 
infection by the FACSCalibur using 4G2 antibody (1 μg/staining) and anti mouse-PE 
(0.5 μg/staining). For the kinetic experiment, mock treated- and DV2 infected-cells 
supernatants were collected at 6, 12, 24, 48, and 72 hours after infection.  
 
Resting/activated PBMCs and/or HUVECs were co-cultured with mock 
treated or DV2-infected DCs (cell numbers - PBMCs: HUVECs: DCs 2x105: 1x105: 
2x104) in a 96-well plate. Cell supernatants were collected at 24 hours after coculture. 
Infectivity was determined at 24 hours after infection by flow cytometry using 4G2 
antibody. For the kinetic experiment, mock treated- and DV2 infected-cells 
supernatants were collected at 6, 12, 24, 48, and 72 hours after infection.  
 
2.10 HUVEC cell culture and infection  
 
Human umbilical vein endothelial cells (HUVECs) were purchased from 
Lonza (Lonza, Switzerland) and grown using the EGM bullet kit (Lonza, 
Switzerland). For infection of HUVECs, 2x104 cells were seeded on a 96-well plate 
and infected with DV2 at a MOI of 5 for 2 hours. Cells were washed with 100μl of 1x 
Hank’s balanced salt solution (HBSS, Lonza, Switzerland) twice before adding 100μl 
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of EGM media. Cell supernatants were collected at 24 and 48 hours after infection. 
Infected cells were observed by immunoperoxidase staining as described above.  
 
2.11 Transwell experiment 
 
HUVECs (2x105 cells) were seeded in a volume of 500μl on a lower chamber 
of a 24-well transwell plate (Transwell permeable support 0.4μm; Corning, USA). 
Activated PBMCs were stimulated with 100 ng/ml PMA and 500 ng/ml ionomycin 
for 24 hours. On the day of co-incubation, EGM was discarded and replaced with 
700μl of R10. 1x106 cells of activated PBMCs or resting PBMCs in 200μl of R10 
were added to an upper chamber of the transwell. Supernatants from the lower 
chamber were collected at 24 hours after incubation. Mixtures of HUVECs and 
resting PBMCs/activated PBMCs were used as controls.  
 
2.12 Flow cytometry 
 
Cells were harvested from containers and centrifuged at 1500 rpm for 5 
minutes to remove supernatant. Following washing once with PBS, antibodies (0.5μg) 
against CD14-PE (eBioscience, USA), CD83-FITC (BD Biosciences, USA), CD69-
FITC (Dako, Denmark), were added directly to the cells for 30 minutes at 4 ºC. 
Isotype controls were used as negative controls. For the CD209 staining, cells were 
incubated with 1μg mouse anti CD209 for 30 minutes at 4 ºC. Following washing 
with PBS 1ml, anti mouse-PE (0.5 μg/staining) was added to the cells for 1 hour at 4 
ºC. Cells were washed with PBS and fixed with FACS fix solution. 
 
For intracellular staining of infection, cells were fixed with 3.7% 
formaldehyde for 30 minutes, washed once with 1x PBS, and permeablized with 0.5% 
saponin/FACS wash for 15 minutes at room temperature. Following washing, cells 
were stained with 4G2 (1 μg/staining) for 1 hour at 4 ºC and washed with 0.5% 
saponin/FACS wash. Anti mouse-PE (0.5μg/staining) was subsequently added and 
incubated for 30 minutes at 4 ºC before washing. Cells were analyzed on a 
FACSCalibur (BD Biosciences, USA). 
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2.13 Activation of MMP-3 
 
Recombinant human MMP-3 (R&D systems, USA) was activated at 20 μg/ml 
in an assay buffer containing 5μg/ml chymotrypsin. The reaction was incubated for 30 
minutes at 37 ºC, and stopped with PMSF (2mM). Assay buffer without MMP-3 was 
used as a negative control. Following the activation, MMP-3 was purified with a Zeba 
spin desalting column (7K MWCO; Thermo Fisher scientific, USA) and eluted with 
the assay buffer without Brij-35.  
 
To test its activity, 50μl of MMP-3 at 2.5 ng/μl was mixed with 50μl of 20 μM 
fluorogenic MMP-3 substrate (MCA-Arg-Pro-Lys-Pro-Val-Glu-NVAL-Trp-Arg-
Lys(DNP)-NH2) in assay buffer. Fluorescence signal was read with a fluorescent plate 
reader (SpectaMax M2; Molecular Devices, USA) in a kinetic mode for 5 minutes at 
320 and 405 nm excitation and emission, respectively. Specific activity 
(pmol/min/μg) was calculated. 
 
Specific Activity = Rate (RFU/sec) x Conversion factor (pmole/RFU) x 60 sec/min 
 MMP-3 amount (μg) 
 
To determine the conversion factor (CF), a standard curve was constructed 
using a peptide fragment linked with only the fluorescence group (MCA-Pro-Leu-OH; 
Enzo Life Sciences, USA). The peptide fragments were added into a 96-well black 
well plate at different amounts in assay buffer (0, 40, 80, 120, 160, and 200 pmoles). 
Relative fluorescence unit (RFU) was read at 320/405 nm. RFU (y-axis) was plotted 
against the amount of peptide (x-axis) and fitted by linear regression (y = mx+c). The 
slope of the line (m) represents RFU at 1 pmole. 
 
The active form of MMP-3 was confirmed by Western blot. 100 ng of 
proMMP-3, active MMP-3 and buffer was heated at 95 ºC for 5 minutes before 
loading onto a 10% reducing SDS-PAGE. Following electrophoresis, proteins on the 
gel were transferred to the nitrocellulose membrane, which was then blocked with 5% 
skimmed milk.  MMP-3 was detected by mouse anti-human MMP-3 (Abcam, UK) at 
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a dilution 1:1000 at 4 ºC overnight, and anti mouse-HRP (1:1000) for 1 hour at room 
temperature.  
 
2.14 In vitro Endothelial Permeability assay 
 
100μl of HUVECs (2x104 cells) were seeded on an upper insert assembly of a 
96-well polyester membrane transwell plate (Corning, USA), which was pre-coated 
with 10 μg/cm2 type I rat tail collagen (Sigma-Aldrich, USA) and 250μl of EGM was 
added in a lower receiver chamber of the plate. Cells were incubated in a moisture 
chamber for 3 days. The confluence of the HUVECs monolayer was examined by 
crystal violet staining. Stained insert was not used for permeability testing. The media 
from both chambers was carefully removed. Media containing TNF-α at 100 ng/ml 
(R&D systems, USA), active MMP-3 at the initial concentration of 1 μg/ml, and the 
assay buffer were added to the cells for 24 hours. EGM media only was added into 
control wells; negative control, background, and no monolayer. Following completion 
of permeability treatment, 100μl of 1 mg/ml 70 kDa FITC-dextran diluted in growth 
media was added in an upper chamber and 250μl of growth medium was added in the 
receiver plate. The FITC-dextran was allowed to permeate at room temperature for 30 
minutes, protected from light. 100μl of media in the lower chamber was removed and 
transferred to a black 96-well plate. Fluorescence was read at 485 nm and 538 nm 
excitation and emission, respectively by a fluorescent plate reader. After completion 
of permeability testing, the cell monolayer was stained for imaging of cell integrity. 
 
2.15 Statistical Analyses 
 
Complement genetics 
 
Hardy-Weinberg equilibrium and Association tests were carried out by using 
the 2 test. The formula is 2 = Ʃ (observed – expected)2/expected. Observed values 
were obtained from the numbers of genotypes counted in the experiment, and 
expected values were calculated according to the Hardy-Weinberg law (p2+2pq+q2).  
Logistic regression model was used to adjust odds ratio with sex and age.  
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Bonferroni’s correction was performed by dividing α-level with the total number of 
polymorphisms compared (n=6) to obtain an adjusted p-value of <0.05/6 = 0.008. The 
analyses were performed on SPSS version 19.0 (SPSS, Inc, USA). 
 
Biomarkers 
 
Analysis was performed using the R statistical programming package [R 
Development Core Team 2011 (Team, 2011)] and SPSS version 19 (SPSS, Inc., 
USA). Mann-Whitney U test and Kruskal-Wallis were used to compare univariates in 
two and three groups, respectively. To avoid the false positive from multiple-
comparison, Bonferroni’s correction was performed by dividing α-level with the total 
number of markers compared (n=66) to obtain an adjusted p value of <0.05/66 = 7.6 x 
10-3. 
 
Multivariate analysis was performed by binary logistic regression and 
classification and regression tree (CART). Of the 66 biomarkers, 35 had > 10% of 
data missing or fell below the lower detection limit and were subsequently removed 
from the multivariate analysis. Data below the limitation were imputed to the low 
limit/2. The dataset was randomly divided by the computer program into a 2/3 
training data set and a 1/3 test data set. The use of separate test and training datasets 
was to avoid the well-known phenomenon of “modeling noise” whereby an 
overoptimistic estimation would be obtained if predictiveness of a model is assessed 
using the same data that was used to obtain the model. A predictive model was 
estimated for each of the two techniques using the training data set and predictions 
obtained using the model for the test dataset. The predictive ability of the two 
methods was then compared by using ROC curve methodology on the predicted 
values.  
 
Matrix Metalloproteinases 
 
Pearson’s correlation was performed to test an association between MMPs and 
peripheral blood cells. Student’s T test was performed for in vitro studies.  Statistical 
significance was considered at a p-value less than 0.01 as the total number of proteins 
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interested was 5 (0.05/5 = 0.01). Analysis was performed using SPSS version 19 
(SPSS, Inc., USA). 
 
2.16 Binary logistic Regression 
 
The markers with a skewness greater than one, according to the R package 
“moments” (Novomestky, 2012),  were log transformed to achieve roughly symmetric 
covariate values  (KAY, 1987, Grund, 2010 #521) and to avoid the potential influence 
of outliers. One was added to each biomarker before transforming to avoid zero 
values being discarded. Logistic regression was employed with DHF/DF as the binary 
outcome variable. This approximates the log odds of the probability of DHF status 
using a weighted combination of a subset of predictive biomarkers by backward 
elimination of non-significant biomarkers using the  “lrm” and “fastbw”  functions 
from the R package rms (Jr, 2012). The goodness of fit was assessed by the Le 
Cessie-van Houwleningen-Copas-Hosmer test (Copas, 1989, Cole, 1991 #524). The 
model was refitted using ordinary generalized linear model (glm) and the fit assessed 
using the Hosmer-Lemeshow function.  
 
2.17 Classification and Regression tree modeling (CART) 
 
Classification tree was performed for categorical outcome using R package 
“rpart”(Ripley, 2011). To measure the purity of the split in which the values are 
predominately of one outcome, the Gini index was used. The minimal number of 
observations in a node was set at 10. The tree output for the training data set gave the 
numbers and proportions of each outcome group in each split. The tree was plotted 
using the “partykit” package (Zeileis, 2012). 
 
2.18 Receiver operating characteristic (ROC) 
 
ROC curve was performed in R package “ROCR” (Lengauer, 2009). Area 
under ROC curve (AUC) was used to evaluate the accuracy of the model. The 
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sensitivity, the specificity and the optimal cutoff of the estimated probability of DHF 
were obtained by Youden’s index which maximizes sensitivity plus specificity.  
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3.1 Introduction 
 
The complement system is an essential part of host defense against flavivirus 
infection and complement activation occurs during a course of infection. There has 
been evidence showing that mice knocking out complement elements (C3, C1q, C4, 
or factor B [FB]) are at risk to get West Nile virus (WNV) infection (Avirutnan et al., 
2008). C1q is able to reduce the antibody-dependent enhancement (ADE) of both 
WNV and Dengue infection, as a result of increase in neutralization activity (Mehlhop 
et al., 2007). In DHF patients, C3 activation is increased while levels of C4 and FB 
are reduced (Bokisch et al., 1973). When compared to DF, levels of C3 are decreased 
while levels of C3a and C3b, fragments of C3 cleavage, are increased in DHF 
(Nascimento et al., 2009). C5b-9 complexes, together with high levels of Dengue NS1 
protein, also correlate with Dengue severity (Avirutnan et al., 2006).  
 
The mechanism by which complement regulates flavivirus infection is not 
completely known. Complement C4, a classical pathway activation protein, is able to 
bind Dengue NS1, leading to C4 degradation (Avirutnan et al., 2010). In addition, 
complement regulatory protein, complement factor H (CFH) can bind to WNV NS1, 
an interaction that prevent complement activation in a solution and  complement-
mediated lysis on infected cells (Chung et al., 2006). In contrast, Japanese 
Encephalitis virus (JEV) NS1 does not interact to CFH and does not influence the host 
innate immune response (Krishna et al., 2009). 
 
Activation of alternative complement pathway can be influenced by genetic 
variations in complement proteins C3, FB and CFH (C3-102: rs2230199; FB-32: 
rs12614 and rs641153; CFH-62: rs800292; collectively called the ‘complotype’); this 
complotype is associated with a 6-fold variation in complement haemolytic activity in 
vitro (Heurich et al., 2011). That the variation in lytic activity governed by these 
polymorphisms is biologically relevant was supported by the association of the 
complotype with age-related macular degeneration (AMD, (Hageman et al., 2005, 
Gold et al., 2006, Yates et al., 2007)). Increased susceptibility to AMD are found in 
individuals with the ‘high’ activation’ complotype (FB-32 R/R: rs12614 [C] and 
rs641153 [G]; CFH-62 V/V: rs800292 [G]; and C3-102 F/F: rs2230199 [G]) whereas 
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those with the ‘low activation’ complotype have decreased risk (FB-32 Q/Q rs12614 
[C] and rs641153 [A]; CFH-62 I/I: rs800292 [A]; and C3-102 S/S: rs2230199 [C]). 
These data support the findings that serum complement activation can be enhanced in 
AMD (Reynolds et al., 2009). 
 
Genetic polymorphisms across the region encoding CFH and CFH-related 
proteins (CFHR) also influence on AMD. These are a polymorphism within CFH 
(CFH-402 Y/H: rs1061170, (Gold et al., 2006)) and a common deletion 
polymorphism that affects CFH-related proteins 1 and 3 (CFHR3-1, (Spencer et al., 
2008)). Recently, polymorphisms in CFH promoter (-332 C/T, rs3753394) and in 
CFH-62 (V/V: rs800292 [G]) have been linked to Dengue disease although the 
function of these polymorphism is not well understood (Pastor et al., 2013). In this 
study, it was hypothesized that Dengue severity during secondary infection is 
influenced by these complement genetic polymorphisms.  Since the variation in the 
complotype (CFH rs800292, FB rs12614/rs641153 and C3 rs2230199) has been 
associated with different degree of complement activation, the relationship between 
Dengue infection and the complotype was specifically observed. The AMD-
associated CFH rs1061170 variant, the CFH promoter rs3753394 variant and the 
CFHR3-1 deletion polymorphism were also included. Besides, the interaction 
between Dengue NS1 and CFH protein was investigated. Because both NS1 and CFH 
have been identified in the extracellular space and on the cell membrane, the 
interaction between these two proteins was tested by three methods: ELISA, Far 
western blot, and Co-immunoprecipitation. 
  
Except for CFH rs800292, all single nucleotide polymorphisms (SNPs) in this 
study were identified by PCR amplification using specific primers and sequencing. 
The genotypes were then recorded. To detect the CFH rs800292 (CFH-62 V/I: G/A) 
polymorphism, Taqman SNP genotyping assay was used. The principal of Taqman 
SNP genotyping is shown in Figure 3.1. Briefly, the first step is PCR amplification 
using specific primers and two Taqman probes for distinguishing between two 
different alleles. Each probe contains a reporter dye at the 5’ end (VIC® dye is linked 
to the allele 1 [A], and FAM™ dye is linked to the allele 2 [G]), a non-fluorescence 
quencher at the 3’ end and a minor groove binder, which allows greater specificity of 
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the probe. During PCR, probes specifically anneal to complementary sequences 
between the primer sites. DNA polymerase, which has 5’ nuclease activity, cleaves 
probes that are hybridized to the target and the reporter dye is therefore separated 
from the quencher, resulting in increased fluorescence signals. A VIC-dye only 
represents homozygosity for allele 1 (A/A), a FAM-dye only represents homozygosity 
for allele 2 (G/G), and both VIC and FAM signals indicate heterozygosity (G/A).  
 
  
 
 
Figure 3.1: The principal of Taqman SNP genotyping assay (Applied Bioscience) 
 
 
To detect the CFHR3-1 polymorphism, a combination of (i) Taqman copy 
number assay probes, (ii) genotyping of CFH rs6677604, and (iii) multiplex ligation-
dependent probe amplification assay (MLPA) was used. 
 
Taqman copy number assay is a duplex real-time PCR, simultaneously 
detecting a target gene of interest (CFHR1 or CFHR3) and a reference gene which is 
known to have a diploid genome (RNAse P) (Figure 3.2). The copy number of the 
target gene is determined by relative quantitation using the comparative cycle 
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threshold (CT). The CT is the point where fluorescence signal exceeds the 
background level. This method measures the CT difference between the target and the 
reference gene (CT), and then compares the CT in the test samples to the reference 
samples in which the target genes are known to have 2 copies. A FAM™ dye probe is 
used to detect the target gene while a VIC® dye-labeled TAMRA™ probe detects the 
reference gene. 
 
 
 
Figure 3.2: The principal of Taqman copy number assay (Applied Bioscience) 
 
 
The CFH rs6677604 is the SNP within intron 12 of the CFH gene. The allele 
‘A’ has been shown to tag the CFHR3-1 deletion allele and the allele ‘G’ has been 
linked to the common CFHR3-1 allele (Gharavi et al., 2011). 
  
The MLPA technology is a multiplex PCR method detecting copy number 
changes (Figure 3.3). MLPA reactions are divided into five steps: 1) DNA 
denaturation and MLPA probes hybridization, 2) ligation reaction, 3) PCR 
amplification, 4) capillary electrophoresis, and 5) data analysis. First, genomic DNA 
is denatured and hybridized with a mixture of MLPA probes. One set of MLPA 
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probes includes two oligonucleotides, each carrying the PCR primer sequences 
(primer X and primer Y; black labelled) and hybridizing sequences (blue labeled). In 
addition, one oligonucleotide also contains a stuffer sequence (green labeled) which 
varies in length in order that PCR fragments can be separated by electrophoresis. The 
two oligonucleotides hybridize to adjacent DNA sequences and can be ligated during 
the ligation reaction. The ligation products are amplified using only one set of primers 
and the number of probes ligated reflects the number of targets in the samples. By 
capillary electrophoresis, the PCR products having unique lengths (113-454 bp) are 
separated. Finally the peak patterns are generated. The relative peak heights are 
compared.   
 
 
 
Figure 3.3: Multiplex ligation-dependent probe amplification assay (MLPA) 
technique (MRC-Holland) 
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3.2 Results 
 
3.2.1 Study population 
 
The demographics of the study population are shown in Table 3.1. The age of 
patients with Dengue infection and other febrile infection (OFI) was between 2-15 years 
while that of healthy controls was 19-47 years. The number of males and females within 
all groups was somewhat equivalent with the exception of the two females in the DHF4 
sub-group. Only patients with secondary Dengue infection were included in this study. 
 
 
Table 3.1: Study population demographics 
Group N 
Sex Age 
Male Female Median Range 
Healthy 22 9 13 21 19-47 
Other febrile illnesses (OFI) 63 28 35 8 2-15 
DF 121 61 60 10 3-15 
DHF1 68 35 33 9.5 2-15 
DHF2 76 47 29 11 5-15 
DHF3 41 19 22 10 4-15 
DHF4 2 0 2 7.5 5-10 
Healthy and other febrile illness (OFI) sub-groups were utilised as non-Dengue controls.  
DF= Dengue fever; DHF1-4 = Dengue Hemorrhagic fever 1-4 
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3.2.2 Complement gene polymorphisms between patients with severe and non-
severe Dengue infection in the Thai population 
 
The individual SNP frequencies in FB (rs12614, rs641153), C3 (rs2230199) and 
CFH (rs3753394, rs1061170, and rs800292) were identified. The SNP frequencies did 
not differ between the patients with Dengue infection and the non-Dengue controls 
(healthy controls and individuals with other febrile illness [OFI]) (Table 3.2). Next, the 
SNP frequencies between Dengue infection sub-groups defined as those with DF (n = 
121) and those with DHF (n = 187) were examined (Table 3.3). The risk of patients 
with the genotype TT (the CFH rs1061170) getting DHF was about two times the risk 
of patients with the other genotypes (CT + CC) getting DHF (adjusted OR =2.03; 95% 
CI = 1.15-3.60; Table 3.3). Although the odd ratio and the 95% CI suggested an 
association between this genotype and getting DHF but the allele frequencies at the 
CFH rs1061170 in patients with DF or those with DHF were not significantly different 
at p-value of 0.008 (p-value = 0.01; Table 3.3; see section 2.15 in Materials and 
Methods for the adjusted p-value) suggesting that the allele T was not associated with 
DHF. No differences in other SNPs were associated with the Dengue infection (Table 
3.3). Nor did genotypes and alleles between patients with shock (n = 43, defined as 
DHF3 and DHF4) and without shock (n= 144, defined as DHF1 and DHF2; Table 3.3) 
differ. 
 
Of note, the minor allele frequencies of C3 rs2230199 and the adjacent rs12614 
and rs641153 FB variants were low (C3: 2% and FB: <10%). This is in contrast to the 
minor allele frequency of the CFH rs800292 polymorphism which was about 42% in 
this population but its frequency was similar in Dengue sup-groups. Since variations at 
the C3 rs2230199, FB rs12614 and FB rs641153 were rare, patients with either the most 
(C3F/F, FB-32R [C/G at the adjacent rs12614/rs641153] and CFH 62V) or least 
(C3S/S, FB-32Q [C/A at the adjacent rs12614/rs641153] and CFH 62I) active 
complotype described in vitro could not be observed (Heurich et al., 2011) (Table 3.4). 
 1
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Table 3.2: Relationship of complement gene polymorphisms between Dengue infection and controls  
 
Locus of SNP Genotype Phenotypea All Dengue infection Controls OFI Healthy P-valueb 
CFH rs1061170 TT 402 Tyr 247 (80.2) 68 (80.0) 51 (81.0) 17 (77.3)  
 CT 402 Tyr/His 57 (18.5) 16 (18.8) 11 (17.5) 5 (22.7)  
 CC 402 His 4 (1.3) 1 (1.2) 1 (1.6) 0 (0.0)  
 Frequency T:C  
0.89:0.11 
N = 308 
0.89:0.11 
N = 85 
0.90:0.10 
N = 63 
0.89:0.11 
N = 22 
1 
CFH rs3753394 CC - 84 (27.4) 22 (25.9) 16 (25.4) 6 (27.3)  
 CT - 154 (50.2) 41 (48.2) 30 (47.6) 11 (50.0)  
 TT - 69 (22.5) 22 (25.9) 17 (27.0) 5 (22.7)  
 Frequency C:T  
0.52:0.48 
N = 307 
0.50:0.50 
N = 85 
0.49:0.51 
N = 63 
0.52:0.48 
N = 22 
0.60 
CFH rs800292 GG 62 Val 104 (34) 32 (37.6) 22 (34.9) 10 (45.5)  
 GA 62 Val/Ile 150 (49) 41 (48.2) 32 (50.8) 9 (40.9)  
 AA 62 Ile 52 (17) 12 (14.1) 9 (14.3) 3 (13.6)  
 Frequency G:A  
0.58:0.42 
N = 306 
0.62:0.38 
N = 85 
0.60:0.40 
N = 63 
0.66:0.34 
N = 22 
0.48 
FB rs12614 CC - 270 (88.8) 77 (90.6) 57 (90.5) 20 (90.9)  
 CT - 33 (10.9) 8 (9.4) 6 (9.5) 2 (9.1)  
 TT - 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)  
 Frequency C:T  
0.94:0.06 
N = 304 
0.95:0.05 
N = 85 
0.95:0.05 
N =63 
0.95:0.05 
N = 22 
0.71 
FB rs641153 GG - 252 (83.2) 69 (81.2) 50 (79.4) 19 (86.4)  
 GA - 50 (16.5) 16 (18.8) 13 (20.6) 3 (13.6)  
 AA - 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)  
 Frequency G:A  
0.91:0.09 
N = 303 
0.91:0.09 
N = 85 
0.90:0.10 
N = 63 
0.93:0.07 
N = 22 
0.64 
C3 rs2230199 CC 102 Arg (C3S) 300 (98) 83 (97.6) 61 (96.8) 22 (100.0)  
 CG 102 Arg/Gly (C3S/C3F) 2 (0.7 2 (2.4) 2 (3.2) 0 (0.0)  
 GG 102 Gly (C3F) 4 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)  
 Frequency C:G  
0.98:0.02 
N = 306 
0.98:0.02 
N =85 
0.98:0.20 
N = 63 
1.00:0.00 
N = 22 
1 
Data shown are the number (percentage) of patients with Dengue fever (DF) or Dengue Hemorrhagic fever (DHF), with genotypic variations and allelic frequency ratio of each complement gene.; SNP, single nucleotide polymorphism 
a) number e.g. 402 refers to amino acid number where methionine = 1, C3S and C3F refer to 'slow' and 'fast' alleles; b)  Dengue  vs controls 
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Table 3.3: Relationship between complement gene polymorphisms and Dengue infection severity 
 
Locus of SNP Genotype Phenotypea 
All Dengue 
infection 
DF DHF P-valuec OR (95%CI) 
Adjusted OR 
(95%CI)b 
DHF without 
shock 
DHF with 
shock 
P-valued OR (95%CI) 
Adjusted OR 
(95%CI)b 
CFH rs1061170 TT 402 Tyr 247 (80.2) 89 (73.6) 158 (84.5)  1.96 (1.11-3.45) 2.03 (1.15-3.60) 121 (84.0) 37 (86.0)  1.17 (0.44-3.10) 0.99 (0.36-2.70) 
 CT 402 Tyr/His 57 (18.5) 29 (24.0) 28 (15.0)  0.56 (0.31-1.00) 0.53 (0.30-0.96) 22 (15.3) 6 (14.0)  0.90 (0.34-2.38) 1.06 (0.39-2.1) 
 CC 402 His 4 (1.3) 3 (2.5) 1 (0.5)  0.21 (0.02-2.06) 0.24 (0.02-2.32) 1 (0.7) 0 (0.0)  - - 
 Frequency T:C  
0.89:0.11 
N =308 
0.86:0.14 
N =121 
0.92:0.08 
N =187 
0.01 2.01 (1.19-3.38) - 
0.92:0.08 
N =144 
0.93:0.07 
N =43 
1 1.16 (0.46-2.95) - 
CFH rs3753394 CC - 84 (27.4) 36 (29.8) 48 (25.8)  0.82 (0.49-1.37) 0.79 (1.47-1.32) 34 (23.8) 14 (32.6)  1.55 (0.74-3.26) 1.66 (0.77-3.57) 
 CT - 154 (50.2) 65 (54.2) 89 (47.8)  0.79 (0.50-1.25) 0.80 (0.51-1.28) 69 (48.3) 20 (46.5)  0.93 (0.47-1.85) 0.92 (0.46-1.84) 
 TT - 69 (22.5) 20 (16.7) 49 (26.3)  1.81 (1.01-3.23) 1.83 (1.02-3.28) 40 (27.9) 9 (20.9)  0.68 (0.30-1.55) 0.66 (0.29-1.50) 
 Frequency C:T  
0.52:0.48 
N =307 
0.57:0.43 
N =121 
0.50:0.50 
N =186 
0.1 0.76 (0.55-1.05) - 
0.48:0.52 
N =143 
0.56:0.44 
N =43 
0.22 1.37 (0.85-2.23) - 
CFH rs800292 GG 62 Val 104 (34) 33 (27.7) 71 (38.0)  1.60 (0.97-2.63) 1.61 (0.98-2.66) 59 (41.0) 12 (27.9)  0.56 (0.27-1.17) 0.57 (0.27-1.22) 
 GA 62 Val/Ile 150 (49) 65 (54.6) 85 (45.5)  0.69 (0.44-1.10) 0.70 (0.44-1.11) 63 (43.8) 22 (51.2)  0.74 (0.38-1.47) 0.78 (0.39-1.56) 
 AA 62 Ile 52 (17) 21 (17.6) 31 (16.6)  0.93 (0.50-1.70) 0.90 (0.49-1.66) 22 (15.3) 9 (20.9)  1.47 (0.62-3.48) 1.54 (0.64-3.71) 
 Frequency G:A  
0.58:0.42 
N =306 
0.55:0.45 
N =119 
0.61:0.39 
N =187 
0.18 1.26 (0.91-1.75) - 
0.63:0.37 
N =144 
0.53:0.47 
N =43 
0.13 0.68 (0.42-1.11) - 
FB rs12614 CC - 270 (88.8) 105 (87.5) 165 (89.7)  1.24 (0.60-2.55) 1.21 (0.59-2.50) 126 (88.7) 39 (92.9)  1.65 (0.46-5.96) 1.64 (0.45-6.02) 
 CT - 33 (10.9) 15 (12.5) 18 (9.8)  0.76 (0.37-1.57) 0.78 (0.37-1.61) 15 (10.6) 3 (7.1)  0.65 (0.18-2.37) 0.67 (0.18-2.46) 
 TT - 1 (0.3) 0 (0.0) 1 (0.5)  - - 1 (0.7) 0 (0.0)  - - 
 Frequency C:T - 
0.94:0.06 
N = 304 
0.94:0.06 
N =120 
0.95:0.05 
N = 184 
0.72 1.16 (0.58-2.31) - 
0.94:0.06 
N =142 
0.96:0.04 
N =42 
0.58 1.72 (0.49-6.01) - 
FB rs641153 GG - 252 (83.2) 99 (83.2) 153 (83.2)  1.00 (0.54-1.85) 1.04 (0.56-1.93) 120 (84.5) 33 (78.6)  0.67 (0.28-1.60) 0.65 (0.27-1.56) 
 GA - 50 (16.5) 20 (16.8) 30 (16.3)  0.96 (0.52-1.79) 0.92 (0.50-1.73) 22 (15.5) 8 (19.0)  1.28 (0.53-3.14) 1.34 (0.54-3.31) 
 AA - 1 (0.3) 0 (0.0) 1 (0.5)  - - 0 (0.0) 1 (2.4)  - - 
 Frequency G:A  
0.91:0.09 
N =303 
0.92:0.08 
N =119 
0.91:0.09 
N =184 
1 0.96 (0.54-1.73) - 
0.92:0.08 
N =142 
0.88:0.12 
N =42 
0.27 0.62 (0.28-1.37) - 
C3 rs2230199 CC 102 Arg (C3S) 300 (98) 118 (99.2) 182(97.3)  0.31 (0.04-2.67) 0.30 (0.03-2.63) 139 (96.5) 43 (100)  - - 
 CG 102 Arg/Gly (C3S/C3F) 2 (0.7) 1 (0.8) 1 (0.5)  0.63 (0.04-10.24) 0.55 (0.03-9.08) 1 (0.7) 0 (0.0)  - - 
 GG 102 Gly (C3F) 4 (1.3) 0 (0.0) 4 (2.2)  - - 4 (2.8) 0 (0.0)  - - 
 Frequency C:G  
0.98:0.02 
N =306 
1.00:0.00 
N =119 
0.98:0.02 
N =187 
0.1 0.17 (0.02-1.36) - 
0.97:0.03 
N =144 
1.00:0.00 
N =43 
0.13 - - 
Data shown are the number (percentage) of patients with Dengue fever (DF) or Dengue Hemorrhagic fever (DHF), with genotypic variations and allelic frequency ratio of each complement gene.; OR, Odds ratio; SNP, single nucleotide polymorphism 
a) Number e.g. 402 refers to amino acid number where Methionine = 1, C3S and C3F refer to 'slow' and 'fast' alleles; b) Adjusted for Sex, and Age at the presence of  Dengue disease by Logistic Regression; c) DF vs DHF; d) no shock vs shock; 
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Table 3.4: Relationship between complotype and Dengue infection severity 
Complotype 
Complement 
activation 
DF  
(n = 115) 
DHF  
(n = 184) P-valuec 
OR 
 (95%CI) 
Adjusted ORb 
(95%CI) 
DHF 
without 
shock 
(n=142) 
DHF with 
shock 
(n=42) P-valued OR (95%CI) 
Adjusted ORb 
(95%CI) 
Combined polymorphisma            
FB32-R/FH62-V/C3F High 0 (0.0) 0 (0.0) - - - 0 (0.0) 0 (0.0) - - - 
FB-32R/FH-62V High 25 (21.7) 53 (28.8) 0.22 1.46 (0.84-2.51) 1.46 (0.84-2.52) 45 (31.7) 8 (19.0) 0.12 
0.51 (0.22-
1.18) 
0.51 (0.22-
1.20) 
FB32-R/C3F High 0 (0.0) 4 (2.2) 0.16 - - 4 (2.8) 0 (0.0) 0.56 - - 
FB32-Q/FH62-I/C3S Low 0 (0.0) 0 (0.0) - - - 0 (0.0) 0 (0.0) - - - 
FH62-I/C3S Low 20 (17.4) 29 (15.8) 0.75 0.89 (0.48-1.66) 0.87 (0.46-1.63) 20 (14.1) 8 (19.0) 0.47 
1.46 (0.84-
2.51) 
1.46 (0.84-
2.52) 
FB32-Q/C3S Low 0 (0.0) 1 (0.5) 1 - - 0 (0.0) 1 (2.3) 0.23 - - 
Data are expressed as number (percentage) of patients, DF - Dengue fever, DHF - Dengue Hemorrhagic fever, OR - odds ratio. a) Number refers to amino acid number where Methionine = 1.  
FB32-R and FB32-Q refer to 'Arginine' and 'Glutamine'. FH62-V and FH62-I refer to 'Valine' and 'Isoleucine'. C3S and C3F refer to 'slow' and 'fast' alleles. b) Adjusted for sex and age at presentation using logistic 
regression, c DF vs. DHF and d no shock vs. shock. 
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 Next, to determine if the SNPs satisfy the Hardy-Weinberg equilibrium (HWE), 
the condition that the genotype frequencies in a population remain constant over the 
generations, a chi-square test was performed. The observed and expected genotype 
frequencies were detected. The observed and expected counts of all SNPs, except the 
C3 rs2230199, were equivalent, indicating that these SNPs were in HWE (Table 3.5).  
 
Table 3.5: Hardy Weinberg Equilibrium (HWE) 
SNPs Genotype Observed  counts Expected counts X2 value  HWE P-value 
CFH rs1061170 CC 5 4.38   
  CT 73 74.24     
 TT 315 314.38   
  Frequency T:C 0.89:0.11   0.11 0.74 
CFH rs3753394 CC 106 105.64   
  CT 195 195.71     
 TT 91 90.64   
  Frequency C:T 0.52:0.48   0.01 0.94 
CFH rs800292 GG 136 137.06   
  GA 191 188.87     
 AA 64 65.06   
  Frequency G:A 0.59:0.41   0.05 0.82 
FB rs12614 CC 347 347.19   
  CT 41 40.62     
 TT 1 1.19   
  Frequency C:T 0.94:0.06   0.03 0.85 
FB rs641153 GG 321 322.98   
  GA 66 62.04     
 AA 1 2.98   
  Frequency G:A 0.91:0.09   1.58 0.21 
C3 rs2230199 CC 383 379.09   
  CG 4 11.82     
 GG 4 0.09   
  Frequency C:G 0.98:0.02   171.08 < 0.0001 
The expected genotype frequencies are computed from Hardy Weinberg equation n(p2+2pq+q2)   
where p and q are the allele frequencies and n is the total number of genotypes   
x2 = Ʃ (observed counts– expected counts)2 /expected counts   
H0: the population is in Hardy–Weinberg equillibrium (HWE); H1:  the population is not in HWE  
H0 is rejected when p-value < 0.05 at degree of freedom 1     
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3.2.3 The CFHR3-1 deletion polymorphism and Dengue infection severity 
 
Since genetic polymorphisms across the region encoding CFH and CFH-related 
proteins (CFHR) influence on AMD, it was interesting to know if the CFHR3-1 deletion 
polymorphim was associated with Dengue infection. The CFHR3-1 deletion 
polymorphism was identified using Taqman CNV assay. The unusual polymorphisms 
were confirmed by tag SNP (CFH rs6677604) and MLPA. The result is shown in Table 
3.6. Most individuals contained two copies of CHFR3-1 (n= 321). In this analysis one 
individual with 3 copies of CFHR3-1 was noted, suggesting duplication of these genes 
on one allele. Moreover, there were nine individuals presenting 2 copies of the CFHR3 
gene with heterozygous deletion of the CFHR1 gene. This might be due to the presence 
of an allele in which there is deletion of both CFHR1 and CFHR4 genes (CFHR4-1). 
Individuals with either 3 copies of CFHR3-1 or CFHR1 heterozygote showed the G/G 
genotype by the tag SNP (the CFH rs6677604). 
 
The CFHR3-1 deletion homozygote (0 copies) was detected in 3 individuals 
whilst the single copy of CFHR3-1 was present in 45 individuals. The A/A genotype 
occurred in 3 of 3 (100%) subjects with the CFHR3-1 deletion and the G/A genotype 
was found in all 45 individuals (100%) with heterozygosity for the combined deletion. 
However, there was one subject in whom a single copy of CFHR3-1 was detected by 
both Taqman CNV assay and MLPA; however the tag SNP (the CFH rs6677604) 
showed the G/G genotype. This subject was excluded from the analysis.  
 
The CFHR3-1 allele frequency in the controls (healthy and OFIs) and the 
patients with Dengue infection was 6.79% and 6.94% respectively and did not 
significantly differ between these two groups or between sub-groupings of Dengue 
infection. This means that a copy number variation in CFHRs is not associated with 
Dengue infection.  
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Table 3.6: Copy number variation in CFHR3 and CFHR1 genes and Dengue virus infection severity 
Sample: 
  CFHR3-1    
CHFR1-CFHR3 deletion  
CHFR3-1 CFHR1 
N 100% 50% 0% P-value 150% 50% 
  (2 copies) (1 copy) (0 copy)    ΔCFHR3-1 allele frequency (%) (3 copies) (1 copy) 
Controls 82 70 11 0  6.79 0 1 
Dengue 297 251 34 3 1.00a 6.94 1 8 
          
DF 113 95 14 0  6.42 0 4 
DHFs 184 156 20 3 0.74b 7.26 1 4 
          
No Shock 142 118 16 3  8.03 1 4 
Shock 42 38 4 0 0.47c 4.76 0 0 
Controls include healthy controls and other febrile illness (OFI)     
150% = 3 copies of CFHR3-1, 100% = 2 copies of CHFR3-1; 50% = 1 copy of CHFR3-1; 0% =  no copies of the CFHR3-1 genes    
ΔCFHR3-1 allele frequency is the percentage of ΔCFHR3-1 alleles divided by total CFHR3-1 alleles   
a Dengue vs. Controls; b DF vs. DHF; c No Shock vs. Shock     
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3.2.4 An interaction between Factor H and Dengue NS1 
 
 An interaction between Dengue NS1 protein and Factor H (CFH) was examined. 
First, the interaction was tested by ELISA.  CFH protein was coated onto the plate, and 
incubated with either mock infected or Dengue virus 2 (DV2) supernatant, the latter of 
which contains soluble NS1 protein. The CFH-NS1 association was detected by anti-
NS1 antibody. As shown in Figure 3.4A, the signal was low to undetectable in both 
mock, and DV2 supernatant, implying that there is no interaction between NS1 and 
CFH. The result was similar in a reciprocal way when anti-NS1 antibody was coated 
onto the plate to capture NS1, followed by the addition of CFH protein, which was then 
detected by anti-CFH antibody (Figure 3.4B). 
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Figure 3.4: An interaction between CFH and NS1 A) ELISA: supernatants were added 
onto the plated coated with human CFH, and detected with anti-NS1 antibody. B) anti-
NS1 antibody was coated onto the ELISA plate; supernatants and CFH were 
sequentially added and anti-CFH antibody was used as a detection antibody. The 
experiments were performed three times independently. 
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Next an interaction between these two proteins was investigated by Far western 
blot. The utility of the system was confirmed by using the binding between CFH and 
Neisseria factor H binding protein (fHBp). The fHBp was loaded onto the gel and 
blotted onto the membrane, which was then incubated with CFH followed by anti-CFH 
antibody. An interaction of these two proteins was detected (Figure 3.5). Next, an 
interaction between CFH and Dengue NS1 was tested (Figure 3.6). CFH proteins were 
loaded onto the gel, transferred to the membrane, which was incubated with either 
supernatants or recombinant NS1 protein and detected with anti-NS1 antibody (Figure 
3.6A; lane 1-4) or anti-CFH antibody (Figure 3.6A; lane 5-8).  The results showed that 
CFH could not bind to either supernatants or rNS1. Similar results were shown in a 
reciprocal way (Figure 3.6B and 3.6C).  
 
Finally, testing for binding between NS1 and CFH was performed by co-
immunoprecipitation (Figure 3.7). Supernatants were incubated with CFH, and pulled 
down by anti-NS1 antibody. Anti-CFH antibody was used to detect CFH in the Western 
blot. To ensure that any NS1 protein was the result of the pull-down, the membrane was 
probed with anti-NS1 antibody. Yet again, no association between these two proteins 
was found. 
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Figure 3.5: Far western blot between Neisseria complement factor H binding protein 
(fHbp) and complement factor H (CFH). The fHbp protein was loaded onto the gel and 
transferred to a membrane which was then incubated with human CFH (lane 1) or buffer 
(lanes 2 and 3). The interaction between gel-immobilised fHbp and the added CFH was 
detected using an anti-CFH antibody (lane 1). Gel-immobilised fHbp was visualized 
using an anti-fHbp antibody (lane 2). The anti-CFH antibody did not recognize gel-
immobilised fHbp in the absence of CFH (lane 3).  
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Figure 3.6: Far western blot between NS1 of DV2 and CFH: A) CFH proteins were 
loaded onto the gel, transferred to the membrane, which was incubated with either 
supernatants or rNS1 and detected with anti-NS1 antibody (lane 1-4) or anti-CFH 
antibody (lane 6-8). B) Supernatants and C) rNS1 were loaded onto the SDS-PAGE gel, 
transferred to a membrane which was then incubated with CFH and the interaction was 
detected with anti-CFH antibody. Positive controls were DV2 supernatant and rNS1 
detected with anti-NS1 antibody. 
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Figure 3.7: Co-immunoprecipitation between NS1 of DV2 and CFH: both mock and 
Dengue supernatants were incubated with CFH and sequentially pulled down with anti-
NS1 antibody (IP), and protein A. Anti-CFH antibody was used to detect CFH in 
western blot (IB). Purified CFH protein was used as a positive control (lane 1). After 
CFH was detected, the membrane was washed with PBS and incubated with anti-NS1 
antibody to confirm that the proteins were pull-down (panel below). 
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3.3 DISCUSSION 
 
In this study the relationship between selected complement gene 
polymorphisms and Dengue infection severity was assessed. The polymorphisms 
included variation within four nucleotides (two adjacent polymorphisms within FB 
and one in each of C3 and CFH) that have been shown to be associated with a 6-fold 
variation in complement haemolytic activity in vitro (Heurich et al., 2011). Due to the 
low minor allele frequency at the C3 and FB polymorphisms (Table 3.2), it would be 
difficult to see the effect of variation at this locus. Indeed, reported minor allele 
frequency at the C3 polymorphism in Asian population is 0% (international human 
haplotype map project; HapMap), which is similar to this result and therefore this is 
considered as ‘rare allele’. The rare allele is generally difficult to interpret in analysis 
since it requires a very large population in order to get strong statistic power to make 
a meaningful statement. As a result most genetic studies exclude single nucleotide 
polymorphisms with the minor allele frequency below 5%. Consequently this rare 
allele does not affect Dengue infection since almost all people contain the same allele. 
Although the minor allele frequency at the CFH rs800292 polymorphism was more 
than 10%, the variation in this genotype did not differ between Dengue sup-groupings 
(Table 3.3). In addition, by using the 2 test, the C3 polymorphism was not in the 
Hardy-Weinberg equilibrium (HWE) meaning that the observed frequency is deviated 
from the expected frequency (Table 3.5). The HWE is that the genotype and/or allele 
frequency proportion in a population remains constant over the generations. A 
departure from HWE might be due to evolutionary influences such as migration, 
inbreeding, and small population size, leading to increased homozygosity in the 
population.  
 
A correlation between Dengue infection severity and complement activation 
has been studied (Bokisch et al., 1973, Nascimento et al., 2009). In DHF, a decrease 
in plasma CFH during the acute phase of infection was detected and its levels returned 
to normal during convalescence (Nascimento et al., 2009). This was in contrast to DF 
patients in whom plasma levels of CFH did not differ throughout the Dengue course 
(Nascimento et al., 2009). The different plasma CFH levels in patients with Dengue 
infection might be due to polymorphisms in the CFH promoter. Pastor et.al. has 
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recently reported an association between the CFH rs3753394 polymorphism and 
Dengue severity (Pastor et al., 2013). However, a significant association between 
Dengue severity and this SNP as well as the AMD-associated CFH rs1061170 SNP 
was not found in this study (p-value> 0.05; Table 3.3).  
 
The deletion of the CFHR1 gene and CFHR3 gene (CFHR3-1) is a copy 
number variation generated from non-allelic homologous recombination within the 
CFHR locus (Gold et al., 2006, Spencer et al., 2008). The absence of CFHR1 and 
CFHR3 is thought to decrease the risk of getting AMD and IgA nephropathy (Spencer 
et al., 2008, Gharavi et al., 2011). Here is the first report investigating the relationship 
between the copy number variation within the CHFR locus and Dengue susceptibility. 
The frequency of the CFHR3-1 allele in the Dengue population was approximately 
7% (Table 3.6) while the reported allele frequencies in Asians, European Caucasians, 
and the African population are 2%, 4.7%, and 16%, respectively (Gold et al., 2006). 
However, there was no evidence that this variation is associated with Dengue 
infection (Table 3.6). Notably, uncommon variations were observed during analysis. 
There was one individual with three copies of the CFHR3 and CFHR1, probably due 
to a duplication of these genes in one allele (Fritsche et al., 2010, Schmid-Kubista et 
al., 2009). Unfortunately, the effect of the three copies of the CFHR3 and CFHR1 
gene has not been demonstrated elsewhere. Nine individuals with the heterozygous 
deletion of the CFHR1 gene but the presence of two copies of the CFHR3 genes were 
also detected. One possible explanation for these findings is the presence of the 
deletion in the CFHR4 and CFHR1 genes (CFHR4-1). This novel deletion was first 
described in atypical hemolytic uremic syndrome (aHUS) in European Caucasians 
where the allele frequency of the CFHR4 and CFHR1 deletion in aHUS patients is 
about 1.4% and that in the control is about 0.9% (Moore et al., 2010). However, this 
has no significance due to the small number of subjects. Similarly the CFHR4 and 
CFHR1 deletion is observed in AMD but this is also insufficient to have statistical 
detection (Kubista et al., 2011). An isolated deletion of the CFHR1 gene with the 
presence of two copies of other CFHR genes might be another explanation for these 
findings (Moore et al., 2010, Kubista et al., 2011). Since there was no probe for 
CFHR4 gene in this study, this remained inconclusive. 
 
 114 
The allele ‘A’ in the tag SNP (the CFH rs6677604) is linked to the CFHR3-1 
deletion allele (Zhao et al., 2011). However, there was one individual containing one 
copy of CFHR3-1 detected by Taqman CNV assay and MLPA in whom the ‘A’ allele 
could not be confirmed by the CFH rs6677604 genotyping. This may suggest that the 
CFH rs6677604 was not in complete linkage disequilibrium (LD) in the Thai 
population. Zhao et. al has reported that 10 in 106 people of Amerindian-European  
descent and 7 in 196 people of African-American descent also present the GG 
genotype with the heterozygote CFHR3-1 deletion (Zhao et al., 2011). 
 
It should be noted that Dengue patients with primary infection were not 
included in this study since most of them have asymptomatic infection. Besides, the 
small sample size for DHF, particularly DHF3 and DHF4, would affect a statistical 
power. To increase a sufficient power, the number of a sample size should be larger. 
Considering the number of minor allele frequencies particularly in C3 in this study, 
the number of DF and DHF should be at least 390 each group (calculated from an 
online sample size estimator for a case-control study; http://osse.bii.a-star.edu.sg). 
When compared between Dengue with shock and without shock, the sample sizes 
needed for each group should be up to 260. This large number of subjects would limit 
the analysis.  
 
Dengue soluble NS1 can modulate complement activation and the levels of 
NS1 protein are correlated with disease severity (Libraty et al., 2002, Avirutnan et al., 
2006). In the presence of anti-Dengue antibodies, complement activation is enhanced 
(Avirutnan et al., 2006). Dengue NS1 has been shown to bind to complement proteins. 
Interaction between NS1 and C4 leads to degradation of C4, resulting in a viral 
evasion of complement-dependent destruction (Avirutnan et al., 2010). Dengue NS1 
is also able to interact with Clusterin, a complement regulatory protein inhibiting 
formation of the terminal complement complex (Kurosu et al., 2007). This interaction 
may contribute to the progression of DHF. Recently, it has been shown that WNV 
NS1, but not JEV, can interact with CFH, reducing complement activities in vitro 
(Chung et al., 2006, Krishna et al., 2009). A direct interaction between CFH and 
Dengue NS1 protein was not detected by ELISA, far-Western blotting or co-
immunoprecipitation (Figure 3.5, 3.6 and 3.7). It might be that interaction between 
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NS1 protein and CFH requires other components. Glycosaminoglycans (GAGs) are 
known to bind CFH and NS1 and might be mediators linking between NS1 and CFH 
(Muller and Young, 2013, Avirutnan et al., 2007, Zipfel et al., 1999). These 
carbohydrate ligands are generally found in close proximity to cell surfaces or 
extracellular matrixes. CFH can bind to these ligands which are rich on healthy cells 
and prevents complement attack. Since NS1 is able to bind to uninfected healthy cells 
via an interaction with GAGs, NS1 might interact with CFH on the cell surface or 
even compete with CFH to bind to the cells, interfering with CFH activity leading to 
vascular leakage in Dengue infection. To test this hypothesis, an interaction of CFH 
and NS1 together with GAGs should be performed. Staining of CFH and NS1 
proteins on the cell surface as well as complement lysis might be tested. In addition, 
GAG expression on a surface of both infected and non-infected cells should be 
observed. Alternatively, CFH may bind to other viral molecules modulating CFH 
activities. As shown in HIV, CFH can bind to glycoproteins (gp120 and gp41) on HIV 
particles (Pinter et al., 1995a, Pinter et al., 1995b). Hence, interaction between CFH 
and Dengue viral particles should be studied. 
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4.1 Introduction 
 
Dengue disease is one of the most concerning public health problems on 
account of there being no effective vaccine, drugs or specific treatment. Suspected 
patients with Dengue infection may need to be hospitalized until the critical period as 
fatal complications may rapidly occur 3 to 7 days after fever drops. The symptoms of 
Dengue disease at an early stage are difficult to discriminate between non-severe and 
severe dengue (DF and DHF respectively). However, with medical care, the mortality 
rate can decrease from 20% to less than 1% . Early prediction/diagnosis can help 
physicians to intensively care for patients with DHF, and reduce the number of 
patients with DF in a hospital, thus reducing the financial burden on the hospital. 
 
Due to a lack of appropriate animal models, clinical studies have been 
important instruments in investigating the pathogenesis of Dengue infection. Several 
studies have identified markers for disease severity as reviewed in the chapter 1 
(section 1.1.8). Platelet counts < 100,000 cells per cu mm together with an increase in 
haematocrit equal to or greater than 20% above average (1997)  are currently used to 
monitor the progression of the disease; however they are not accurate enough to use 
as early predictors for the disease severity (Potts et al., 2010). The plasma level of 
Dengue soluble NS1 antigen is higher in DHF cases than those with DF during the 
febrile phrase (Libraty et al., 2002). ELISA detected NS1 antigen would be useful in 
the early days of illness even after fever for several days. The sensitivity of the test for 
Dengue primary infection is more than 90% (Simmons et al., 2012) and the test can be 
more powerful when it is used with a combination of serological methods (Blacksell, 
2012). However, the sensitivity and the accuracy of the test are lower when it is used 
for the secondary infection (Ty Hang et al., 2009, Tricou et al., 2010, Felix et al., 
2012). NS1 antigen therefore, might be a promising marker if there is a reliable and 
practical diagnostic test available.  In addition, several circulating cytokines and 
chemokines including TNFα, IL8, sVEGFRII, IP10, ITAC, RANTES, to name a few 
have been detected. There are however, conflicting results for some of these cytokines 
(Potts et al., 2010). For example, the levels of IFNγ in severe Dengue was higher than 
those in mild Dengue in one study whereas conflicting evidence has been reported in 
another study showing no significant difference between these two groups (Bozza et 
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al., 2008, Braga et al., 2001). This might be due to numerous factors such as 
differences in the timing of sample collection and sample processing, methods in 
grading the disease severity, and the number of samples used in the study.  The 
published soluble markers associated with Dengue illness are summarized in the 
chapter 1 (Table 1.1). 
 
In this study, predictive markers to identify DHF during the early days of 
infection were defined. Clinical markers and biomarkers from a large scale of samples 
collected in the same way were assembled and plasma proteins were measured by 
multiplex assays and analyzed by statistical methods. 
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4.2 Results 
 
4.2.1 Study population 
 
Subjects in this study appeared with a fever, signs and symptoms of Dengue 
disease and they were hospitalized at Songkla and Khonkan hospitals in the southern 
and northeastern provinces in Thailand during 2001 to 2008. The process of sample 
collection, grading the disease severity and confirmation of Dengue serotype were 
performed by staff in Thailand (see in Materials and Methods, section 2.2: patients 
and controls,). Plasma samples in this experiment were collected from children 
clinically presenting with Dengue disease during the acute stage before fever 
subsided. Plasma samples from children clinically presenting with other febrile 
illnesses (OFI) were used as control and baseline. 
 
Demographic information of the individuals in this study is shown in Table 
4.1. The total number of Dengue patients in this study was 453 (DF = 226 and DHF = 
227). DHF was classified according to the WHO protocol into 4 grades and the 
numbers of subjects in DHF1 to 4 were 73, 119, 33 and 2 respectively. Patients with 
mild disease (DF) and with severe Dengue Hemorrhagic Fever (DHF) had an average 
age of 9.67 and 10.20 years olds respectively (range 3-15 years old). The number of 
female and male patients in both groups was somewhat equivalent. Almost all patients 
had a secondary infection and appeared at the hospitals between the 3rd and 5th day 
following the onset of illness.  Those with other febrile illnesses (OFI) were used as 
controls (n = 69). Average age in OFI group was 8.43 years (range 2-14 years old). 
Dengue serotype was confirmed by RT-PCR. The numbers of Dengue serotypes 1 to 
4 were 174, 102, 15, and 100 respectively. There were 60 samples in which viral 
genome could not be detected.  
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Table 4.1: Demographic information of the study population 
 
 
4.2.2 Clinical and biological characteristics during the acute stage of infection 
 
4.2.2.1 Clinical characteristics 
 
The assessment of clinical markers was done by staff in Thailand, as described 
in Materials and Methods (Section 2.2). Clinical markers included hematocrit (hct), 
total white blood cell (wbc), polymorphic mononuclear cell (pmn), lymphocyte, 
atypical lymphocyte, monocyte, basophil, eosinophil, platelet cell, liver aspartate 
aminotransaminases (ast), liver alanine aminotransaminases (alt), liver total protein 
(lft_protein), and liver albumin (lft_albumin). The clinical profiles are shown in Table 
4.2 and Figure 4.1. A reduction of platelet cell count, together with an induction of hct 
and of liver transaminases (ast and alt), was observed in the plasma of Dengue 
patients and was associated with disease severity (Figures 4.1A, I, L and M). 
Although elevated liver enzymes were detected in the plasma, levels of albumin 
appeared to be reduced in Dengue plasma particularly in DHF (Figure 4.1K). A 
decrease in the total liver protein was also shown only in DHF (Figure 4.1J). A lower 
wbc count in individuals with Dengue infection was confirmed (Figure 4.1B). When 
measuring each white blood cell by the differential count method, the numbers of the 
polymorphonuclear cells (PMN), the lymphocytes and the monocytes were reduced 
while those of the atypical lymphocyte were elevated in Dengue group (Figures 4.1C, 
D, E and F). In addition, the number of the lymphocytes was much lower in DHF 
(Figure 4.1D). No differences in the frequency of basophils and eosinophils were 
shown in any group (Figures 4.1G and H).  
 
Disease 
severity 
Age (yr)* 
Gender (n) Type of infection Day since onset 
Males Females Primary Secondary 1 2 3 4 5 6 7 8 10 
DF (n = 226) 9.67± 2.6 106 120 11 215 4 25 57 81 43 10 4 1 1 
DHF (n= 227) 10.20±2.7 123 104 3 224 1 15 67 80 51 9 4 0 0 
OFI (n = 69) 8.43±2.9 37 32 - - - - - - - - - - - 
DF: mild Dengue fever, DHF: Dengue hemorrhagic fever, OFI: other febrile illnesses;  * mean± SD 
 1
2
1
 
Table 4.2: Clinical characteristics of the study population 
Clinical characteristics  DF DHF OFI p-valuea p-valueb p-valuec 
Hematocrit (hct) (mean % ±SD) 36.45±3.00 37.57±3.83 34.79±3.62 2.79 x 10-4 2.00 x 10-4 4.50 x 10-7 
White blood cell (wbc) (x1000)  (mean cells/cu mm ±SD ) 2.99±1.11 2.87±1.26 5.72±2.88 0.78 1.20 x 10-19 3.70 x 10-21 
PMN (x1000) (mean cells/cu mm ±SD) 1.48±0.92 1.48±0.97 3.56±2.24 0.99 1.80 x 10-18 6.25 x 10-19 
Lymphocyte (x1000) (mean cells/cu mm ±SD) 1.14±0.56 1.05±0.60 1.68±0.95 4.80 x 10-3 3.89 x 10-7 5.38 x 10-10 
Atypical lymphocyte (mean cells/cu mm ±SD) 91.26±136.87 116.76±222.70 25.80±60.32 0.30 2.24 x 10-6 8.89 x 10-8 
Monocyte (x1000) (mean cells/cu mm ±SD) 0.21±0.16 0.19±0.15 0.38±0.32 0.12 4.47 x 10-8 3.77 x 10-8 
Basophil (mean cells/cu mm ±SD) 3.35±12.28 4.99±13.79 9.93±28.96 0.08 0.23 0.97 
Eosinophil (mean cells/cu mm ±SD) 27.19±81.90 13.63±57.18 55.35±173.78 0.38 0.20 0.06 
Platelet count (x1000) (mean cells/cu mm ± SD) 149.53±60.78 94.53±50.77 210.38±64.53 1.15 x 10-21 2.80 x 10-12 2.80 x 10-27 
Liver total protein (lft_protein) (mean g/dl ± SD) 6.96±0.56 6.59±0.76 7.08±0.60 9.20 x 10-7 0.14 5.20 x 10-6 
Albumin (lft_albumin) (mean g/dl ± SD) 3.69±0.35 3.49±0.50 3.79±0.44 2.78 x 10-5 0.02 3.70 x 10-6 
Liver aspartate aminotransaminases (ast) (mean IU/L ± SD) 81.07±76.40 155.28±169.81 46.09±28.87 3.30 x 10-13 6.40 x 10-10 4.00 x 10-21 
Liver alanine aminotransaminases (alt)  (mean IU/L ± SD) 53.27±38.43 82.01±78.77 35.77±23.47 1.90x 10-10 1.60x 10-9 1.10x 10-17 
DF: mild Dengue fever, DHF: Dengue hemorrhagic fever, OFI: other febrile illnesses; a DF vs DHF b OFI vs DF c OFI vs DHF 
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Figure 4.1: Clinical characteristics of patients with OFI, DF and DHF during the 
acute stage of disease. Horizontal lines represent mean values with SEM. Statistical 
significance was determined by the Kruskal-Wallis test for 3 groups and the Mann-
Whitney test for 2 groups (*, p < 0.05; **, p < 0.001; ***, p < 0.0001).    
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4.2.2.2 Biological characteristics 
  
Cytokines, chemokines, soluble receptors, growth factors, and matrix 
metalloproteinases (MMPs) in the plasma were measured by multiplex bead 
immunoassay as described in the Materials and Methods (section 2.7). Of 66 markers, 
nineteen markers were below the limit of detection in most samples.  These were 
MMP7, IL1β, IL13, IL4, IL5, IL7, IL17, Eotaxin3, SDF1, TNFα, IFNα, IFNγ, MIP1α, 
HGF, EGF, VEGF, FGF, GCSF, and GMCSF. The number of measurable samples in 
this group of markers was too low to compare and therefore excluded from further 
analysis. However, IL1β, IL13, IL4, IL7, TNFα, IFNα, IFNγ, VEGF and GMCSF 
have been shown to associate with DHF elsewhere (Table 1.1).  Sixteen markers that 
contained missing data greater than 10% were MCSF, ENA78, IL1RA, IL2, IL6, 
IL15, IL16, IL23, IL33, Eotaxin, MIG, I309, TARC, IL2R, 6Ckine, and GCP2. The 
markers that have previously been reported are IL1Ra, IL2, IL6 and MIG (Table 1.1). 
Data missing in this group was due to a combination of insufficient samples and/or no 
samples and technical issues during experiments such as pipetting error, plate-to-plate 
variation as well as protein stability. It is noteworthy that in these markers, plasma 
protein concentrations in many samples fell below or at the lowest limit of 
quantitation. For MCSF, although the number of samples was sufficient, the quality of 
the data was not great since half of the samples had protein concentrations below the 
lowest limit of detection. In addition, due to missing data in the control group, IL2, 
IL6, IL23 and MIG were compared only between DF and DHF. The percentage of 
markers classified as detectable and undetectable markers, as well as markers with 
>10% missing data are shown in Figure 4.2.  
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Figure 4.2: Classification of biological markers into three groups: detectable, low to 
undetectable and missing data greater than 10%. Percentage of markers in each group 
is shown. Total biological markers in the experiment were 66 markers (100%). 
 
 
When compared to the control group, elevated plasma levels of sTNFRII, 
IP10, ITAC, BCA1, MCP2, MCSF and IL15 were detected in Dengue patients and 
appeared to be associated with Dengue severity (DHF > DF > OFI) (Tables 4.3, 4.4 
and 4.5 and Figures 4.3.2D, 4.3.3B-D, 4.3.4D, 4.3.7A and 4.3.7D ). Conversely, 
levels of RANTES decreased in Dengue groups (DF and DHF), particularly in DHF 
(OFI > DF > DHF) (Tables 4.3 and4.5 and Figure 4.3.4C). There were eleven markers 
in which plasma levels differed between the control and Dengue groups but this 
difference did not relate to the severity. Of 11 markers, plasma MMP8 and MMP9 
were lower in Dengue groups than the control group (OFI > Dengue) (Tables 4.3 and 
4.5, Figures 4.3.1D and 4.3.1.E) while increased concentrations of sIL2Ra, sIL6R, 
MCP1, MIP1β, MIP3β, IL10, TRAIL, IL33 and IL2R were detected (Dengue > OFI) 
(Tables 4.3, 4.4 and 4.5 and Figures 4.3.2F, 4.3.2H, 4.3.4A, 4.3.4B, 4.3.4F, 4.3.5A, 
4.3.5C, 4.3.7F and 4.3.7J). Moreover, increases in plasma levels of MMP3, sTNFRI, 
29%
24%
47%
Low  to undetectable
>10% missing data
Detectable markers
MMP7, IL1β, IL13, IL4, 
IL5, IL7, IL17, Eotaxin3, 
SDF1, TNFα, IFNα, 
IFNγ, MIP1α, HGF, EGF, 
VEGF, FGF, GCSF, 
GMCSF 
  MCSF, ENA78, IL1RA, IL2,    
IL6, IL15, IL16, IL23, IL33, 
Eotaxin, MIG, I309, TARC, 
IL2R, 6Ckine, GCP2 
MMP1, MMP2, MMP3, 
MMP8, MMP9  
 
sEGFR, sIL1RII, sTNFRI, 
sTNFRII, sVEGFRII, 
sIL2Ra, sIL4R, sIL6R, 
sgp130 
 
IL8, IP10, ITAC, BCA1, 
MCP1, MIP1β, RANTES, 
MCP2, MIP1δ, MIP3β, 
MIP3α, Eotaxin2,  
CTACK, TRAIL 
IL10, IL12, TPO  
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IL8, MIP3α, CTACK, TPO and IL16 were observed in DHF (DHF > DF and OFI) 
(Tables 4.3, 4.4 and 4.5 and Figures 4.3.1C, 4.3.2C, 4.3.3A, 4.3.4G, 4.3.4I, 4.3.6 and 
4.3.7E) while sVEGFRII and IL12 markedly decreased (DF and OFI > DHF) (Tables 
4.3 and 4.5 and Figures 4.3.2E and 4.3.5B). In contrast to these proteins, plasma 
levels of I309 were elevated only in DF (DF > DHF and OFI) (Tables 4.4 and 4.5 and 
Figure 4.3.7H). In addition, decreased Eotaxin2 levels were detected in DF (DHF and 
OFI > DF) (Tables 4.3 and 4.5 and Figure 4.3.4H). Elevated MIP1δ proteins were 
detected in DHF plasma when compared to the control (DHF > OFI) (Tables 4.3, and 
4.5 and Figure 4.3.4E) whereas MMP1, sIL4R, and ENA78 levels were significantly 
down-regulated in DHF (OFI > DHF) (Tables 4.3, 4.4 and 4.5 and Figures 4.3.1A, 
4.3.2G, and 4.3.7B). Increased IL6 levels were detected in DHF when compared to 
DF (DHF > DF) (Tables 4.4 and 4.5 and Figure 4.3.7N) but there was no significant 
difference in plasma levels of IL2, IL23 and MIG between these two groups (Tables 
4.4 and 4.5 and Figures 4.3.7M, 4.3.7O and 4.3.7P). Among three groups, no 
significant differences were found in nine markers including MMP2, sEGFR, sIL1RII, 
sgp130, IL1Ra, Eotaxin, TARC, 6Ckine and GCP2 (Tables 4.3, 4.4 and 4.5 and 
Figures 4.3.1B, 4.3.2A, 4.3.2B, 4.3.2I, 4.3.7C, 4.3.7G, 4.3.7I, 4.3.7K and 4.3.7L). The 
descriptive statistical analysis for all biological markers is shown in Tables 4.3 and 
4.4 and Figures 4.3.1- 4.3.7. 
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Table 4.3: Statistical analysis of the detectable biological markers in DF, DHF and OFI 
Bio-Markers 
DF DHF 
p-value
a
 
Other Febrile Illness (OFI) 
p-value
b
 N Mean±SD Median Range N Mean±SD Median Range N Mean±SD Median Range 
Matrix metalloproteinases (MMPs):             
MMP1 (pg/ml) 225 486.52±470.01 332.30 3294.93 226 529.73±1297.32 352.10 18668.35 0.56 69 653.20±567.42 519.86 2863.00 0.0013 
MMP2 (pg/ml) 211 170682.49±37415.54 165553.94 203509.25 216 172109.83±35408.03 170471.63 205141.74 0.63 69 159712.72±41197.33 161271.48 193882.50 0.1272 
MMP3 (pg/ml) 225 3149.37±1951.17 2874.92 16782.81 226 4462.11±2938.73 4003.35 27325.27 1.1x10-9 69 3171.85±3198.16 2340.36 18765.90 3.00x10-11 
MMP8 (pg/ml) 211 3479.90±3925.80 2500.40 37352.56 216 3600.66±3322.96 2557.29 22687.79 0.31 69 15300.53±23915.04 6869.82 117735.06 3.54x10-14 
MMP9 (pg/ml) 211 23843.42±15973.25 19936.29 108499.42 216 27000.58±24849.13 22039.55 306779.64 0.03 69 75315.09±99454.20 39579.22 556554.41 3.10x10-15 
               
Soluble cytokine receptors:               
sEGFR (pg/ml) 224 40704.80±10632.76 38750.04 74400.18 227 44270.27±13448.30 41385.22 80704.36 0.0057 69 38063.33±5709.65 38009.33 34814.91 0.0014 
sIL1RII (pg/ml) 224 4194.20±1355.33 3972.45 14300.39 227 4589.49±3062.07 4275.92 44627.45 0.02 69 4046.00±959.84 4020.25 5062.79 0.0268 
sTNFRI (pg/ml) 224 1258.83±355.33 1209.62 2671.08 227 1435.59±414.87 1403.93 3197.50 6.36x10-8 69 1190.45±498.50 1096.20 2472.94 5.11x10-10 
sTNFRII (pg/ml) 224 15704.69±5415.28 15345.15 30185.94 227 19156.49±6094.68 18519.54 35839.80 6.49x10-10 69 8804.71±4815.25 7562.88 27120.32 2.02x10-31 
sVEGFRII (pg/ml) 207 19003.52±3231.21 19177.23 20638.29 204 16376.35±3889.52 16476.45 21928.39 1.14x10-12 69 20498.44±6537.77 20020.80 26903.45 9.98x10-13 
sIL2Ra (pg/ml) 224 1545.23±690.79 1388.98 3853.55 226 1608.31±677.05 1487.94 4236.74 0.20 69 1073.16±569.34 945.57 2944.10 1.26x10-9 
sIL4R (pg/ml) 223 1587.43±174.17 1564.38 1391.86 227 1556.34±164.01 1540.93 1390.44 0.05 69 1657.40±179.40 1628.38 1047.09 5.79x10-5 
sIL6R (pg/ml) 224 22873.96±6681.72 21738.93 42992.42 226 23304.81±6161.84 22184.45 38072.09 0.38 69 19270.67±6982.47 17165.05 34998.00 4.51x10-7 
sgp130 (pg/ml) 224 197473.75±28057.87 198057.15 202620.61 226 194993.36±26114.59 197855.10 156888.70 0.66 69 194901.51±19075.76 193371.20 111985.40 0.6969 
               
Chemokines:               
CXC family:               
IL8 (CXCL8) (pg/ml) 225 34.54±16.28 31.58 121.89 226 46.60±33.57 38.03 314.04 4.67x10-6 69 29.64±12.41 27.78 60.22 4.12x10-8 
IP10 (CXL10) (pg/ml) 225 4076.82±4083.07 2988.66 38758.84 226 6532.80±6079.57 4096.61 42170.39 3.34x10-10 69 2980.47±6700.51 209.55 29508.38 2.57x10-24 
ITAC (CXCL11) (pg/ml) 225 1064.58±1244.00 608.90 7683.84 227 2046.73±4227.77 1167.74 52349.29 6.45x10-8 69 421.68±649.28 81.30 6631.92 2.54x10-23 
BCA1 (CXCL13) (pg/ml) 221 104.26±57.25 94.73 460.86 217 159.86±117.03 122.18 700.57 1.94x10-9 69 78.34±31.07 76.58 223.16 1.53x10-15 
 
Cut-off of adjusted P-value = 7.6x10-4 (0.05/66); the bold and underlined values mean significant difference between groups at p-value < 7.6x10-4 
Range means maximal value-minimal value 
a: compared between DF and DHF and analyzed by Mann-Whitney U test; 
b: compared among OFI, DF and DHF and analyzed by Kruskal-Wallis test 
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Bio-Markers 
DF DHF 
p-value
a
 
Other Febrile Illness (OFI) 
p-value
b 
N Mean±SD Median Range N Mean±SD Median Range N Mean±SD Median Range 
CC family:               
MCP-1 (CCL2)  (pg/ml) 225 611.30±299.10 622.90 2557.00 226 810.7±447.20 706.90 2662.70 5.30x10-3 69 611.28±375.08 503.83 2556.87 6.78x10-7 
MIP-1β (CCL4) (pg/ml) 225 127.95±104.46 96.39 774.96 226 133.04±91.69 117.38 870.92 0.04 69 135.03±231.27 40.91 1189.26 1.12x10-8 
RANTES (CCL5) (pg/ml) 225 3090.33±5281.21 1082.37 49539.19 226 2400.98±5840.98 720.21 61899.19 2.15x10-4 69 3673.27±3425.05 2080.09 12342.04 6.27x10-11 
MCP-2 (CCL8) (pg/ml) 221 205.43±111.42 187.03 928.61 217 265.36±150.47 249.19 827.04 8.47x10-6 69 149.05±138.77 111.70 703.38 4.92x10-12 
MIP-1δ (CCL15) (pg/ml) 221 4458.63±2767.35 3881.90 16071.17 217 5338.96±3340.13 4699.02 21982.91 6.00x10-3 69 3625.48±2638.44 2704.76 10760.49 1.69x10-5 
MIP3β (CCL19) (pg/ml) 225 302.17±142.74 260.63 988.57 226 319.20±158.99 285.10 1042.29 0.22 69 118.69±108.00 98.08 610.11 6.31x10-25 
MIP3α (CCL20) (pg/ml) 225 30.09±18.19 25.97 159.38 227 45.88±47.04 36.57 553.57 6.08x10-8 69 26.64±20.74 21.00 112.42 5.03x10-10 
Eotaxin-2 (CCL24) (pg/ml) 221 63.32±50.15 48.48 362.44 216 91.12±89.44 63.34 653.98 4.01x10-5 69 69.13±57.33 61.22 355.25 2x10-4 
CTACK (CCL27) (pg/ml) 221 922.44±344.33 919.76 2201.59 217 1074.43±406.29 1031.32 2523.03 8.75x10-5 69 767.63±331.19 747.15 1692.24 7.98x10-9 
               
Cytokines:               
IL family:               
IL10 (pg/ml) 225 139.37±127.81 103.63 560.48 226 146.61±136.66 114.60 771.59 0.39 69 20.35±41.45 4.6 253.31 2.1x10-26 
IL12 (pg/ml) 225 324.89±112.30 315.51 659.14 226 291.15±124.48 268.96 1074.39 2.25x10-4 66 484.93±559.44 376.76 3496.34 1.5x10-7 
Others:               
TRAIL (pg/ml) 221 98.29±59.79 88.43 383.61 217 97.01±64.96 89.18 402.64 0.83 69 69.67±46.76 50.95 196.26 7.33x10-5 
               
Growth factor:               
Thrombopoietin (TPO) 
(pg/ml) 221 701.78±758.00 493.37 6674.55 217 1062.04±2085.94 635.99 22965.96 2.50x10-4 69 557.36±544.47 426.99 2678.66 8.28x10-7 
 
Cut-off of adjusted P-value = 7.6x10-4 (0.05/66); the bold and underlined values mean significant difference between groups at p-value < 7.6x10-4 
Range means maximal value-minimal value 
a: compared between DF and DHF and analyzed by Mann-Whitney U test; 
b: compared among OFI, DF and DHF and analyzed by Kruskal-Wallis test 
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Table 4.4: Statistical analysis of the biological markers with missing data greater than 10% in DF, DHF and OFI 
Bio-Markers 
DF DHF 
p-value
a
 
Other Febrile Illness (OFI) 
p-value
b
 N Mean±SD Median Range N Mean±SD Median Range N Mean±SD Median Range 
MCSF (pg/ml) 223 820.72±1251.84 390.76 9459.52 227 2051.28±3394.76 1136.57 26557.82 2.73x10-6 69 334.70±1077.81 0 8340.503 3.20x10-12 
ENA78 (pg/ml) 193 121.66±197.35 60.87 1178.53 185 103.47±272.13 43.15 3325.99 0.01 67 176.21±285.53 73.37 1874.36 1.10x10-4 
IL1Ra (pg/ml) 196 992.83±374.40 953.32 2373.30 194 1096.59±1350.81 956.32 18564.57 0.94 69 1259.22±3277.66 768.62 27542.398 5x10-3 
IL2 (pg/ml) 115 12.11±14.96 8.78 113.27 109 19.26±95.83 8.83 1007.78 0.97 - - - - - 
IL6 (pg/ml) 158 12.94±14.62 9.98 115.00 158 16.45±17.06 12.21 146.78 5.00x10-4 - - - - - 
IL15 (pg/ml) 177 525.90±205.29 502.86 1130.43 161 681.31±353.98 619.41 2749.70 7.90x10-15 66 293.81±337.43 158.57 1982.18 1.89x10-6 
IL16 (pg/ml) 165 159.03±154.84 113.11 1139.31 154 199.08±159.30 149.53 1162.98 3.00x10-4 66 137.90±147.09 98.09489 850.178 4.04x10-5 
IL23 (pg/ml) 159 144.18±259.97 77.58 2256.72 159 229.27±842.69 71.04 8134.62 0.93 - - - -  
IL33 (pg/ml) 165 48.40±47.92 33.44 337.70 154 77.37±176.1 38.24 1703.00 0.26 66 34.75±39.11 21.72 176.1 1.00x10-4 
Eotaxin (pg/ml) 186 32.50±15.47 28.53 101.45 203 35.62±34.67 29.63 413.24 0.70 68 42.45±58.51 29.22 464.12 0.93 
MIG (pg/ml) 192 187.20±125.23 160.35 1033.36 199 194.85±225.46 153.26 2541.66 0.22 - - - - - 
I309 (pg/ml) 193 6.54±5.54 4.77 35.93 186 5.25±8.01 3.62 92.07 7.83x10-5 68 4.11±2.78 3.70 13.53 3.70x10-5 
TARC (pg/ml) 193 11.58±13.04 7.22 90.65 186 8.72±8.64 6.73 69.98 0.03 68 12.27±10.84 7.892096 43.823931 0.03 
IL2R (pg/ml) 206 609.91±318.85 512.07 1779.77 193 657.18±395.76 599.61 3875.31 0.05 66 484.93±559.44 376.76 3496.34 7.50x10-9 
6Ckine (pg/ml) 165 351.33±168.84 349.63 897.24 154 386.41±207.90 366.18 1116.76 0.36 66 379.67±192.15 350.8098 994.2249 0.59 
GCP2 (pg/ml) 182 31.42±18.45 26.70 136.86 195 35.32±22.01 29.72 164.61 0.09 69 29.69±17.72 26.92 101.91 0.10 
 
Cut-off of adjusted P-value = 7.6x10-4 (0.05/66); the bold and underlined values mean significant difference between groups at p-value < 7.6x10-4 
Range means maximal value-minimal value 
a: compare between DF and DHF and analyzed by Mann-Whitney U test; 
b: compare among OFI, DF and DHF and analyzed by Kruskal-Wallis test 
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Table 4.5: Summary of the findings for biological markers in DF, DHF and OFI during acute febrile stage 
Findings Soluble factors 
DHF > DF > OFI sTNFRII, IP10, ITAC, BCA1, MCP2, IL15, and MCSF  
OFI > DF > DHF RANTES  
OFI > Dengue MMP8 and MMP9  
Dengue > OFI sIL2Ra, sIL6R, IL2R, IL10, MCP1, MIP1β, MIP3β, TRAIL, and IL33 
DHF > DF and OFI MMP3, sTNFRI, IL8, MIP3α, CTACK, TPO and IL16  
DF and OFI > DHF sVEGFRII and IL12 
DF > DHF and OFI I309  
DHF and OFI > DF Eotaxin2  
DHF > OFI MIP1δ 
OFI > DHF MMP1, sIL4R, and ENA78 
DHF > DF IL6 
DHF ≈ DF IL2, IL23 and MIG  
DHF ≈ DF ≈ OFI MMP2, sEGFR, sgp130, sIL1RII, Eotaxin, TARC, 6Ckine, IL1Ra and GCP2 
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Figure 4.3.1: Plasma concentrations of matrix metalloproteinases (MMPs) in OFI, DF 
and DHF groups during the acute stage of the disease. Horizontal lines represent 
median values. Statistical significance was determined by the Mann-Whitney test (**, 
p < 0.00076; ***, p < 0.0001).    
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Figure 4.3.2: Plasma concentrations of soluble cytokine receptors in OFI, DF and 
DHF groups during the acute stage of the disease. Horizontal lines represent median 
values. Statistical significance was determined by the Mann-Whitney test (**, p < 
0.00076; ***, p < 0.0001).    
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Figure 4.3.3: Plasma concentrations of chemokines (CXC family) in OFI, DF and 
DHF groups during the acute stage of the disease. Horizontal lines represent median 
values. Statistical significance was determined by the Mann-Whitney test (**, p < 
0.00076; ***, p < 0.0001).    
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Figure 4.3.4: Plasma concentrations of chemokines (CC family) in OFI, DF and DHF 
groups during the acute stage of the disease. Horizontal lines represent median values. 
Statistical significance was determined by the Mann-Whitney test (**, p < 0.00076; 
***, p < 0.0001).    
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.5: Plasma concentrations of cytokines in OFI, DF and DHF groups during 
the acute stage of the disease. Horizontal lines represent median values. Statistical 
significance was determined by the Mann-Whitney test (**, p < 0.00076; ***, p < 
0.0001).    
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Figure 4.3.6: Plasma concentrations of growth factor in OFI, DF and DHF groups 
during the acute stage of the disease. Horizontal lines represent median values. 
Statistical significance was determined by the Mann-Whitney test (**, p < 0.00076; 
***, p < 0.0001).    
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Figure 4.3.7: Plasma concentrations of biological characteristics with missing data 
greater than 10% in OFI, DF and DHF groups during the acute stage of disease. 
Horizontal lines represent median values. Statistical significance was determined by 
the Mann-Whitney test (**, p < 0.00076; ***, p < 0.0001).    
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4.2.3 Levels of clinical and biological characteristics over the time course of 
illness 
 
4.2.3.1 Clinical characteristics 
 
 Since Dengue disease is a time course-dependent illness, kinetics of biological 
markers were determined over the onset and during the acute phase in DF and DHF 
patients. Only plasma samples of the Dengue patients collected between day 2 and 6 
were observed due to the small sample size on day 1, 7, 8 and 10 (Table 4.1 and 
Figure 4.4). Since there are different numbers of samples in each day, interpretation in 
term of symptom must be careful. 
 
 Over the time course of disease, an increase in the hct readings was found in 
DHF on day 4 of the illness while the wbc count was not significant different in both 
groups (Figures 4.4.A and B). When measuring the number of each white blood cell, 
trends in PMN, atypical lymphocyte, monocyte, basophil, and eosinophil numbers 
were similar and showed no significant difference in two groups (Figures 4.4C, E, F, 
G and H). Only lymphocytes slightly decreased in DHF on day 4; however there was 
no difference found on day 5 and 6 (Figure 4.4D). The platelet cell count, particularly 
in DHF, progressively declined (Figure 4.4I). At day 4, the frequency of platelet cells 
in DHF was below 100,000 cells per cu mm, which is the criterion to determine DHF. 
Decreases in the liver proteins and albumin, together with increases in the liver 
enzymes (ast and alt) were pronounced in DHF at days 3, 4 and 5 after the onset of 
disease (Figures 4.4J-M). 
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Figure 4.4: Clinical characteristics of patients with DF and DHF between day 2 and 6 
after disease onset. The lines represent mean values with SEM (Standard error of 
mean). Statistical difference between DF and DHF at each time point was determined 
by Mann-Whitney test (*, p < 0.05; **, p < 0.001; ***, p < 0.0001).    
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4.2.3.2 Biological characteristics 
 
Biological characteristics between DF and DHF were observed during day 2 to day 6 
of the illness and the time course was constructed with different numbers in each day 
(Table 4.1 and Figures 4.5.1-4.5.6). Similar to clinical experiment, interpretation in 
term of symptom must be careful. Elevated plasma levels of MMP3 were detected in 
DHF between day 2 and day 6 and a significant difference was found on day 4 while 
other MMPs had no difference throughout this period (Figures 4.5.1A-E). Although 
there was no significant difference in these MMPs, patterns of their concentrations 
were quite similar in both DF and DHF. The levels of MMP1 and MMP8, which are 
collagenases, declined greatly on day 4 and increased afterwards (Figures 4.5.1A and 
4.5.1D). MMP2 secretion increased in both groups in the first five days (Figure 
4.5.1B). On day 6, the secretion of MMP2 in DF declined (Figure 4.5.1B). Unlike 
MMP2, MMP9 levels gradually decreased until day 5 (Figure 4.5.1E). On day 6, 
MMP9 concentration was increased in DHF whereas it was still low in DF (Figure 
4.5.1E). 
 
Next, the plasma levels of soluble receptor proteins were observed. sVEGFRII 
levels were markedly decreased in DHF and a significant difference was detected on 
day 4 and day 6 (Figure 4.5.2E). Higher levels of sTNFRI and sTNFRII were detected 
in DHF throughout the period; this was significant only at an early time-point during 
the disease (day 3) (Figures 4.5.2C and 4.5.2D). Apart from these three molecules, 
other soluble proteins showed no difference between DF and DHF. In general, 
concentrations of sEGFR and sIL6R levels increased in both groups (Figures 4.5.2A 
and 4.5.2H). The levels of sIL2Ra in DHF were constantly high over the time course 
(Figure 4.5.2F) while the levels of this protein in DF gradually increased; as seen in 
Figure 4.3.2F, sIL2Ra levels in the Dengue group were higher than those in the 
control group.  Also, similar trends in sIL1RII and sgp130 levels were observed in DF 
and DHF (Figures 4.5.2B and 4.5.2I). Their concentrations were quite constant until 
day 6 when a decrease in these protein levels was detected in DHF. Lastly, patterns of 
sIL4R expression fluctuated in both groups (Figure 4.5.2G).   
 
For the neutrophil chemotactic factors (IL8, ENA78 and GCP2), none of these 
markers showed a significant difference between the 2 groups from day 2 to day 6 
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(Figures 4.5.3A, 4.5.7B and 4.5.7P). IL8 levels in DHF were high throughout this 
period while those in DF gradually increased before declining again on day 6 (Figure 
4.5.3A). Concentrations of GCP2 increased in both groups and the trend was similar 
(Figure 4.5.7P). For ENA78, levels were quite low and the number of samples was 
small; therefore, the pattern of expression was not clearly seen (Figure 4.5.7B).   
 
Furthermore, three members in the CXCR3 family (IP10, ITAC and MIG) and 
BCA1, a chemokine that attracts B cells, were observed. Both IP10 and ITAC are 
known to chemoattract activated T cells and NK cells. Plasma levels of IP10 and 
ITAC were higher in DHF in the early days of the illness and significance was 
detected on day 3 (Figures 4.5.3B-C). A rapid decline of these chemokines was 
clearly seen in DHF after the 4th day. Unlike IP10 and ITAC, plasma levels of MIG 
were slightly elevated throughout this period in both groups and presented the same 
patterns (Figure 4.5.7K). However, on day 6, the level of MIG in DHF decreased.  An 
increase in BCA1 concentration was inclined similarly in both groups but a profound 
rise in BCA1 was found in DHF only on days 5 and 6 (significant on day 5) (Figure 
4.5.3D).  Similar to IP10 and ITAC, plasma levels of MCP1 and MCP2, monocyte 
attracting chemokines, were high in the early days, particularly in DHF, and then 
declined after day 4 (Figures 4.5.4A and 4.5.4D). Only MCP2 levels showed 
statistical significance on day 3 (Figure 4.5.4D). Likewise, high levels of MIP1β in 
DHF were seen during the early days and declined later while the levels of RANTES 
in DHF were lower than those in DF throughout the acute stage (Figures 4.5.4B and 
4.5.4C). Next, a rise in MIP1δ, MIP3β and MIP3α levels was detected in DHF but the 
levels of these proteins subsequently dropped afterwards (Figures 4.5.4E, 4.5.4F and 
4.5.4G). Increases in Eotaxin2 and TPO levels were also observed in both DF and 
DHF but their concentrations in DF declined after day 5 (Figures 4.5.4H and 4.5.6). In 
contrast to these two markers, concentrations of CTACK continuously increased 
throughout this stage in both groups (Figure 4.5.4I). Induction of IL10 was also 
detected in the plasma of Dengue patients and peaked on the 5th day of the illness 
before declining (Figure 4.5.5A). In contrast to IL10, high levels of TRAIL were 
detected early and progressively dropped up to day 6 (Figure 4.5.5C). The levels of 
IL12 and I309 in DHF, similar to RANTES, were lower than those in DF (Figures 
4.5.5B, and 4.5.7L). 
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Kinetic patterns of MCSF and TARC levels changed drastically over time in 
the DHF group. An induction of these proteins was found and peaked between day 3 
and day 5 but levels greatly decreased thereafter to a very low level by day 6 (Figures 
4.5.7A and 4.5.7M). Similarly, plasma levels of IL23 in DHF were markedly induced 
early during the disease (day 3) but declined afterwards (Figure 4.5.7H). In addition, 
reductions of IL1Ra and IL15 concentrations, together with inductions of IL16 and 
IL33, were observed in DHF while the concentrations of these proteins did not present 
a noticeable change in DF (Figures 4.5.7C, 4.5.7F, 4.5.7G and 4.5.7I). High 
concentrations of IL6 were also detected in DHF from the 2nd to the 4th day of illness 
and considerably decreased during the late days (Figure 4.5.7E). A change of IL6                                   
levels in DF was not noticeably seen (Figure 4.5.7E). Finally, a rise in IL2R appeared 
in both groups (Figure 4.5.7N) whereas patterns of IL2, Eotaxin and 6Ckine were 
similar in both groups at every time point and there were no drastic changes in these 
markers (Figures 4.5.7D, 4.5.7J and 4.5.7O).  
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Figure 4.5.1: Comparison of plasma MMPs of patients with DF and DHF between 
day 2 and 6 of disease. The lines represent median values. Statistical difference 
between DF and DHF at each time point was determined by the Mann-Whitney test 
(**, p < 0.00076; ***, p < 0.0001).    
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Figure 4.5.2: Comparison of plasma soluble receptors of patients with DF and DHF 
between day 2 and 6 of disease. The lines represent median values. Statistical 
difference between DF and DHF at each time point was determined by the Mann-
Whitney test (**, p < 0.00076; ***, p < 0.0001).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.3: Comparison of plasma chemokines (CXC family) of patients with DF 
and DHF between day 2 and 6 of disease. The lines represent median values. 
Statistical difference between DF and DHF at each time point was determined by the 
Mann-Whitney test (**, p < 0.00076; ***, p < 0.0001).    
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Figure 4.5.4: Comparison of plasma chemokines (CC family) of patients with DF and 
DHF between day 2 and 6 of disease. The lines represent median values. Statistical 
difference between DF and DHF at each time point was determined by the Mann-
Whitney test (**, p < 0.00076; ***, p < 0.0001).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.5: Comparison of plasma cytokines of patients with DF and DHF between 
day 2 and 6 of disease. The lines represent median values. Statistical difference 
between DF and DHF at each time point was determined by the Mann-Whitney test 
(**, p < 0.00076; ***, p < 0.0001).    
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Figure 4.5.6: Comparison of plasma cytokines of patients with DF and DHF between 
day 2 and 6 of disease. The lines represent median values. Statistical difference 
between DF and DHF at each time point was determined by the Mann-Whitney test 
(**, p < 0.00076; ***, p < 0.0001).    
 152 
A B 
C D 
E F 
G H 
 153 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.7: Comparison of biological markers with missing data greater than 10% 
of patients with DF and DHF between day 2 and 6 of disease. The lines represent 
median values. Statistical difference between DF and DHF at each time point was 
determined by the Mann-Whitney test (**, p < 0.00076; ***, p < 0.0001).    
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4.2.4 The relationship between soluble mediators in Dengue disease 
 
To determine if soluble proteins induced during Dengue disease are 
associated, the correlation between markers was tested in Dengue groups. As seen in 
Table 4.6, a strong relationship was seen between IP10 and IL15 (r = 0.86) and ast 
and alt (r = 0.82). A high correlation was also observed in a pair of IL23 and IL33 (r = 
0.74) and a pair of wbc and PMN (r = 0.73). Moreover, moderate correlations 
(0.5≤r<0.7) were found between MMP8 and MMP9, IL12 and IL1Ra, MCP1and 
IL15, MCP1 and Eotaxin, MCP1 and IP10, MCP1 and ITAC, MCP1 and MCP2,  
sIL2Ra and IL2R, sIL2Ra and sTNFRII, sTNFRII and IL10, sTNFRII and sTNFRI, 
sTNFRII and platelets, sTNFRII and ast, ENA78  and RANTES, ENA78 and TARC, 
Trail and MCP2, ITAC and IL15, ITAC and IP10, ITAC and MCP2, IL33 and TPO, 
BCA1 and platelets, lft_albumin and lft_protein, ast and platelets, and alt and 
platelets. In addition, a weak correlation was found between several pairs of markers 
such as IL6 and IL8, MMP9 and IL10, to name a few. Of note, there were some 
negative correlations found. For example, a reduction of platelet cells was associated 
with increased levels of sTNFRII, BCA1, ast, and alt. The strong relationship between 
soluble mediators is drawn in Figure 4.6. 
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Table 4.6 Correlation between markers 
MMP1 MMP2 MMP3 MMP8 MMP9 IL-6 IL-8 IL-1RA IL-10 IL-2 IL-2R IL-12 IL-15 EOTOXIN IP-10 MCP-1 MIG MIP-1b RANTES
MMP1 1.00
MMP2 0.01 1.00
MMP3 0.03 0.26 1.00
MMP8 0.12 -0.11 0.01 1.00
MMP9 0.11 0.02 0.06 0.66 1.00
IL-6 -0.04 -0.01 0.03 0.01 0.09 1.00
IL-8 0.00 0.08 0.11 -0.05 -0.07 0.38 1.00
IL-1RA -0.06 -0.08 -0.08 -0.02 -0.06 0.40 0.25 1.00
IL-10 -0.13 0.14 0.03 -0.18 -0.30 0.20 0.36 0.11 1.00
IL-2 -0.02 0.04 -0.01 0.12 0.16 0.34 0.12 0.35 -0.01 1.00
IL-2R 0.02 0.18 0.12 0.06 -0.06 0.25 0.29 0.21 0.42 0.18 1.00
IL-12 -0.02 -0.13 -0.17 0.04 -0.10 0.10 0.02 0.60 -0.06 0.12 0.12 1.00
IL-15 -0.05 0.06 0.19 0.03 -0.02 0.41 0.44 0.36 0.23 0.18 0.33 0.12 1.00
EOTOXIN -0.02 0.19 0.08 0.01 0.04 0.14 0.22 0.30 -0.05 0.18 0.18 0.24 0.40 1.00
IP-10 -0.11 0.13 0.22 -0.09 -0.05 0.29 0.42 0.31 0.23 0.11 0.27 0.03 0.86 0.33 1.00
MCP-1 -0.10 0.17 0.11 -0.12 -0.07 0.45 0.37 0.34 0.15 0.12 0.20 0.15 0.64 0.51 0.58 1.00
MIG -0.04 -0.03 -0.07 0.02 -0.15 0.24 0.34 0.40 0.39 0.18 0.42 0.30 0.46 0.22 0.38 0.23 1.00
MIP-1b -0.08 -0.09 -0.05 0.06 -0.03 0.45 0.25 0.42 0.18 0.31 0.22 0.38 0.34 0.28 0.16 0.36 0.40 1.00
RANTES -0.02 -0.05 -0.06 0.12 0.06 -0.14 -0.25 0.08 -0.21 0.13 -0.03 0.39 -0.10 0.19 -0.20 -0.02 0.05 0.26 1.00
sEGFR -0.06 0.08 0.15 0.05 0.00 0.03 0.16 0.09 0.16 0.10 0.24 -0.04 0.33 0.08 0.29 0.12 0.15 0.03 -0.01
sgp130 0.07 0.13 -0.05 -0.07 -0.04 0.03 0.15 0.20 -0.01 0.00 0.03 0.10 0.15 0.21 0.16 0.18 0.08 0.00 -0.06
sIL1RII 0.02 -0.01 0.23 0.06 0.07 -0.01 0.14 0.04 -0.08 -0.04 0.00 -0.05 0.21 0.11 0.20 0.13 0.00 0.01 -0.04
sIL-2Ra -0.02 0.22 0.15 0.04 -0.05 0.13 0.26 0.18 0.43 0.13 0.64 0.01 0.27 0.14 0.30 0.13 0.35 0.02 -0.10
sIL-4R -0.12 0.17 0.05 -0.04 -0.02 -0.10 -0.07 0.04 0.06 0.09 0.04 -0.01 0.03 0.11 0.04 0.06 0.09 -0.07 0.08
sIL-6R 0.01 0.29 0.09 -0.12 -0.11 0.03 0.08 -0.05 0.15 -0.02 0.13 -0.09 0.08 0.00 0.12 -0.01 0.08 -0.04 -0.04
sTNFRI 0.07 -0.02 0.29 0.05 0.02 0.25 0.37 0.26 0.26 0.07 0.33 0.03 0.35 0.05 0.36 0.28 0.26 0.19 -0.21
sTNFRII -0.02 0.20 0.27 -0.05 -0.09 0.27 0.40 0.11 0.51 0.04 0.42 -0.09 0.37 0.02 0.42 0.26 0.27 0.15 -0.28
sVEGFRII -0.03 -0.02 -0.16 -0.08 -0.17 -0.10 -0.11 0.21 -0.05 0.06 -0.07 0.20 -0.05 0.10 -0.06 0.11 0.03 0.00 0.22
MCP-2 -0.06 -0.12 0.03 -0.04 0.03 0.34 0.27 0.33 -0.03 0.02 0.06 0.18 0.41 0.29 0.40 0.61 0.11 0.37 0.02
ENA-78 0.07 -0.11 -0.07 -0.02 -0.07 0.01 -0.16 0.18 -0.09 0.11 0.02 0.31 -0.03 0.20 -0.10 -0.01 0.15 0.26 0.66
BCA-1 -0.03 0.07 0.17 0.07 0.01 0.14 0.34 0.06 0.29 0.00 0.33 -0.10 0.34 0.09 0.35 0.10 0.31 0.11 -0.18
I-309 0.01 0.17 -0.07 -0.02 -0.10 -0.11 -0.12 0.11 0.01 -0.05 0.07 0.25 0.05 0.19 0.06 0.12 0.11 0.02 0.16
IL-16 0.07 -0.01 0.08 -0.01 -0.08 -0.01 0.26 0.05 0.16 0.03 0.17 0.12 0.17 0.13 0.22 0.12 0.09 0.15 -0.02
MIP-1d -0.01 0.09 0.08 0.03 -0.02 0.05 0.06 -0.01 0.04 -0.05 0.10 0.06 0.05 0.07 0.04 0.09 0.06 0.10 0.00
TARC -0.01 -0.02 -0.10 0.09 -0.03 -0.02 -0.03 0.15 0.08 0.11 0.09 0.33 0.06 0.18 -0.01 0.04 0.20 0.25 0.48
6Ckine 0.03 0.04 -0.01 -0.01 -0.12 0.14 0.19 0.19 0.20 0.06 0.24 0.25 0.24 0.23 0.26 0.20 0.27 0.24 0.06
Eotaxin-2 0.05 0.10 0.15 -0.02 -0.03 0.09 0.31 0.03 0.21 -0.09 0.25 -0.06 0.37 0.16 0.36 0.18 0.22 0.03 -0.21
CTACK -0.03 0.10 0.25 0.04 -0.01 0.12 0.15 -0.02 0.07 0.05 0.23 -0.01 0.27 0.14 0.19 0.15 0.12 0.09 -0.05
IL-23 -0.02 0.10 -0.02 -0.17 -0.14 0.01 0.06 0.13 0.15 0.02 0.15 0.09 0.19 0.16 0.19 0.14 0.22 0.11 0.20
TPO -0.07 0.05 0.08 0.02 -0.09 0.19 0.20 -0.04 0.23 0.09 0.21 -0.03 0.22 0.06 0.09 0.10 0.15 0.17 -0.10
TRAIL 0.04 -0.03 -0.03 -0.05 0.00 0.13 0.07 0.25 -0.16 -0.09 -0.11 0.18 0.28 0.17 0.25 0.39 0.04 0.11 -0.10
IL-33 -0.11 -0.02 -0.01 -0.05 -0.14 0.16 0.24 0.22 0.35 0.09 0.26 0.10 0.31 0.06 0.28 0.19 0.42 0.18 0.00
M-CSF 0.01 -0.03 0.10 -0.04 -0.03 0.24 0.21 0.04 0.13 0.04 0.09 -0.04 0.16 -0.14 0.19 0.12 0.15 0.07 -0.19
GCP2 -0.13 0.02 0.06 -0.10 -0.14 0.12 0.34 0.18 0.33 0.04 0.21 -0.01 0.32 0.14 0.36 0.17 0.34 0.09 -0.15
I-TAC -0.06 0.00 0.08 -0.08 -0.10 0.24 0.41 0.23 0.21 -0.05 0.14 0.00 0.53 0.27 0.58 0.52 0.34 0.19 -0.32
MIP3b -0.09 0.19 0.00 0.00 -0.11 0.09 0.13 0.15 0.22 0.03 0.12 0.11 0.18 0.25 0.24 0.25 0.24 0.14 -0.02
MIP3a -0.01 0.03 0.17 0.02 -0.05 0.28 0.35 0.15 0.17 0.08 0.18 0.05 0.34 0.23 0.36 0.29 0.22 0.18 -0.15
hct 0.09 0.16 0.22 0.07 0.05 -0.07 0.08 -0.11 0.11 -0.06 0.14 -0.17 0.10 -0.07 0.10 -0.07 0.05 -0.04 -0.06
wbc 0.11 -0.11 -0.03 0.35 0.31 -0.05 -0.18 0.04 -0.23 0.06 -0.01 0.00 -0.11 0.04 -0.14 -0.20 -0.01 -0.10 0.16
pmn 0.10 -0.24 -0.05 0.41 0.34 0.08 -0.17 0.08 -0.30 0.07 -0.12 -0.02 0.00 -0.03 -0.04 -0.05 -0.03 0.00 0.11
lymphocyte 0.01 0.20 0.05 0.03 0.01 -0.12 -0.03 -0.03 0.08 -0.02 0.11 0.00 -0.11 0.10 -0.12 -0.20 0.03 -0.15 0.06
atyp. lymphocyte 0.04 -0.01 -0.01 -0.04 -0.06 -0.08 0.03 -0.14 0.18 0.05 0.05 -0.16 -0.02 -0.06 -0.02 -0.20 0.09 -0.11 -0.07
monocyte 0.06 -0.05 0.03 0.17 0.20 -0.08 -0.14 -0.03 -0.17 -0.09 -0.06 -0.01 -0.22 0.04 -0.27 -0.22 -0.22 -0.10 0.18
basophil 0.04 -0.03 0.03 0.05 0.01 0.09 0.07 0.03 0.05 0.11 0.05 0.07 0.01 0.00 0.01 0.03 0.08 0.11 0.00
eosinophil 0.12 0.06 0.02 0.05 0.04 0.03 -0.03 -0.10 0.02 0.01 0.13 -0.02 -0.01 0.06 -0.08 -0.08 -0.03 0.01 0.04
platelet 0.11 -0.23 -0.28 0.00 -0.03 -0.14 -0.29 0.15 -0.36 -0.03 -0.27 0.35 -0.21 0.07 -0.28 -0.01 -0.08 0.02 0.37
lft_protein 0.08 -0.11 -0.10 -0.01 -0.07 -0.07 -0.19 0.13 -0.12 0.07 -0.17 0.16 -0.01 0.02 -0.10 -0.07 0.10 0.10 0.23
lft_albumin 0.02 -0.14 -0.12 -0.05 -0.10 -0.03 -0.17 0.19 -0.14 0.02 -0.16 0.25 -0.08 0.07 -0.09 0.02 0.10 0.14 0.16
lft_ast -0.03 0.22 0.24 -0.02 -0.06 0.15 0.38 -0.01 0.36 0.07 0.35 -0.20 0.32 -0.01 0.33 0.09 0.22 0.03 -0.24
lft_alt 0.02 0.17 0.22 0.02 0.02 0.10 0.29 -0.05 0.27 0.03 0.23 -0.20 0.23 -0.02 0.24 0.04 0.14 -0.01 -0.17
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sEGFR sgp130 sIL1RII sIL-2Ra sIL-4R sIL-6R sTNFRI sTNFRII sVEGFRII MCP-2 ENA-78 BCA-1 I-309 IL-16 MIP-1d TARC 6Ckine Eotaxin-2 CTACK IL-23 TPO
sEGFR 1.00
sgp130 0.12 1.00
sIL1RII 0.19 0.22 1.00
sIL-2Ra 0.33 0.16 0.11 1.00
sIL-4R 0.04 0.10 0.00 0.09 1.00
sIL-6R 0.17 0.14 0.11 0.26 0.14 1.00
sTNFRI 0.27 0.22 0.32 0.48 0.00 0.10 1.00
sTNFRII 0.35 0.14 0.16 0.60 -0.02 0.30 0.64 1.00
sVEGFRII 0.11 0.15 0.07 0.06 0.14 0.06 -0.08 -0.18 1.00
MCP-2 0.00 0.19 0.23 0.01 -0.10 -0.14 0.31 0.12 0.03 1.00
ENA-78 0.07 0.00 -0.01 -0.10 -0.01 -0.03 -0.16 -0.26 0.21 0.08 1.00
BCA-1 0.32 0.06 0.10 0.43 0.00 0.16 0.33 0.48 -0.25 0.04 -0.07 1.00
I-309 -0.03 0.05 -0.07 0.20 0.08 0.10 -0.09 -0.05 0.20 0.07 0.12 -0.03 1.00
IL-16 0.16 0.09 0.06 0.16 -0.07 0.08 0.25 0.31 -0.07 0.15 0.09 0.24 0.08 1.00
MIP-1d 0.04 0.05 0.08 0.02 -0.03 0.13 0.10 0.13 -0.06 0.12 -0.01 0.16 0.11 0.14 1.00
TARC 0.12 -0.04 -0.08 0.04 -0.03 -0.01 -0.12 -0.11 0.12 0.06 0.62 0.10 0.36 0.10 0.01 1.00
6Ckine 0.12 0.01 0.11 0.24 -0.09 0.13 0.22 0.21 0.00 0.24 0.20 0.28 0.23 0.35 0.26 0.23 1.00
Eotaxin-2 0.32 0.15 0.25 0.35 0.01 0.20 0.34 0.43 -0.11 0.11 -0.14 0.37 0.10 0.23 0.12 0.07 0.26 1.00
CTACK 0.20 -0.01 0.06 0.25 -0.03 0.07 0.18 0.27 -0.15 0.17 -0.12 0.27 0.16 0.17 0.18 0.06 0.12 0.25 1.00
IL-23 0.22 0.00 -0.02 0.14 0.17 0.10 0.02 0.03 0.17 0.07 0.41 0.18 0.15 0.38 0.00 0.37 0.33 0.12 -0.05 1.00
TPO 0.10 -0.06 -0.10 0.16 -0.02 0.08 0.17 0.26 -0.11 0.05 -0.23 0.27 0.06 0.34 0.13 0.06 0.26 0.18 0.28 0.21 1.00
TRAIL -0.11 0.22 0.09 -0.14 -0.05 -0.07 0.11 -0.08 0.13 0.57 0.00 -0.12 0.18 0.08 0.05 -0.05 0.05 0.04 0.09 0.05 -0.10
IL-33 0.31 -0.05 -0.11 0.27 0.08 0.05 0.20 0.30 0.08 0.09 0.09 0.38 0.06 0.38 0.04 0.21 0.29 0.21 0.13 0.74 0.67
M-CSF 0.20 -0.06 0.04 0.07 -0.25 -0.02 0.21 0.30 -0.13 0.17 -0.02 0.20 -0.20 0.01 0.13 -0.03 -0.02 0.08 0.24 0.03 0.09
GCP2 0.33 0.12 0.11 0.32 0.21 0.13 0.33 0.39 -0.02 0.13 0.02 0.37 0.00 0.25 0.08 0.13 0.28 0.39 0.03 0.25 0.27
I-TAC 0.08 0.25 0.17 0.25 0.04 -0.01 0.39 0.38 -0.09 0.55 -0.24 0.29 0.07 0.27 0.13 -0.13 0.24 0.35 0.18 0.13 0.20
MIP3b -0.05 0.14 -0.04 0.26 0.16 0.10 0.13 0.19 0.00 0.17 -0.13 0.24 0.24 0.12 0.16 0.05 0.23 0.17 0.16 0.09 0.23
MIP3a 0.24 0.06 0.13 0.26 -0.06 0.07 0.31 0.37 -0.07 0.22 -0.06 0.44 -0.03 0.27 0.15 0.06 0.32 0.27 0.24 0.12 0.20
hct 0.13 0.13 0.19 0.09 0.08 0.24 0.09 0.18 -0.03 -0.07 -0.06 0.14 -0.05 -0.02 0.03 -0.01 0.00 0.14 0.01 -0.01 -0.01
wbc -0.02 -0.10 -0.02 -0.01 0.08 -0.01 -0.09 -0.15 0.04 -0.17 0.12 -0.02 0.08 -0.08 -0.05 0.10 0.09 0.02 -0.12 0.00 -0.14
pmn -0.09 -0.05 0.10 -0.18 0.06 -0.17 -0.04 -0.24 0.05 0.07 0.10 -0.06 -0.02 -0.12 -0.01 0.03 0.03 -0.09 -0.20 -0.06 -0.14
lymphocyte 0.11 -0.06 -0.14 0.22 0.07 0.21 -0.07 0.11 0.02 -0.30 0.04 0.04 0.20 0.01 0.00 0.10 0.08 0.18 0.16 0.09 0.03
atyp. lymphocyte 0.16 -0.10 -0.07 0.10 -0.01 0.22 -0.05 0.20 -0.15 -0.28 -0.08 0.13 -0.01 0.07 -0.03 -0.02 -0.08 0.18 0.08 0.03 0.00
monocyte -0.11 0.02 0.06 -0.11 0.13 -0.02 -0.13 -0.25 0.15 -0.14 0.11 -0.06 0.03 -0.17 0.00 -0.02 0.03 -0.12 -0.17 -0.10 -0.15
basophil -0.05 0.02 -0.06 0.08 -0.01 0.05 0.08 0.06 0.02 0.01 0.02 0.06 0.05 -0.03 0.00 0.05 0.03 0.10 0.00 -0.02 0.04
eosinophil -0.10 -0.04 -0.04 0.13 -0.02 0.01 -0.02 0.01 -0.02 -0.09 -0.05 0.06 0.04 -0.01 -0.03 0.01 0.07 0.00 0.01 -0.09 0.05
platelet -0.31 0.10 -0.05 -0.30 0.06 -0.18 -0.26 -0.56 0.47 0.10 0.33 -0.50 0.17 -0.20 -0.05 0.14 -0.02 -0.35 -0.26 0.02 -0.31
lft_protein -0.08 0.12 -0.03 -0.19 0.14 0.02 -0.18 -0.34 0.35 -0.05 0.25 -0.14 0.03 -0.12 -0.07 0.12 -0.02 -0.20 -0.20 0.12 -0.10
lft_albumin -0.10 0.15 0.04 -0.26 0.10 -0.04 -0.16 -0.34 0.33 0.08 0.17 -0.22 0.08 -0.21 -0.02 0.06 -0.02 -0.20 -0.19 0.03 -0.12
lft_ast 0.46 0.11 0.20 0.41 0.03 0.26 0.38 0.61 -0.27 0.02 -0.15 0.49 -0.11 0.29 0.15 -0.06 0.20 0.42 0.29 0.13 0.28
lft_alt 0.37 0.11 0.23 0.29 0.01 0.23 0.31 0.44 -0.22 -0.02 -0.09 0.33 -0.13 0.22 0.11 -0.05 0.11 0.33 0.24 0.06 0.19
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5
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The color coding for a correlation: strong (r≥ 0.7, red), moderate (0.5≤r<0.7, yellow), fair (0.3 ≤r<0.5, green) and weak (r<0.3, white). The grey color is an identity of the same marker. The spearman’s 
correlation coefficient (r) was calculated from Dengue groups. 
TRAIL IL-33 M-CSF GCP2 I-TAC MIP3b MIP3a hct wbc pmn lymphocyte
atyp. 
lymphocyte monocyte basophil eosinophil platelet lft_protein lft_albumin lft_ast lft_alt
TRAIL 1.00
IL-33 -0.01 1.00
M-CSF 0.13 0.19 1.00
GCP2 -0.08 0.40 0.04 1.00
I-TAC 0.41 0.23 0.14 0.42 1.00
MIP3b 0.13 0.12 -0.12 0.34 0.44 1.00
MIP3a 0.08 0.29 0.20 0.30 0.36 0.31 1.00
hct -0.02 0.00 -0.06 0.05 0.08 0.06 -0.02 1.00
wbc -0.15 -0.07 -0.20 -0.06 -0.22 -0.14 -0.04 -0.01 1.00
pmn -0.01 -0.12 -0.13 -0.04 -0.08 -0.08 0.00 0.02 0.73 1.00
lymphocyte -0.14 0.11 -0.06 0.01 -0.21 -0.05 -0.05 -0.05 0.47 -0.13 1.00
atyp. lymphocyte -0.18 0.09 -0.01 0.06 -0.07 -0.04 0.06 0.07 0.08 -0.21 0.24 1.00
monocyte -0.11 -0.20 -0.23 -0.14 -0.25 -0.14 -0.10 0.14 0.44 0.32 0.09 -0.15 1.00
basophil 0.02 0.05 0.02 0.01 0.00 0.08 0.05 0.01 0.01 -0.03 0.03 -0.01 0.04 1.00
eosinophil -0.04 -0.05 -0.12 -0.04 -0.06 0.07 -0.02 0.05 0.07 -0.02 0.09 -0.03 0.16 0.21 1.00
platelet 0.24 -0.23 -0.27 -0.28 -0.21 -0.08 -0.23 -0.24 0.18 0.26 -0.05 -0.36 0.21 0.02 0.02 1.00
lft_protein 0.08 0.04 -0.22 -0.08 -0.09 0.00 -0.06 0.14 0.12 0.19 -0.09 -0.12 0.21 0.00 0.01 0.42 1.00
lft_albumin 0.19 -0.08 -0.17 -0.12 -0.03 0.01 -0.16 0.09 0.01 0.15 -0.16 -0.24 0.14 0.01 0.01 0.40 0.65 1.00
lft_ast -0.19 0.29 0.34 0.39 0.26 0.11 0.29 0.16 -0.09 -0.18 0.13 0.29 -0.20 -0.01 -0.07 -0.65 -0.29 -0.29 1.00
lft_alt -0.20 0.17 0.24 0.26 0.15 0.04 0.18 0.25 -0.05 -0.11 0.06 0.25 -0.10 0.02 -0.06 -0.51 -0.18 -0.21 0.82 1.00
<0.3 0.3≤r<0.5 0.5≤r<0.7 ≥0.7
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Figure 4.6: The relationship between soluble mediators in Dengue infection. The 
numbers presented in the figure are the correlation coefficient (-1 ≤r ≤1). 
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4.2.5 Identification of predictive markers  
 
4.2.5.1 Binary logistic regression 
 
 To identify predictive markers for discriminating between DHF and DF, binary 
logistic regression was performed as described in Materials and Methods (section 2.16) 
under the suggestion of Dr. Bernard North, the Imperial College Statistical Advisory 
Service. Logistic regression was employed with DHF and DF as a binary outcome, 
approximating the log odds of the probability of DHF status (logit of DHF) by a weighted 
combination of a subset of predictive biomarkers from the data set by backward 
elimination of non-significant biomarkers. 
 
First, the markers which were associated with Dengue severity (Table 4.2, p-
valuea <0.05; Table 4.3, p-valuea <7.6x10-4, and Figure 4.2) and contained fewer than 50 
missing values (<10% missing value) were chosen. These markers consisted of 7 clinical 
parameters and 15 biomarkers including hct, lymphocyte platelet, lft albumin, lft protein, 
ast, alt, MMP3, sTNFRI, sTNFRII, sVEGFRII, IL8, IP10, ITAC, BCA1, RANTES, 
MCP2, MIP3α, Eotaxin2, CTACK, IL12 and TPO. Of these markers, MMP3, BCA1, 
MIP3α, Eotaxin2, and CTACK are newly identified. Before using the logistic regression 
for analysis, the concentrations of these markers should be in a normal distribution; 
otherwise the model obtained might be skewed. Any markers with skewed distribution 
were log-transformed. These markers were ast, alt, MMP3, sTNFRI, IL8, IP10, ITAC, 
BCA1, RANTES, MCP2, MIP3α, Eotaxin2, IL12 and TPO.  
 
 The data set was divided into a training set (2/3 of the whole data) and a testing 
set (1/3 of the whole data) in order to avoid over-fitting of the data. Next, to test how well 
a statistical model fits the set of observed data, the goodness of fit test was performed in 
the training data set. The goodness of fit is used for measuring how far the observed data 
deviate from the expected data under the null hypothesis that a model is fit. The p-value 
was 0.08, which indicated that there was no lack of fit (p-value > 0.05), suggesting the 
model would be accurate enough. Then, a final model was obtained from the training set. 
Platelets and MCP2 were found to be predictive with low platelet cell count and high 
concentration of MCP2 associated with DHF.  The model generated was shown in Figure 
4.7. 
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Figure 4.7: The predictive model generated from the binary logistic regression. A 1 unit 
change of the platelet cell count (platelet cell counts per cu mm x1000) can decrease by -
0.0203 unit the logit of DHF while 1 unit change of logeMCP2 (pg/ml) can increase by 
0.8119 unit the logit of DHF. 
 
 
The model was refitted using ordinary GLM and the Hosmer-Lemeshow function 
was also used to assess the fit as described in Material and Methods (section 2.16). The 
result showed that it gave an adequate fit as p-value is greater than 0.05 (p-value = 0.31). 
Next, the model was evaluated by ROC curve in the test data set, as described in 
Materials and Methods (section 2.18) (Figure 4.8). Briefly, an accuracy of the model can 
be evaluated by an AUC (area under the curve). Sensitivity, specificity and optimal cutoff 
of the estimated probability of DHF were obtained by Youden’s index. The accuracy of 
the model estimated by the AUC was 0.82. In general, the AUC of 0.5 (below the 
diagonal line) means random guessing while the AUC of 1 reflects the best forecast. In 
this result, the AUC of 0.82 is considered good enough for prediction. Sensitivity of the 
test (the probability that a test result will indicate DHF among those with the DHF) was 
0.7317 (73.17%) while specificity (the probability that a test result will indicate DF 
among those with the DF) was 0.8313 (83.13%). In other words, a test of 73.17% 
sensitivity correctly detects 73.17% of people with DHF but 26.83% of those with DHF 
present undetected (false negatives) while a test with 83.13% specificity correctly 
identifies 83.13% of those with DF but 16.87% of those with DF are reported as DHF 
(false positives). In addition, an optimal cutoff of the estimated probability of DHF was 
considered by 1) Youden’s index, which maximizes the sensitivity plus the specificity 
and 2) the shortest distance from the concave line to the upper-left corner of the graph 
(x,y: 0, 1) (Figure 4.8).  From the graph the Youden’s index is 0.5647 (0 ≤ Youden’s 
index ≤ 1) and Youden cut-off of the probability was at 0.5919 (0 ≤ Youden cut-off ≤ 1). 
 
 
  
Predicted logit of DHF   =   -1.7601 - 0.0203 (platelet counts) + 0.8119(loge MCP2) 
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The predicted logit of DHF can be changed to the probability of DHF and 
compared to the Youden cut-off as a formula below: 
 
P (DHF) = _________________________________                                                                                                        
1+e – (-1.7601-0.0203 platelet count + 0.8119 logeMCP2) 
 
P (DHF) that presents equal or over 0.5919 will be reported as ‘DHF’ while it will 
be reported as ‘DF’ when P (DHF) falls below 0.5919.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: The receiver operator characteristic (ROC) curve showing a true positive rate 
(sensitivity) and a false positive rate (1-specificity) of the model obtained from the 
logistic regression. Each point of the ROC curve represents a pair of sensitivity and 
specificity corresponding to the probability of DHF. The black diagonal line connecting 
(0, 0) and (1, 1) corresponds to random guessing and the area under this line is 0.5. The 
red vertical line is Youden’s index and the red diagonal line is the shortest distance from 
the ROC line to the point (0, 1).  The red circle is the optimal cut-off of the probability 
obtained from the analysis. 
1 
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 Since high sensitivity is much more important where the test is used to screen a 
serious but preventable illness, 90% or greater sensitivity was therefore computed from 
the ROC curve. A cut-off of the estimated probability with 90% sensitivity was shifted 
from 0.5919 to 0.3485. The sensitivity of the test was increased to 0.91 (91%) but the 
specificity dropped to 0.47 (47%).  
  
4.2.5.2 Classification and Regression Tree (CART) model 
 
Since CART is easy to interpret and nonlinear relationship between variables does 
not affect an analyze of a tree model, this method is therefore used for identifying 
predictive markers. To compare a predictive model with the binary logistic regression, 
CART was computed in the same training data set, as described in Materials and 
Methods. CART is a binary recursive partitioning based on individual markers. To 
construct the classification tree, selection of predictors depends on how much purity 
those markers have to classify the class (in this case DF or DHF). Moreover, the decision 
to split a new tree node is based on the minimal number of observations that must exist in 
the node. The default minimal number is set at 10 (the number of observations in a node 
must be 10 before attempting a split). The terminal nodes can be assigned after the tree 
grows large and is pruned back by considering the minimal error in a cross validation. 
Nodes with predictors that do not improve the tree’s purity are trimmed.  
 
The output of the training data gave the cut-offs of predictors, the numbers and 
proportions of DHF and DF as shown in Figure 4.9. The predictive marker obtained from 
the analysis was only the platelet cell count and the cut-off was assigned at 125.5 cells 
per cu mm (x1000). High platelet cell count was associated with DF (≥ 125.5). The 
number of total observations in the left node was 136 and that in the right node was 166. 
The class on the left node was classified as DF where the true DF count was 97 and the 
probability of DF was 0.713 (the DF class count = 97/136) while the class on the right 
node was classified as DHF where the true DHF count was 116 and the probability of 
DHF was 0.699 (the DHF class count = 116/166). The tree model was estimated by the 
ROC curve in the testing data set (Figure 4.10). The AUC of the model was 0.72 which 
was fair. The sensitivity was 77.77% and the specificity was 67.09%. This means a test of 
77.77% of people with DHF but  22.23% of those with DHF present undetected (false 
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negatives) while a test with 67.09% specificity correctly identifies 67.09% of those with 
DF but 32.91% of those with DF are reported as DHF (false positives). 
 
 
 
Figure 4.9: Classification tree of Dengue severity. Platelet cell count was a predictive 
marker to classify DF and DHF and the cut-off was 125.5. The class count was shown as 
the probability whose value is between 0 and 1. The light grey area is the probability of 
DF while the dark grey area is the probability of DHF. The number of observations is 
shown on the top of each node.  
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Figure 4.10: The ROC curve showing a true positive rate (sensitivity) and a false 
positive rate (1-specificity) of the model obtained from the CART.  
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4.3 Discussion 
  
 In this experiment, clinical and biological markers were identified in plasma 
samples from Dengue infected children during the acute phase.  The concentration of 
these plasma proteins as well as the number of peripheral blood cells were determined 
and compared. The correlation between these markers was also observed and predictive 
models analyzed by binary logistic regression and CART was used to discriminate DF 
and DHF. Platelet cells together with MCP2 were identified as predictive markers for 
Dengue severity.  
  
 When clinical features were observed among DHF, DF and OFI groups, the 
increase in haematocrit (hct) was present in the Dengue groups but was less than 20% 
higher than the control (OFI) group (Table 4.2 and Figure 4.1A), based on WHO criteria 
to determine DHF (Organization, 2009). The hct values found in this study also remained 
within the average (mean) range of hct found in Thai children aged between 2 and 10 
(35-40%). This different result might be due to the small number of samples in the 
experiment and the duration of sample collection. The platelet cell count, as expected, 
was below 100,000 cells per cu mm in DHF patients (Table 4.2 and Figure 4.1I). A 
reduction in platelet cells was also observed in DF patients and this was below the normal 
range of the platelet cell count (150,000–400,000 cells per cu mm; (Torcharus)). A 
decrease in white blood cell count (wbc) was also observed in Dengue patients when 
compared to the control group (Table 4.2 and Figure 4.1B) and the normal range of wbc 
count in Thai children (4.5-15 x1000 cells per cu mm; (Torcharus)). When viewing the 
longitudinal experiment, the hct values in DHF peaked at day 4 when the number of wbc 
was lowest (Figures 4.4A and 4.4B). This day might be a critical period of Dengue 
illness. Moreover, this trend was similar to the trend described in WHO literature (Figure 
1.4, (Organization, 2009)). Like wbc, the number of polymorphonuclear cells (PMN or 
neutrophils) was reduced in Dengue patients (Table 4.2 and Figure 4.1C). Possible 
mechanisms to explain the low number of PMN are: recruitment of these cells to the site 
of infection, neutrophil adherence to the endothelium, and neutrophil cell death due to 
phagocytosis (Avirutnan et al., 1998, DiStasi and Ley, 2009). Next, reduced lymphocyte 
numbers were detected in Dengue patients and the number of lymphocytes in DHF was 
lower than those in DF (Table 4.2 and Figure 4.1D). This result was confirmed by other 
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reports showing that fewer lymphocytes are found during acute DHF (Kumar et al., 2012, 
Green et al., 1999a). Apoptosis of activated lymphocytes can contribute to this 
phenomenon. Activated cells may migrate to infected tissues and undergo apoptosis after 
eradicating virus-infected cells (Mongkolsapaya et al., 2003). Likewise, elevated atypical 
lymphocytes were observed in Dengue patients, particularly in DHF (Table 4.2 and 
Figure 4.1E).  A reduction in liver proteins and albumin together with an increase in liver 
aminotransferases (ast and alt) was observed as similar to WHO criteria (Table 4.2 and 
Figure 4.1J-M). Low protein levels as well as increased liver enzymes in plasma indicate 
impaired liver function in Dengue illness (Seneviratne et al., 2006).  
 
When observing biological features, there were several indicators associated with 
Dengue disease (Table 4.3 and Figure 4.3). Some of these markers have been previously 
reported and replicated in other studies (Table 1.1). High levels of T cell activation 
markers, soluble IL2Rs, for example, were detected in Dengue patients when compared 
to the control group, although no significant difference between DF and DHF was 
detected as earlier reported (Figure 4.3.2F) (Kurane et al., 1991, Green et al., 1999b). 
High plasma levels of MIP1β, IL10 and TRAIL were found in Dengue patients and these 
results match to the other studies (Figure 4.3.4B, 4.3.5A and 4.3.5C; (Azeredo et al., 
2001, Becerra et al., 2009)). Similarly, over-production of soluble TNF receptors 
(sTNFRI and sTNFRII), TPO and inflammatory chemokines including IL6, IL8, IP10, 
ITAC, MCP1 and MCP2 were also detected in Dengue patients (Figure 4.3.2C, 4.3.2D, 
4.3.3A-C, 4.3.4A, 4.3.4D, 4.3.6 and 4.3.7N; (Green et al., 1999b, Dejnirattisai et al., 
2008, Avirutnan et al., 1998, Becerra et al., 2009, Chen et al., 2006, Matondang et al., 
2004, Cardier et al., 2006)). Moreover, some of these markers including sTNFRII, TPO, 
IL6, IL8, IP10 and ITAC were associated with disease severity as previously shown 
(Green et al., 1999b, Dejnirattisai et al., 2008, Chen et al., 2006, Matondang et al., 2004, 
Cardier et al., 2006). Decreases in plasma levels of sVEGFRII, IL12 and RANTES were 
detected in DHF patients  and the lower plasma levels of neutrophil-secreted MMP9 was 
found in Dengue patients (Figures 4.3.1E, 4.3.2E, 4.3.4C and 4.3.5B). These results 
matched to the previous reports (Srikiatkhachorn et al., 2007, Pacsa et al., 2000, Pérez et 
al., 2004, Voraphani et al., 2010). There was one marker, MIG, that the result was 
different from the previous experiment. An increase in plasma levels of MIG was not 
detected here (Figure 4.3.7P) (Dejnirattisai et al., 2008). Supposing that this observation 
was not certain, a possible cause of the different result would have been a great number 
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of missing value in MIG, generating unreliable data due to a random sampling error 
(Table 4.4). 
 
   Although these soluble proteins have been shown to be associated with Dengue 
infection, they are still not defined as good early indicators for classifying Dengue 
severity and only a few reports have shown a function for these proteins in disease such 
as IP10, ITAC and sVEGFRII (Dejnirattisai et al., 2008, Srikiatkhachorn et al., 2007). So 
far, attempts to find better early indicators of Dengue severity are still ongoing. In the 
present study, many biomarkers associated with Dengue infection were newly identified.  
Increases in plasma levels of MMP3, BCA1, MIP3α, and CTACK were found in Dengue 
patients (Figures 4.3.1C, 4.3.3D, 4.3.4G, and 4.3.4I) whereas Eotaxin2 seemed to be 
lower in DF (Figure 4.3.4H). MMP1, MMP8, sIL4R, sIL6R, MIP1δ and MIP3β were 
also associated with Dengue infection when compared to the control (Figures 4.3.1A, 
4.3.1D, 4.3.2G, 4.3.2H, 4.3.4E and 4.3.4F).  
 
Looking at the kinetics of soluble mediator expression in DF and DHF patients, 
there were some markers for which the plasma levels were significantly different 
although interpretation in term of symptom must be careful since the time course were 
constructed between day 2 and 6 of disease and the number of samples in each day are 
small and different in each day. Plasma levels of five markers including sTNFRI, 
sTNFRII, IP10, ITAC and MCP2 were highly increased in DHF on day 3 (Figures 
4.5.2C, 4.5.2D, 4.5.3B, 4.5.3C and 4.5.4D). Plasma levels of MMP3 and sVEGFRII were 
significantly different between these two groups on day 4 where increased hct and 
reduced wbc were also detected (Figures 4.5.1C and 4.5.2E). Increased plasma BCA1 
was also detected in DHF later on day 5 (Figure 4.5.3D). Differential expression of these 
soluble mediators may give clues as to how proteins interplay in Dengue infection. Over-
produced soluble TNF receptors may respond to TNFα production since both type I and 
II receptors act as TNF antagonists, inhibiting TNFα activities (Chizzolini et al., 2009). 
The sVEGFRIIs are soluble receptors for VEGF, a vascular permeability factor, and a 
decline in these receptors is believed to be associated with vascular leakage occurring 
during the critical period in Dengue illness (Srikiatkhachorn et al., 2007).  
 
Apart from these mediators, several markers are likely to be associated with the 
Dengue illness, such as MCSF, IL15, IL16 and I309 (Table 4.4 and Figure 4.3.7). 
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Unfortunately, it could not be absolutely confirmed whether these markers are related to 
Dengue infection due to a large amount of missing data. Data can be missing on account 
of the quality and quantity of the proteins since some plasma proteins have short half-
lives and some are degraded easily.  Differences in the time from onset day can also 
affect the amount of these proteins in the plasma since it cannot exactly determine when 
patients became developed illness. Lot-to-lot variation of multiplex assay kits and their 
sensitivity can also cause a deviation of the sample median. Technical difficulties in 
measuring protein concentrations in the plasma samples during the experiment can 
further lead to inaccurate analysis. 
 
When the relationship between markers was tested (Table 4.6 and Figure 4.6), a 
high degree of correlation was seen between liver enzymes (r = 0.82). Liver enzymes 
may share similar biological activities; both of them are leaked from the liver to the blood 
stream and are used as liver-injury markers. Liver protein and liver albumin were also 
moderately correlated. Indeed, albumin is a major subset of the liver protein. A 
correlation between wbc and PMN was also high (r = 0.74). This is due to the fact that 
neutrophils compose about 40-60% of total white blood cells. 
 
A strong relationship was seen between IP10 and IL15 (r = 0.86; Table 4.6 and 
Figure 4.6). IL15 can stimulate T cell proliferation and activation while IP10 functions in 
T cell and monocyte recruitment. Besides, IL15 and IP10 were moderately correlated 
with MCP1 and ITAC, both of which have a similar function to IP10. In addition, MCP2 
were correlated with both MCP1 and ITAC. Eotaxin, a cytokine inducing eosinophil 
recruitment, seemed to be associated with MCP1 as well. Nevertheless, it was quite 
unexpected that MIG did not have a strong correlation with IP10 and ITAC since it is in 
the same CXC3 family and shares similar biological activities. It might be due to a 
different spatial and temporal expression, regulating by different cell sources and stimuli 
(Groom and Luster, 2011a, Groom and Luster, 2011b). For example, IP10 and ITAC are 
mostly triggered by innate stimuli which can induce type I and II IFNγ as well as TNF-α 
wheras MIG is restricted to IFNγ (Groom and Luster, 2011b). Moreover, IP-10 can be 
induced by innate immune sensors such as TLRs (Toll like receptors) and RIG-I 
(Retinoic acid inducible gene I) (Groom and Luster, 2011b). Additionally, in the murine 
cerebral model, MIG is mostly expressed in brain endothelial cells whereas IP10 is 
expressed by neuron (Campanella et al., 2008). Similarly, IP10 is produced in hepatic 
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dendritic cells in a murine model of liver disease and MIG is produced in parenchyma 
cells (Yoneyama et al., 2002). Again, the weak correlation might also be due to the 
number of missing values in MIG. What’s more, IL15 generally has a similar structure 
and function to IL2 (http://www.ncbi.nlm.nih.gov/gene/3600) but these molecules were 
not correlated. In Dengue illness, up-regulation of CXCR3-reactive chemokines (MIG, 
IP10 and ITAC) may recruit T cells to the site of infection, inducing other soluble 
mediators such as TNFα and IFNγ while MCP-1 may recruit monocytes (Dejnirattisai et 
al., 2008, Avirutnan et al., 1998, Antony et al., 1993). Although roles of IL15, MCP2 and 
Eotaxin have not been characterized in Dengue illness, with similar structures, functions 
as well as close correlation between these molecules, they may serve similar activities as 
CXCR3-reactive chemokines and MCP1. However, it cannot overlook the effects of their 
receptors that express on different cell sources, causing different outcome. 
 
Another strong relationship was observed between IL23 and IL33 (r = 0.74). IL23 
functions in the differentiation of naïve T helper cells to Th17 cells which can produce 
IL17, IL6 and TNFα but not IFNγ and IL4; it also acts on dendritic cells and macrophage 
to produce IL1, IL6 and TNFα (Iwakura and Ishigame, 2006). Although plasma IL23 was 
not associated with Dengue severity in this study and it could not be detected in the 
control group due to the very low concentration in the plasma (Table 4.4), it is still 
interesting that this cytokine might locally accumulate at the site of infection, inducing 
numerous proinflammatory cytokines such as TNFα. IL33 is a potent activator of 
eosinophils, mast cells and basophils which are important in preventing against parasite 
infection (Miller, 2011). Nevertheless, IL33 can also stimulate type 2 cytokine secretion 
such as IL5 and IL13 as well as induce a LPS-stimulated production of TNFα in 
macrophages (Miller, 2011, Espinassous et al., 2009). Since TNFα is one of a key factor 
in Dengue illness, IL33 may also play a role in TNFα production in this disease. In 
addition, IL23 is a new member of the IL12 family; however an association was not 
found between this pair. IL12 seems to be important for the induction of IFNγ and T cell 
regulation (Langrish et al., 2004, Gee et al., 2009). It was found to be moderately 
correlated with IL1Ra, which is an antagonist for IL1α. Interestingly, both IL33 and 
IL1Ra are members of the interleukin 1 cytokine family.  
 
IL33 was also associated with TPO (thrombopoietin). TPO has a role in 
stimulating the proliferation and maturation of megakaryocytes, regulating the number of 
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circulating platelets (Kuter, 1996). It was, nevertheless, not know a relationship between 
these two markers while a negative correlation between TPO and platelet was found in 
this study. The levels of TPO increased in the DHF group where the platelet cell count 
was much reduced when compared to the DF group as previously reported (Figure 4.3.6) 
(Matondang et al., 2004, Cardier et al., 2006).  A decrease in the platelet cell count might 
stimulate TPO secretion as to induce platelet production during the early stage of 
infection (Matondang et al., 2004). Furthermore, a moderate correlation was observed in 
many pairs of predictors such as MMP8 and MMP9, sIL2Ra, and IL2R, sTNFRI and 
sTNFRII, to name a few.  
 
MMP8 and MMP9 are released from neutrophils and play roles in inflammation, 
including the regulation of cytokine activities, neutrophil migration and degradation of 
the extracellular matrix (Manicone and McGuire, 2008, Van den Steen et al., 2003). A 
previous study has demonstrated that MMP9 may involve in endothelial leakage since 
anti-MMP9 antibody and an MMP inhibitor are able to enhance endothelial permeability 
in vitro and reduce expressions of PECAM1 and VE-cadherin, adhesion molecules on 
endothelial cells (Luplertlop et al., 2006). Seeing that infected endothelial cells can 
recruit neutrophils to the site of infection (Avirutnan et al., 1998), secreted MMPs may be 
mediators for the vascular leakage in Dengue infection. 
 
  sIL2Ra and IL2R are different forms of IL2 receptors; they have the same ligand 
which is IL2. sTNFRII was associated with many markers including sIL2Ra, sTNFRI, 
IL10, platelet, and ast. The relationship between these markers may involve several 
mechanisms.  For example, sTNFRs can mediate TNFα-induced apoptosis while IL10 
can regulate TNFα production (Micheau and Tschopp, 2003, Shibata et al., 1999, 
Armstrong et al., 1996). Additionally, an association was found between the following 
pairs; MCP2 and TPO, BCA1 and platelet, ENA78 and RANTES as well as ENA78 and 
TARC. Although several correlations were detected in this study, the obvious link 
between these markers is not known. It might be either causality or presumably occur at 
the same time but different pathway. 
 
 Predictive markers in this experiment were defined by two different methods: 
binary logistic regression and CART (Figures 4.7 and 4.9).  By the logistic regression 
analysis the platelet cell count and the plasma MCP2 levels were defined as predictive 
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markers. Low platelet cells and high levels of MCP2 generated an increased predicted 
probability of DHF. When the data was analyzed by CART, only the platelet cell count 
was obtained as a predictive marker and the cut-off discriminating between mild and 
severe Dengue was 125,500 cells per cu mm. The CART result did not follow the WHO 
protocol in which a platelet cell count below 100,000 cells per cu mm is a criterion for 
DHF (1997). Samples collected at different time points may lead to a deviation in the 
results. In this study, samples were collected during the 1st day to 10th day of illness 
(Table 4.1) but the platelet cell count below 100,000 cells per cu mm in the DHF group 
was observed after day 4 (Figure 4.4I). Since the objective of the study is to identify early 
predictive indicators, it could be possible that the platelet cell count is greater than that 
established by the WHO criterion. However, there are some difficulties to collect samples 
during the early stage of infection particularly during the first three days. These are 
undifferentiated fever during the early febrile stage, variation in incubation period of the 
disease and unease to access to hospitals. To overcome these problems, surveillance of 
Dengue disease and early warnings may require. 
 
From the analyses, the sensitivities of the diagnostic models were not very high 
and somewhat equivalent (regression: 73%; CART: 78%) while the specificity and the 
accuracy of the logistic regression was much greater than those of the CART (regression: 
83% specificity and AUC of 0.82; CART: 67% specificity and AUC of 0.72). When 
comparing these two methods, the logistic regression gave greater accuracy and better 
specificity and was found to be suitable as a predictive test. However, the sensitivity is 
generally more important than the specificity in a screening test since false negative 
(actual DHF but defined as DF) is more dangerous than false positive (actual DF but 
defined as DHF). Patients who are predicted to develop DHF will stay in a hospital while 
patients who are considered as DF will be sent back home. There is a higher risk for any 
patient who develops DHF at home, away from intensive medical care.  Attempts to 
increase the sensitivity of the logistic regression analysis may reduce the number of false 
negatives but the specificity also dropped to 47%. Decreased specificity made the model 
unpromising since it cannot actually reduce the number of patients with DF in a hospital. 
Apart from the sensitivity, the regression analysis is quite difficult to interpret and use 
since the MCP2 concentration and the platelet cell count need to be converted to the 
probability before comparing to the cut-off. As a result, to understand how to interpret the 
analysis users may need to know some basic statistics.  
 172 
 Many studies have tried to define early predictive markers for Dengue severity. 
Brasier et. al. have shown that IL10, platelet and lymphocytes were possible predictors  
by using logistic regression and CART analysis (Brasier et al., 2012). The accuracy of the 
logistic regression was greater than CART since the AUC of the regression gave 0.96 
whereas the CART analysis gave a value of 0.85. However, the number of subjects was 
somewhat low (total Dengue =51, DF = 38 and DHF =11) while they used 11 parameters 
including 8 clinical analyzes, gender, day of fever and diarrhea. In addition, they did not 
provide information about type of infection. The model obtained therefore might not be 
reliable due to an overfitting [“an overly optimistic model results” (Babyak, 2004)]. 
Another study has developed a diagnostic model analyzed by CART (Potts et al., 2010). 
They collected samples during the first 72 hours from the onset of disease. Clinical 
features, age and gender were included in this study.  The subjects in this study were 
comprised of 208 DHF, 374 DF and 648 OFI. However, they did not categorize DHF and 
DF as severe and mild Dengue respectively, but they did classify the disease using 
several criteria such as Dengue shock syndrome (as defined by WHO), DSS or pleural 
effusion index (PEI) >15, DSS or received intravenous fluid etc. They also combined 
non-severe Dengue with OFI. Their model was obtained from wbc, monocyte and platelet 
cell count, and hct. They claimed that the sensitivity of the model to identify severe 
Dengue was 97% but only 48% of non-severe Dengue was classified correctly. Hence, 
their model might not truly discriminate DF and DHF. Moreover, a recent experiment has 
identified predictive markers from the serum proteome, inflammatory markers and 
cytokines in 62 adult Dengue patients (44 DF and 18 DHF) at an early febrile stage 
(Kumar et al., 2012). They collected samples 48-72 hours after the onset of disease and 
selected samples with primary infection. Their analysis combined several statistical 
methods to select predictors and find the model for classifying Dengue severity. They 
proposed 4 different models with >70% sensitivity and the AUCs gave values about 0.86-
0.92.  However, the small number of samples and the large number of predictors used 
might generate an overfitted model. In addition, since they used both a multiplex 
immunoassay and a multiple mass spectrometry to identify markers, it is quite expensive 
to use these assays, particularly in developing countries. When compared to their 
experiments, only complete blood count test (CBC) and MCP2 singleplex bead assay are 
required in this study. 
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There are some suggestions to improve the model. Firstly, to obtain a model that 
will replicate in a new sample, the sample size should be big enough to generate the 
estimates of the model. It would have been more accurate if the sample size had been 
larger, particularly for those samples collected between the 3rd and 5th day of the illness. 
Indeed, analysis of samples collected on the same period might give a more precise 
prediction. Secondly, the number of markers should not exceed the sample size. Ideally, 
one marker requires about 10 to 15 samples (Babyak, 2004). Therefore, the number of 
markers should be less than 45 markers because the number of samples was about 450. 
Herein this study, 31 markers were used for the analysis, which was in this criterion.  
However, the greater the number of markers in the model, the greater the difficulty in 
generating the model since high dimensional data generates complex correlations among 
the markers. The highly correlated markers (high degree of correlation among predictors; 
multicolinearity; r > 0.8) can violate the regression assumption that the predictors in the 
regression must be linearly independent. Thus, those markers that highly correlated 
among each other should be excluded. Lastly, an approach that statisticians propose to 
avoid overly optimistic modelling, a technique called bootstrapping, could be employed.  
Bootstrapping is a random resampling method with replacement from the data at hand 
multiple times, creating several new datasets. Bootstrapping was shown to be superior to 
the use of training and testing sets to validate a model (Babyak, 2004). This method can 
treat the data as a population from which smaller samples are taken and the descriptive 
statistics can be calculated from the bootstrap samples.  
 
There are some considerations when deciding which predictors should be 
included in the regression model. Generally, markers with a good theoretical grounding 
are chosen and maintained in the model. In the review of Babyak, several papers chose 
markers associated with the disease by prescreeining with univariate analysis such as 
Mann-Whitney U test; yet many statisticians do not recommend using univariate 
prescreening to select the markers since it can increase the number of errors (Babyak, 
2004). The relationship between markers and the outcome might not be associated in the 
univariate test but may appear important after adjusting with other markers in 
simultaneous screenings. As a result, limiting the number of predictors by univariate 
pretesting might be inappropriate. Unfortunately, without awareness of this issue at the 
very first time, pretesting with Mann-Whitney U test was also done in this study; the 
results therefore, might not be accurate. It is quite difficult to choose the reasonable a 
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priori choices from the data at hand since there is limited biological information. One 
approach that might solve this problem is to combine closely related markers, based on 
good theoretical grounding, into a new variable using a clustering algorithm such as 
factor analysis (Babyak, 2004). This strategy may ideally limit the number of predictors 
but is in fact a more sophisticated approach and requires prior knowledge of data mining. 
In addition, many predictors are still required for the prediction. Therefore, this might not 
be a good strategy for this study. 
 
 Some limitations of the diagnostic tests in this study were shown. Since this 
model was developed from screening of Thai children, it might not be applied to other 
ethnicities or to patients of a different age. The predictive model therefore needs to be 
verified in another cohort. Sensitivity of the test was not very high and this could affect 
the ability of the test to screen severe Dengue infection.  
 
 In conclusion, platelet cells and MCP2 were defined as the markers for classifying 
DHF and DF in an early prediction model. With these predictors, physicians may identify 
people who have mild DF, decreasing the number of in-patients requiring hospitalization. 
In addition, the kinetic study of plasma proteins and the pair-wise correlation among 
predictors may be useful in other studies such as protein pathways/networks, and drug 
design.  
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Chapter 5 
 
Results 
Matrix Metalloproteinases in Dengue disease 
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5.1 Introduction 
 
Matrix metalloproteinases (MMPs) have important roles in several systems 
including the immune response to infection. MMPs are involved in the process of 
leukocyte extravasation by degrading extracellular matrix as well as regulating 
cytokine/chemokine activities (Parks et al., 2004). MMPs are required for migration of 
immune cells such as T lymphocytes, neutrophils, and dendritic cells (Parks et al., 2004, 
Warner et al., 2001, Wang et al., 1999, Chabot et al., 2006, Saalbach et al., 2010). They 
are also important for eradicating pathogens. For example, MMP-3 is necessary for 
infiltration of T lymphocytes and clearance of bacteria in the gut (Li et al., 2004). 
However, excess MMPs activity may contribute to tissue damage. Over-production of 
MMP-3, as a consequence of T cell activation by poke-weed mitogen, causes injury to 
small intestine explants (Pender et al., 1997). Inhibition of  the gelatinases (MMP-2 and 
MMP-9) by specific inhibitors reduced T cell proliferation and activation in vitro and 
abolished T cell-mediated lung injury in vivo (Benson et al., 2011). Moreover, MMPs can 
benefit pathogens and that may lead to immunopathology. MMP-9 facilitates West Nile 
virus (WNV) to enter into the brain by enhancing blood-brain barrier (BBB) permeability 
(Wang et al., 2008). Infection of endothelial cells and dendritic cells with Dengue virus 
leads to over-production of MMP-2 and MMP-9, resulting in enhanced endothelial 
leakage (Luplertlop et al., 2006). MMP-3 has an effect on the rat glomerular barrier, 
increasing albumin permeability which may  lead to proteinuria in kidney diseases 
(Sharma et al., 1996). 
 
The picture of Dengue pathogenesis is not complete. Several host factors 
including MMPs have been reported to determine Dengue severity.  Up-regulation of 
circulating MMP-9 has been shown in Dengue disease and associated with the disease 
severity (Kubelka et al., 2010). However, another study has reported no association 
between plasma levels of MMP-9 and Dengue infection during the acute phase 
(Voraphani et al., 2010). Indeed, this latter study showed that MMP-9 levels were 
reduced when compared to the follow-up stage as well as in the control group (Voraphani 
et al., 2010). Since the association between circulating MMPs and Dengue is not well 
defined, the plasma levels of MMPs (MMP-1, -2, -3, -7, -8, and -9) in Thai children 
infected with Dengue virus were investigated to find out if they are associated with 
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disease severity. It is also hypothesized that MMPs may play a role in Dengue 
pathogenesis; therefore, an interplay between Dengue virus, immune cells and non-
immune cells can also influence MMPs secretion in vitro was also explored.  
 
To investigate MMPs, a multiplex assay was used since this can simultaneously 
detect multiple analytes in a small sample volume. In principle, fluorophore-coded beads, 
precoated with specific antibodies for the proteins of interest (in this case MMPs), 
capture the analytes in the sample, followed by binding of biotinylated detection 
antibodies and phycoerythrin (PE)-conjugated streptavidin (Figure 5.1). The beads are 
read with dual lasers: one determines the analytes and another detects the magnitude of 
PE signal, which is directly proportional to the amount of protein. 
 
 
 
 
Figure 5.1: Principle of the multiplex assay (R&D systems)
Color-coded beads, pre-coated with analyte-
specific capture antibodies for the molecule of 
interest, are added. Multiple proteins can be 
simultaneously detected in the same sample.  
Analyte specific antibodies capture the analyte 
of interest. Biotinylated detection antibodies 
specific to the analyte of interest are added 
and form an antibody-antigen sandwich.  
Streptavidin conjugated to Phycoerythrin (PE) is 
added.  The microparticles are read using a 
Luminexฎ 100™ or 200™ analyzer. One 
laser classifies the microparticle and 
determines the analyte that is being 
detected. The second laser determines 
the magnitude of the PE-derived signal, 
which is in direct proportion to the amount 
of bound analyte  
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5.2 Results 
 
5.2.1 Patients’ characteristics 
 
To examine the circulating MMPs, plasma samples were collected from children 
clinically presenting with Dengue disease or other febrile illnesses (OFI). Samples were 
collected during the acute and convalescent phases. Samples during the acute phase were 
analyzed from the first hospital day in order to get a predictive test. Demographics and 
clinical profiles during the acute stage are summarized in Tables 4.1- 4.2 and Figure 4.1  
 
 
5.2.2 MMPs profiles in Dengue disease 
 
Plasma levels of MMPs (MMP-1, -2, -3, -7, -8, and -9) during acute phase were 
measured (Figure 5.2). Levels of MMP1, MMP-8 and -9 in Dengue patients (DF and 
DHF) were significantly lower than those in patients with OFI while MMP-3 levels were 
up-regulated. Levels of MMP-2 were comparable among three groups. MMP-7 was 
below the level of detection. When comparing results within Dengue groups (DF = 226, 
DHF1 = 73, DHF2 = 119, and DHF3 = 33; Figure 5.3), MMP-3 levels were higher in 
DHFs than in DF. The plasma levels of MMP-9 in DF and DHF1 were low and showed 
significance when compared to DHF3. No significant differences were detected within 
other MMPs. Secreted plasma MMPs were also compared between acute and 
convalescent stages (Table 5.1 and Figure 5.2). Increases of plasma MMP-1, -2, -8 and -9 
levels were observed during the convalescent phase whereas plasma MMP-3 declined.  
 
Next, the levels of MMPs over the time course of infection were investigated (DF 
= 24, DFH = 32; Figure 5.4). Surprisingly, the levels of MMP-1, -8, and -9 during the 
febrile stage were lower in DHF than those in DF and increased in the convalescent stage 
even though significance was found only in MMP-1 and MMP-8 on day -2. The levels of 
MMP-2 increased in both groups between fever day -3 and the critical day 0 (the day of 
defervescence); however the peak occurred on day -1, during which time higher MMP-2 
was observed in DHF. No significant difference was found after day 0 in both DF and 
DHF. In contrast, a significant difference in the MMP-3 levels could not be detected, 
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even though it was higher in DHF.  Elevated MMP-3 was found throughout the febrile 
period, peaked at day -1 and returned to normal after recovery. 
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Figure 5.2: Plasma levels of MMPs during the acute and convalescent stages: Horizontal 
lines represent median values. Statistical analysis was determined by the Kruskal-Wallis 
test for 3 groups and Mann-Whitney test for 2 groups (**, p < 0.01; ***, p < 0.001).    
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Figure 5.3: Plasma levels of MMPs graded according to disease severity during the acute 
phase: Horizontal lines represent median values. Statistical analysis was determined by 
the Kruskal-Wallis test for 3 groups and Mann-Whitney test for 2 groups (**, p < 0.01; 
***, p < 0.001).  
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Table 5.1: Plasma MMPs in acute and convalescent samples 
MMPs 
(mean pg/ml ± SD) 
DF  DHF  OFI 
Acute  
(n =226) 
Convalescent 
(n =175) 
Acute 
 (n =227) 
Convalescent 
(n =176) 
Acute 
 (n=69) 
Convalescent 
(n =22) 
MMP1  486.52±470.01 1021.92±778.54 529.73±1297.32 1056.28±903.35 653.20±567.42 1100.75±583.51 
MMP2 170682.49±37415.54 212326.54±35568.58 172109.83±35408.03 212132.76±34044.49 159712.72±41197.33 200831.60±25766.51 
MMP3  3149.37±1951.17 2607.87±1688.90 4462.11±2938.73 2757.61±1954.2 3171.85±3198.16 2861.22±88345.56 
MMP8 3479.90±3925.80 8242.75±14500.14 3600.66±3322.96 6337.59±6532.66 15300.53±23915.04 9101.89±65012.79 
MMP9 23843.42±15973.25 89096.33±105851.34 27000.58±24849.13 80523.87±65017.29 75315.09±99454.20 88345.56±63764.33 
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Figure 5.4: Plasma levels of MMPs over the time course: Day 0 is defined as the day that 
fever subsides, and 2M is the convalescent stage. Blue dots and red dots are represented 
for DF and DHF, respectively. Horizontal lines represent median values. Statistical 
analysis was determined by Mann-Whitney test for 2 groups (**, p < 0.01; ***, p < 
0.001).  
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5.2.3 Correlation between peripheral blood cells and MMPs 
 
There are several cellular sources of MMPs in plasma. Peripheral blood 
mononuclear cells (PBMCs) are known to release MMPs (Bar-Or et al., 2003, Matache et 
al., 2003). In activated neutrophils, MMP-8 and -9 are released from the granules into the 
extracellular space (Faurschou and Borregaard, 2003). Recent studies have identified that 
MMPs are stored in resting platelets and can be released during platelet activation (Jurasz 
et al., 2002). Therefore the association between plasma levels of MMPs and peripheral 
blood cells was examined. Positive correlations between MMP-8, MMP-9, white blood 
cells (wbc) and neutrophils (pmn) during the acute phase (r > 0.3, Table 5.2) were found; 
however, there were no correlation to lymphocytes and platelet counts. MMP-9 was also 
partially correlated with monocytes.  The correlation between MMP-1 and peripheral 
blood cells was very small while MMP-2 was partially correlated with platelet cells, 
lymphocytes and neutrophils and MMP-3 was moderately associated with platelet counts. 
Association between MMPs and basophils, or eosinophils was not observed. 
 
 
Table 5.2: Pearson's correlation (r) between MMPs and peripheral blood cells in Dengue 
disease 
MMPs 
Platelet 
counts log (WBC) Lymphocytes  Monocytes Neutrophils 
log (MMP1) 0.14 0.14 0.03 0.10 0.13 
MMP2 -0.23 -0.11 0.22 -0.07 -0.27 
log (MMP3) -0.31 0.00 0.06 -0.01 -0.03 
log (MMP8) 0.00 0.38 0.04 0.17 0.40 
log (MMP9) -0.03 0.37 -0.05 0.21 0.32 
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5.2.4 Influence of Dengue virus, immune cells and non-immune cells on MMPs 
secretion in vitro 
 
Although the immune responses against Dengue infection are generally focused 
on clinical experiments due to the lack of appropriate animal models, in vitro studies are 
also important. However, most studies have been carried out by infection of a single cell 
type which cannot fully correlate with and explain Dengue pathogenesis. Therefore, an 
experiment was set up to co-culture dendritic cells, which are the primary target of 
Dengue virus, endothelial cells, the physical barrier between peripheral tissues and the 
blood stream, and PBMCs. 
 
To test if Dengue virus per se can induce MMP secretion, monocyte-derived 
immature dendritic cells (DCs) were infected with Dengue virus type 2 (DV2) and cell 
supernatant was collected at 6, 12, 24, 48 and 72 hours after infection. Mock infected 
supernatant was used as a control.  First, the characteristics of the immature DCs and 
infectivity levels were tested. The features of immature DCs were CD14-, CD83- and 
CD209+ (Figure 5.5a) and infectivity was about 33-79% (Figure 5.5b). Next, the levels of 
MMP-1, -2, -3, and -9 in the supernatant were determined by multiplex assay. MMP-7 
and -8 levels were low or undetectable in the cell supernatant. DCs constitutively express 
MMP-9 and MMP-1; however, induction of MMPs from infected DCs could not be 
detected (Figure 5.6). Endothelial cells, which are susceptible to Dengue virus, were also 
infected. Infection on HUVECs was confirmed by immunostaining at 48 hours after 
infection (Figure 5.7a). Supernatants were collected at 24 and 48 hours after infection. 
Up-regulation of MMP-1, and MMP-2, which are mainly produced by endothelial cells, 
was not found, nor was the induction of any other MMPs (Figure 5.7b).  
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Figure 5.5: Cell surface expression and DV2 infection on Dendritic cells (DCs). CD14+ 
cells isolated from PBMCs were harvested and cultured in RPMI with GM-CSF and IL4 
for 5 days to generate DCs. Dendritic cells were mock infected or infected with DV2 for 
24 hours. A) Cell surface staining against CD14, CD83 and CD209 on the infected cells 
were tested. B) Infectivity at 24 hours post infection was confirmed by flow cytometry.  
This figure is representative of three independent experiments. 
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Figure 5.6: MMPs secretion in the supernatant of dendritic cells (DCs). CD14+ cells 
isolated from PBMCs of three different donors were harvested and cultured in RPMI with 
GM-CSF and IL4 for 5 days to generate Dendritic cells. Dendritic cells were mock 
infected or infected with DV2 for 24 hours. Supernatants were collected at the indicated 
time points after infection (Hours) to measure MMP levels. Only MMP-1 and -9 were 
detectable. Results are representative of three independent experiments. 
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Figure 5.7: MMP secretion in the supernatant of HUVECs. HUVEC were mock infected 
or infected with DV2 at MOI of 5. A) Infection of HUVECs was confirmed by 
immunoperoxidase staining against the viral E protein. Infected cells are the darkly 
stained cells. B) Cell supernatants were collected at the indicated time points after 
infection to measure MMP levels. Only MMP-1 and -2 were detectable. Results from 3-
independent experiments are shown as mean±SEM. 
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Next, secretion of MMPs from DCs, HUVECs, resting PBMCs and activated 
PBMCs, as well as from co-culture between these cells, was measured (Figure 5.8). 
HUVECs secreted MMP-1, -2 and a small amount of MMP-3 while DCs mainly released 
MMP-9. Only a small amount of MMP-9 from resting and activated PBMCs could be 
detected. Activation of PBMCs was confirmed by the expression of surface CD69 
(Figure 5.9). Co-culture of HUVECs and DCs (mock-treated and DV2-infected cells) did 
not affect MMP-1 and -3 secretions while expression of MMP-2 and -9 varied a lot. Co-
culture of resting PBMCs and HUVECs had no effect on MMP levels.  On the other 
hand, when either HUVECs or DCs were mixed with activated PBMCs, MMP levels 
considerably increased, suggesting that activated PBMCs were able to induce secretion of 
MMP-1, -3, and -9 from both HUVECs and DCs (Figure 5.8a, c and d).  In contrast, 
MMP-2 levels were moderately reduced when HUVECs were incubated with activated 
PBMCs. There was no effect of activated PBMCs on MMP-2 secretion from DCs. Since 
PMA/I, which is used to activate PBMCs, can change MMP expression (R Hanemaaijer, 
1993), the enhanced MMP levels in this experiment might be an effect of this stimulator. 
To test this possibility, the last wash of activated PBMC was added to HUVECs for 24 
hours; the supernatant was harvested to measure MMP levels. No change of MMP 
expressions was observed (Figure 5.10). Therefore, altered MMPs levels in the presence 
of activated PBMCs were not the result of PMA/I.  Finally, there was no synergistic 
effect on MMP-1, -3, and -9 secretions when activated PBMCs, DCs and HUVECs were 
co-cultured; however, this interaction greatly reduced MMP-2 levels (Figure 5.8). 
 
To investigate whether the effect of activated PBMCs on MMPs secretion is 
mediated by soluble factors, activated PBMCs were coincubated in a transwell system in 
which HUVECs were separated from activated PBMCs. Soluble factors were found to 
partially alter MMPs secretion (Figure 5.11).  
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Figure 5.8: Secreted MMPs in the supernatant of HUVECs, DCs (mock treated or 
DV2 infected) and resting PBMCs or PMA/I-activated PBMCs. Resting/activated 
PBMCs and/or HUVECs were co-cultured with mock treated or DV2-infected DCs. 
Cell supernatants were collected at 24 hours after coculture. A) MMP-1, B) MMP-2, 
C) MMP-3, and D) MMP-9 in the supernatants were measured at 24 hours after 
incubation. Results are from 3-independent experiments. DC-M: mock-infected 
dendritic cells, DC-DV2: DV2-infected dendritic cells. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9: Cell surface expression on activated PBMCs. PBMCs were activated with 
PMA/I for 24 hours and washed for 3 times. Cell surface staining against CD69, the 
early activation marker, was performed by flow cytometry. Isotype control was used 
as a negative control. 
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Figure 5.10: MMP levels measured in the supernatant of HUVECs treated with the 
last wash of activated PBMCs. Activated PBMCs were washed in R10 for three times. 
The supernatant of the last wash of activated PBMCs was collected. HUVECs were 
incubated with the last wash for 24 hours and the supernatant was harvested. Co-
culture between activated PBMCs (PBMC’’) and HUVECs was used as a control. 
MMP-1, -2, -3, and -9 were measured. The result is representative of 2-independent 
experiments. 
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Figure 5.11: Secreted MMPs in the supernatant of HUVECs incubated with resting 
PBMCs (PBMC) or activated PBMCs (PBMC’’) on the transwell. HUVECs were 
plated on a lower chamber of the transwell, whereas PBMCs or activated PBMCs 
were seeded on an upper chamber. Co-culture between HUVECs and either PBMCs 
or activated PBMCs were used as the controls. Incubation was performed for 24 hours 
and the supernatant in the lower chamber was collected to measure MMPs. The 
results from 3-independent experiments are shown as mean±SD. 
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5.2.5 MMP-3 and endothelial permeability 
 
The hallmark of DHF is vascular permeability which is regulated by several 
factors. There is evidence showing that MMP-3 is capable of increasing albumin 
permeability of isolated rat glomeruli (Sharma et al., 1996). Thereby, it is 
hypothesized that increased plasma MMP-3 may be involved in the vascular leakage 
seen in Dengue infection. First, an inactive form of recombinant MMP-3 (rMMP-3) 
was activated to get an active enzyme. To test its activity, the active rMMP-3 was 
mixed with the fluorogenic peptide substrate containing a cleavage site specific for 
MMP-3, causing an increase in fluorescence signal (Figure 5.12a). The rMMP-3 can 
specifically cleave its substrate. The specific activity (pmol/min/μg) was >150 
pmol/min/μg as measured under the conditions described in the manufacturer’s 
protocol (see section 2.13 in Materials and Methods). Active rMMP-3 was also 
detected as a 45 kDa species by western blot (Figure 4.12b). Next, the activity of 
active rMMP-3 on endothelial permeability was tested. HUVECs were seeded on an 
upper insert assembly of a transwell plate for 3 days. Media containing TNF-α at 100 
ng/ml, active MMP-3 at the initial concentration of 1 μg/ml, and the assay buffer were 
added to the cells for 24 hours. FITC-dextran was added in an upper chamber and 
growth medium was added in the receiver plate. The FITC-dextran was allowed to 
permeate for 30 minutes and media in the lower chamber was removed and 
transferred to a black 96-well plate. Fluorescence was read at 485 nm and 538 nm 
excitation and emission, respectively by a fluorescent plate reader. Although the 
initial concentration of rMMP-3 used was about one thousand times higher than that 
found in vivo, neither rMMP-3 at 1 μg/ml nor the buffer induced endothelial 
permeability (Figure 5.13).  
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Figure 5.12: Characteristics of active rMMP-3. A) rMMP-3 at 2.5 ng/μl or buffer was 
mixed with the fluorogenic peptide substrate. A negative control contained only the 
substrate. Fluorescence signal was read after 5 minutes at 320 and 405 nm. The 3-
independent experiments are shown as mean±SD. B) Active form of rMMP-3 was 
confirmed by Western blot. The 52 kDa proform and the 45 kDa active form were 
detected.  Mouse anti-MMP-3 and anti-mouse HRP were used as a primary antibody 
and a secondary antibody respectively, at a dilution 1:1000. 
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Figure 5.13: Endothelial permeability. rMMP-3 at the initial concentration of 1 μg/ml 
or buffer was added to the HUVECs on a transwell for 24 hours. HUVECs treated 
with TNF-α (100 ng/ml) and cell monolayers without treatment (only growth 
medium) were used as a positive and a negative control, respectively. No monolayer 
was demonstrated to be 100% permeable. FITC-dextran was added in an upper 
chamber for 30 minutes and the media in a lower chamber was transferred to a black 
96-well plate. The fluorescence signal was measured at the wavelength of 485/538 
nm. The 3-independent experiments are shown as mean±SD.  
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5.3 Discussion 
 
In this study the plasma levels of MMPs in Thai children infected with 
Dengue virus were investigated.  The data showed that up-regulation of MMP-3 was 
associated with dengue disease severity during the acute phase and returned to normal 
during the convalescent phase. In contrast to MMP-3, other MMPs were down-
regulated. However, when the level of these MMPs was observed over the time 
course of the disease, a significant difference in MMP-3 levels between DF and DHF 
was not observed. The unexpected results may be due to a small sample size (DF =24 
and DHF =32). An adequate sample size should be at least 10-15 times greater than 
the number of markers tested (Babyak, 2004). 
 
Previous studies have investigated the relationship between plasma MMPs and 
Dengue disease (Kubelka et al., 2010, Voraphani et al., 2010).  Lower plasma MMP-9 
levels are observed during the febrile stage, compared to the convalescent phase. This 
does not correlate with the severity of disease in Thai children (Voraphani et al., 
2010). This study confirms our MMP-9 results. In contrast, another study has found 
that an induction of plasma MMP-9 is associated with Dengue severity (Kubelka et 
al., 2010). Also, they have found increases of MMP-12 and -13 in Dengue patients 
when compared to the healthy controls, whereas MMP-2 did not change (Kubelka et 
al., 2010). This study was conducted in Brazilian adult patients whose levels of 
plasma MMPs may differ from the levels in children. In addition, they used a new 
World Health Organization guideline which provides a different strategy to 
discriminate between severe and mild Dengue (with or without warning signs, 
respectively; new edition in 2009 (2009)), whereas our study classified Dengue cases 
by the existing classification using DF and DHF as non-severe and severe Dengue 
respectively. Moreover, Kubelka et al. did not report when the samples were 
collected; this could affect the levels of plasma MMPs. These contradictory 
observations in the Brazilian population may also be influenced by ethnicity, age, 
criteria to grade the disease severity as well as the virus strain. 
 
This is the first report showing that MMP-1, -2, -8 and -9 decreased whereas 
MMP-3 increased in Dengue infection. The reason for the low levels of MMPs during 
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the febrile stage is not clear. One of the possible explanations is that the number of 
MMPs-producing cells is reduced. Peripheral blood cells are known as sources of 
several MMPs; however in Dengue disease, both leucopenia and thrombocytopenia 
are usually detected. Only a moderate correlation between MMP-8, -9, WBC count 
and neutrophils (r> 0.3), but not the platelet count, was observed. This result does not 
fully explain the whole story of low MMPs.  Alternative explanations can be that 1) 
synthesis of MMPs might be inhibited, 2) MMPs might be rapidly consumed, 3) 
MMPs may anchor to the cell membrane as membrane-bound forms, as a result of 
decreasing soluble forms (review in (Parks et al., 2004, Greenlee et al., 2007)), 4) 
MMP expression may be induced later at the time of plasma leakage, and 5) 
proMMPs may locally bind to their substrates in tissues and accumulate there. An 
example of localized expression of MMPs is reported in inflammatory bowel disease 
(IBD). MMP-8 is predominantly localized at the surface of epithelial cells during IBD 
and also expressed in the ulcer base of both ulcerative colitis and Crohn’s disease, 
mediating tissue destruction (Ravi et al., 2007). With these possibilities, measuring 
plasma MMPs might not reflect total MMPs. To investigate these possibilities, 
mRNA, intracellular and membrane-bound forms of MMPs from PBMCs as well as 
tissue staining might be tested. Besides this, measurement of samples after 
defervescence may be required.  
 
Altered levels of MMPs may be influenced by virus, soluble factors, or cell-
cell contact. Recent experiments have shown that Dengue infected DCs and 
endothelial cells overproduce MMP-9 and MMP-2 (Luplertlop et al., 2006, Luplertlop 
and Misse, 2008). Their studies have also shown that anti-MMP antibodies and an 
MMP inhibitor decreased endothelial permeability and retained expression of vascular 
endothelial-cadherin (VE-cadherin) and platelet endothelial adhesion molecule-1 
(PECAM-1), suggesting that MMPs may be involved in the vascular leakage 
observed. Our study, indeed, did not find a significant change of MMPs production 
from infected cells at any time point. However, activated PBMCs were found to affect 
MMPs secretion from DCs and endothelial cells. It is not surprising that activated 
PBMCs induce MMP-1, -3, and -9 secretions from endothelial cells since previous 
studies have also observed this result (François Mach, 1999, Mitola et al., 2003). Yet, 
none has shown that these cells also affect MMPs production from DCs. While MMP-
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1, -3, and -9 were augmented in the co-culture system, secreted MMP-2 was 
surprisingly reduced.  
 
In Dengue infection, massive numbers of activated T cells are produced in 
vivo during secondary infection (Mathew and Rothman, 2008, Rothman, 2011). These 
T cells can interact with both dendritic cells and endothelial cells lining the blood 
stream, inducing MMPs as well as several kinds of soluble proteins. Uncontrolled 
induction and activation of MMPs, despite virus-independence, can contribute to 
immunopathogenesis. They can degrade extracellular matrix (ECM) components such 
as collagen, gelatin, and stromelysin, causing tissue destruction such as the capillary 
leakage commonly found in Dengue disease. MMPs can also cleave 
cytokine/chemokine molecules, resulting in either their activation or inactivation and 
possibly leading to a cytokine storm. For example, MMP-9 is able to increase the 
activity of IL-8 (Manicone and McGuire, 2008), which is known as a potent 
neutrophil chemoattractant. Elevated IL-8 has been detected in plasma of Dengue 
patients and it is associated with disease severity (see chapter 4 and (Raghupathy et 
al., 1998). Since activated PBMCs can induce MMP-9 from endothelial cells, this 
incidence may trigger IL-8 activity in Dengue disease. In addition, MMPs can cleave 
VEGF, latent TNF-α, TGF-β, IL1-β, and MCPs etc., all of which are detected in 
Dengue disease (Manicone and McGuire, 2008, Parks et al., 2004, Srikiatkhachorn 
and Green, 2010). Cytokines such as TNF-α, IL-6 and IL-8, on the other hand, can 
also induce MMPs production (R Hanemaaijer, 1993, Kossakowska et al., 1999, 
Kothari et al., 2014, Li et al., 2003, Chakrabarti and Patel, 2005). Moreover, MMPs 
might facilitate leucocyte migration to the site of infection and inflammation. For 
example, MMP-3 null mice have impaired neutrophil recruitment to the lung in an 
acute lung injury model (Warner et al., 2001).  
 
In these experiments soluble factors from activated PBMCs were not powerful 
enough to modulate MMPs production. A previous report has shown that activation of 
endothelial cells by interaction with T cells increases MMP-1 and -3 secretions, 
induces de novo expression of MMP-9, and activates MMP-2 through CD40-CD40L 
interaction (François Mach, 1999). A decrease in levels of MMP-2 was not present in 
this study. Although a great effect of these soluble factors in vitro was not seen, they 
may trigger MMPs production/activation in vivo. In addition, these in vitro 
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experiments showed that MMP production varied greatly, particularly in MMP-2 and 
-9 levels. Despite the fact that technical errors during experiments cannot be excluded, 
this variation might be due to genetic polymorphisms in each donor. Also, activated 
PBMCs in different individuals may show variability in secretion of cytokines such as 
TNF-α and IFN-γ. This may induce different degrees of MMP production since IFN-γ 
is able to inhibit TNF-α induction of MMPs (R Hanemaaijer, 1993, Balasubramanian 
et al., 2011, Cornelius et al., 1995). In Dengue cases, it has been proposed that 
individuals with activated T cells that produce high TNF-α but low IFN- γ levels are 
at risk of developing DHF; however those with greater levels of IFN- γ than the levels 
of TNF-α seem to have mild DF (Mathew and Rothman, 2008). This phenomenon 
might be explained by the fact that TNF-α can induce MMP secretion, damaging host 
tissues, while IFN- γ is able to suppress TNF-α activity. To test this possibility, 
cytokines from supernatants of the co-culture system might be measured. 
  
Up-regulation of plasma MMP-3 may be involved with the 
immunopathogenesis of Dengue infection. The ability of MMP-3 to induce 
endothelial leakage was tested. High concentrations of rMMP-3 were added directly 
to the endothelial cell in vitro. Disappointingly, rMMP-3 did not lead to enhanced 
permeability. It is possible that rMMP-3 might be degraded either by some proteases 
in the endothelial media or by autocatalytic cleavage. Activity of rMMP-3 after cell 
culture for 24 hours might be tested. Moreover, MMP-3 might require interplay with 
other factors to mediate such an effect. A study of metastasis has reported that 
angiopoietin-2, MMP-3, and MMP-10 synergistically increase vascular permeability, 
contributing to extravasation of circulating tumor cells and the increased permeability 
of pulmonary vasculatures (Huang et al., 2009). In addition, MMP-3 might be 
involved in other mechanisms. For example, MMP-3 knock-out mice infected with 
intestinal bacteria show delayed clearance of bacteria and infiltration of CD4 T cells 
in the lamina propria, suggesting a role in T cell migration (Babyak, 2004). MMP-3 
production in human fetal small intestine explants is a consequence of T cell 
activation with pokeweed mitogen (Pender et al., 1997) and increased production of 
MMP-3 could degrade the lamina propria matrix, leading to mucosal inflammation 
and gut injury (SCHUPPAN and HAHN, 2000). They also found that nanomolar 
concentrations of recombinant MMP-3 are able to induce severe tissue damage when 
added to the fetal explants.  Since intestinal fibroblasts are a source of MMP-3 and 
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TNF-α released by T lymphocytes is a powerful inducer of this protease, this could 
provide a link between mucosal inflammation and tissue destruction. Therefore, it is 
possible that MMP-3 might play a role in intestinal mucosal injury in Dengue 
infection. Vejchapipat et. al. have demonstrated an association between Dengue 
infection and intestinal mucosal injury (Vejchapipat et al., 2006).  They found that 
serum levels of intestinal fatty acid binding protein, which is a specific marker for 
mucosal injury, increased in the Dengue patients, particularly in DHF grade 4 
compared to the control group (Vejchapipat et al., 2006).  In addition, Tsai et. al. have 
shown that most of the Dengue patients with upper gastrointestinal bleeding had 
gastric ulcers or duodenal ulcers as well as hemorrhagic gastritis (Tsai et al., 1991); 
these wounds might be the result of MMP-3 activity. To test this possibility, 
expression of MMP-3 might be tested by staining of the intestinal tissue of Dengue 
patients with gut injury; intestinal fibroblasts as well as T lymphocytes in the gut 
should be the targets. Additionally, testing MMP-3 activity might be performed. 
 
In summary, up-regulation of MMP-3, together with low levels of other 
MMPs, was associated with Dengue infection in a Thai cohort. MMPs production was 
not directly influenced by Dengue virus, but by interaction between immune and non-
immune cells. Finally, MMP-3 did not play a direct role in endothelial permeability in 
vitro. Although the roles and mechanisms of MMPs in Dengue disease are not well 
understood, targeting MMPs as therapeutic agents might be of interest. Since excess 
MMPs activity can contribute to host tissue damage, regulating the over-production of 
MMPs might relieve the symptoms of the disease. In addition, MMPs might be useful 
as biomarkers to discriminate between DF and DHF.  
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6.1 Introduction 
  
 Dengue disease is a life threatening disease particularly in children. Mild and 
severe illness is graded on account of the symptoms of the disease. Pathogenesis of 
Dengue infection is not well understood. It is believed that variations in genetics as 
well as host immune responses are important factors contributing to Dengue severity. 
So far, there have been no good early predictive markers to classify mild DF and 
severe DHF. Attempts to find these markers are still ongoing and both genetic 
polymorphisms and biomarkers have been studied. With powerful early predictive 
mediators, physicians can precisely identify and treat those who are susceptible to 
developing severe DHF, thus reducing the mortality rate. In addition, knowing the 
function of these mediators could help in understanding the pathogenesis of the 
disease and may help generate therapeutic agents in the future.  
 
 
6.2 Complement alternative pathway genetic variation and 
Dengue infection in the Thai population 
 
 The complement system appears to respond during an early stage of Dengue 
infection. A correlation between complement activation and severe DHF has been 
reported previously (Nascimento et al., 2009, Avirutnan et al., 2006, Bokisch et al., 
1973). Nascimento et. al. have shown that plasma complement factor H (CFH) was 
lower in patients with DHF during the acute phase of the illness, returning to 
normal during convalescence while CFH levels in DF did not change (Nascimento 
et al., 2009). A reduced CFH is able to generate nonspecifically uncontrolled 
complement activation. This can cause tissue damage in Dengue illness. Recently, a 
polymorphism in the CFH promoter [CFH promoter (-332 C/T: rs375339)] was 
associated with Dengue susceptibility (Pastor et al., 2013). The authors proposed 
that this variant might affect expression of CFH. However, in this present study, 
association between this variant and Dengue severity was not found (Table 3.2 and 
3.3). Polymorphisms in a group of complement proteins called the ‘complotype’ 
(CFH-62: rs800292; FB-32: rs12614 and rs12615; and C3-102: rs2230199) were 
also tested. The complotype has been previously described to play a role in age-
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related macular degenerative disease (AMD) (Hageman et al., 2005, Gold et al., 
2006, Yates et al., 2007). Individuals with the ‘high activation’ complotype have an 
increased susceptibility to develop AMD (FB-32 R/R: rs12614 [C] and rs641153 
[G]; CFH-62 V/V: rs800292 [G]; and C3-102 F/F: rs2230199 [G]) whereas the 
‘low activation’ complotype confers a reduced risk of developing AMD (FB-32 
Q/Q rs12614 [C] and rs641153 [A]; CFH-62 I/I: rs800292 [A]; and C3-102 S/S: 
rs2230199 [C]). This evidence was supported by an in vitro study showing that the 
high activation complotype generates a high complement hemolytic activity 
(Heurich et al., 2011). However, a relationship between these variants and Dengue 
susceptibility could not be detected here (Tables 3.3-3.4). Similarly, CFH-402 
(Y/H; rs1061170), the AMD-associated polymorphism, was not correlated with 
Dengue (Tables 3.2-3.3). In addition to these single nucleotide polymorphisms, a 
copy number variation in the complement related proteins (CFHRs) is able to affect 
complement regulation (Jozsi and Zipfel, 2008). Although the absence of CFHR1 
and CFHR3 (CFHR3-1) is associated with protection against AMD (Spencer et 
al., 2008), there was no evidence that this variation conferred protection against 
Dengue infection or even its severity (Table 3.6). These data demonstrate that the 
severity of Dengue infection is not strongly influenced by complement alternative 
genetic variation in the Thai population. However, we cannot exclude this 
possibility in other different ethnicities. In addition, other polymorphisms in 
complement genes could influence Dengue infection. This possibility might be 
tested by genome-wide association studies (GWAS). 
  
 Many pathogens are able to modulate complement mediated responses by 
binding to CFH (Ferreira et al., 2010). NS1 of West Nile virus (WNV) is able to 
recruit CFH, suppressing complement activation in solution and complement-
dependent lysis of infected cells (Chung et al., 2006). However, this phenomenon 
does not happen with NS1 of Japanese encephalitis virus (JEV) (Krishna et al., 
2009). In this study, the direct binding between NS1 of Dengue virus and CFH 
could not be detected (Figures 3.5-3.7). The interaction between these two 
molecules may require other components. For example, NS1 might bind to CFH via 
an interaction of carbohydrate ligands such as heparin sulfate (Muller and Young, 
2013, Avirutnan et al., 2007, Zipfel et al., 1999). NS1 might also compete with 
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CFH for binding to ligands on the surface of healthy, uninfected cells, leading to 
complement activation and complement-induced vascular leakage. It is also 
possible that NS1 might not be a key component in the modulatation of CFH 
activities. Nor do other non-structural proteins fulfill this role since these proteins 
present inside the infected cells.  Numerous microbes can recruit CFH to their 
surface to avoid complement attack (Ferreira et al., 2010). This might happen with 
Dengue virus particles. To test these hypotheses, a binding between Dengue 
particles and CFH might be performed.  
 
 
6.3 Early predictive markers to classify Dengue severity 
 
  Not only are genetic polymorphisms studied to identify markers of Dengue 
severity, peripheral blood cell counts and plasma protein concentrations of Dengue 
patients are also widely explored. Clinical profiles found in this study were similar 
to those described in the WHO criteria: reductions in platelet cell, wbc, neutrophil 
counts, lymphocytes, liver protein and albumin levels as well as increases in hct, 
atypical lymphocytes, and liver aminotransferases (ast and alt) (Table 4.2). In 
addition to these clinical features, many soluble proteins have been correlated with 
Dengue susceptibility (Tables 4.3-4.4). Some of them have been previously 
reported and confirmed in this study whereas others have been newly identified by 
this study. These newly identified markers that associated with Dengue severity are 
MMP3, BCA1, MIP3α, CTACK and Eotaxin2; those that associated with Dengue 
susceptibility are MMP1, MMP8, sIL4R, sIL6R, MIP1δ and MIP3β (Table 4.3). 
 
 Although numerous publications have proposed early predictive markers, 
none of them can discriminate DF and DHF accurately. This may be due to 
variations in the duration/time of sample collection, sample collection method, age 
of the patients, etc. Attempts to define biomarkers discriminating DF and DHF 
were also performed in this study. Binary logistic regression and classification tree 
(CART) were applied to search for good indicators or predictors of disease 
severity. With the binary regression, platelet cell count and MCP2 were defined as 
the markers for classifying DHF and DF in early stages of the disease while CART 
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gave only the platelet cell count as an early predictive marker (Figures 4.7 and 4.9). 
When considering the sensitivity, specificity and accuracy of the models from these 
two methods, the binary logistic regression gave the better prediction and accuracy 
scores although there are some difficulties using this method (Figures 4.8 and 
4.10). Importantly, the sensitivity of the test should be high enough to reduce the 
number of false negative results (true DHF but defined as DF) since there is a 
greater risk that patients will develop DHF at home, where they cannot access the 
intensive medical attention that is required. However, when attempting to improve 
the sensitivity, the number of false positives (true DF but defined as DHF) was also 
highly increased. A model with high false positives is unpromising as well since it 
cannot reduce the number of in-patients, representing a considerable burden for 
hospitals. In future experiments, biomarkers defined here should be verified in 
another cohort to confirm their utility in defining DF from DHF at early stages of 
the disease.  
 
 
6.4 Matrix Metalloproteinases in Dengue disease 
  
 Plasma leakage in Dengue infection is a hallmark of severe DHF but a 
mechanism for this phenomenon is not well defined. Matrix metalloproteinases 
(MMP), zinc-dependent endopeptidases, may be involved in this process since they 
can degrade extracellular matrices, regulate cytokine/chemokine activities, induce 
T cell migration and activation, etc. (Parks et al., 2004, Pender et al., 1997). 
Recently, correlations between plasma levels of MMPs and Dengue susceptibility 
have been observed. Up-regulation of circulating MMP9 was correlated with the 
disease severity, but this could not be replicated in another study showing that 
decreasing MMP9 levels were detected during the acute stage of infection when 
compared to the follow-up stage as well as to the control group (Kubelka et al., 
2010, Voraphani et al., 2010). In this study, a reduction in plasma MMP1, -8, and -
9 during the acute stage were correlated with Dengue susceptibility but these were 
not associated with the disease severity (Figure 5.2 and 5.3). The levels of MMP2 
were not correlated with Dengue infection since the concentrations of this enzyme 
were comparable in both the Dengue and control groups (Figure 5.2 and 5.3). 
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However, it is of interest that the levels of MMP2 were low during the acute stage 
even in the control group, increasing during convalescence. While it remains 
uncertain why these plasma MMP1, -2, -8, and -9 levels were reduced during the 
acute stage, up-regulation of MMP3 could be observed in Dengue patients and 
correlated with the disease severity (Figure 5.2 and 5.3). In future experiments, the 
number of Dengue samples observed over the time course should be bigger in order 
to increase the statistical power of the analysis.   
 
 It is postulated that local expression of uncontrolled MMPs could mediate 
tissue destruction as well as vascular leakage. Previous in vitro experiments have 
demonstrated that MMP2 and -9 were over-produced in infected cells (Luplertlop 
et al., 2006, Luplertlop and Misse, 2008). They also showed that these over-
produced MMPs were able to increase endothelial permeability and were associated 
with a reduced expression of adhesion molecules on the cell surface (Luplertlop et 
al., 2006). This permeability is reduced when MMP specific inhibitors and an anti-
MMP9 antibody are used. However, in this present study, over-production of 
MMPs from infected cells could not be detected (Figure 5.6 and 5.7). Although 
MMPs production was not directly changed by the virus, it was confirmed that 
activated PBMCs could alter production of MMP1, -3, and -9 in both dendritic cells 
and endothelial cells in vitro (Figure 5.8). These results were supported by previous 
studies (François Mach, 1999, Mitola et al., 2003). Moreover, MMP levels, 
particularly MMP-9, secreted from activated PBMCs could be different from those 
of resting PBMCs (Figure 5.11). In addition, a reduction of MMP2 in the 
supernatant was surprisingly found when activated PBMCs were added into 
endothelial cells. A decrease in plasma MMP2 might be inferred from this 
experiment (Figure 5.2). Massive activation of T cells is generally observed in 
Dengue illness especially in severe Dengue cases (Mongkolsapaya et al., 2003). 
These activated T cells can migrate to the site of infection and interact with 
dendritic cells and endothelial cells lining the blood vessels (Martina et al., 2009, 
Dejnirattisai et al., 2008). They may be key cells contributing to 
immunopathogenesis by triggering the release of many soluble factors including 
MMPs. Even though attempts to mimic an interaction between activated PBMCs, 
endothelial cells and infected dendritic cells were not successful due to variations in 
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the results (Figure 5.8), it is still possible that the interaction of these cells might 
induce production and activation of MMP in vivo.  
 
 Up-regulation of MMP3 during Dengue infection is a new insight but the 
role of MMP3 in the illness is still unknown. MMP3 is generally able to degrade 
extracellular matrices such as collagen, fibronectin, elastin, and laminin 
(http://www.ncbi.nlm.nih.gov/gene/4314). This enzyme is also involved in the  
activation of other MMPs, tissue remodeling, and T cell migration and activation 
(Li et al., 2004, SCHUPPAN and HAHN, 2000). In addition, there is evidence 
showing that MMP3 has an effect on the glomerular barrier in rats, increasing 
albumin leakage (Sharma et al., 1996). With these myriad abilities, MMP3 may 
have multiple functions in Dengue infection. Since a recent study has shown that 
MMP9 can increase endothelial leakage in vitro (Luplertlop et al., 2006), it was of 
interest to see if MMP3 had the ability to cause vascular leakage. Unfortunately, 
MMP3 alone appeared not to have a direct effect on endothelial permeability 
(Figure 5.12). A study in tumor extravasation has shown that a combination of 
MMP3, angiopoietin-2 and MMP10 can increase the permeability of the pulmonary 
vasculature, leading to tumor cell migration across endothelial barriers (Huang et 
al., 2009). This evidence suggests that MMP3 might be able to cause endothelial 
permeability in Dengue infection but may require companions to do so.  However, 
it is uneasy to investigate companion proteins since MMP3 can bind to numerous 
proteins such as MCP1-4 (monocyte chemotactic proteins), CXCL7, CXCL12, and 
other MMPs (Parks et al., 2004).  
  
 
6.5 Conclusion 
 
 All in all, factors contributing to Dengue severity were investigated in this 
study. Genetic polymorphisms in the alternative complement pathway were not 
associated with Dengue illness in a Thai population. In contrast, several plasma 
mediators were found to increase the risk of developing DHF. Up-regulation of 
plasma MMP3 was associated with Dengue severity although the role of MMP3 in 
Dengue pathogenesis remains uncertain and should be investigated further. Finally 
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a predictive model to predict DHF identified low platelet cell count and high 
concentration of MCP2 as potential markers. These data help to broaden our 
knowledge of Dengue pathogenesis and may prove helpful in the development of 
therapeutic agents as well as predictive indicators for Dengue disease severity.  
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Appendices 
Appendix 1: SNPs studied, primers sequences and product sizes 
 
Gene Location ID Number Primer Sequence (5'--3') 
Product 
size (bp) 
Factor H 
Promoter rs3753394 
TCTTTACCTTCTCAATATCCAGC 
867 
ACTCCTGTGAAAAGCATCATTAG 
Exon 2 rs800292 
Pre-designed  by applied bioscience 
- 
Pre-designed  by applied bioscience 
Exon 9 
 
rs1061170 
CCTTTGTTAGTAACTTTAGTTCGTC 
490 
GGTCCATTGGTAAAACAAGG 
Intron 12 rs6677604 
TTGCTTGAGGAAAGTTGTGC 
707 
TGCTCATTTTCCTTCCCATC 
Factor B Exon 2 
rs12614, 
rs641153 
CAAGCCAGGACACACCATC 
1800 
TCTTCCGCTTCTGTTGTTCC 
C3 Exon 3 rs2230199 
GAAGACCAAGAATAATGGGCA 
511 
TCTTTCTCTGTCTCTCTCGAT 
 
 
Appendix 2: Biological markers  
  
Matrix Metalloproteinases (MMPs) (R&D systems, USA) 
MMP1, MMP2, MMP3, MMP7, MMP8,  and MMP9 
 
Soluble cytokine receptors (Millipore, USA) 
sTNFRI, sTNFRII, sVEGFRII, sEGFR, sgp130, sIL1RII, sIL2Ra, sIL4R, and sIL6R. 
 
Cytokine/chemokine panel II (Millipore, USA) 
MCP2, ENA78, SDF1α+β, BCA1, I309, IL16, MIP1δ, TARC, 6Ckine, Eotaxin2, CTACK, IL23, TPO, 
TRAIL, IL33, and Eotaxin3 
 
Cytokine/chemokine panel III (Millipore, USA) 
ITAC, MIP3α, MCSF, GCP2, and MIP3β 
 
Human cytokine 30-plex (Invitrogen, USA) 
TNFα, IFNγ, IL6, IL8, IL1β, IL10, IL13, IL2, IL2R, IL12, IL15, IL4, IL5, IL7, IL17, Eotaxin, IP10, 
MCP1, MIG, MIP1α, MIP1β, RANTES, HGF, FGF, GCSF, EGF, VEGF, GMCSF 
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